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Abstract 
Asthma is a common inflammatory airway disease affecting over 2.5-3 million 
Canadians. This disease involves a Th2-driven immune response. Th2-type 
cytokines, (interleukin (IL)-4, IL-5, and IL-l3) are upregulated in human 
asthmatics and in animaIs models of allergie airway inflammation. A recently 
characterized cytokine, IL-17E (IL-25), expressed in vitro by Th2 lymphocytes, 
macrophages and mast cells, generates a Th2 phenotype in mice. 
Overexpression of IL-17E promotes asthma-like features in animal models, 
namely, elevated levels of IL-4, IL-5 and IL-l3, increased airway 
hyperreaetivity, eosinophilia, increased IgE, aIrway epithelial cell 
hypertrophy/hyperplasia, and airway mucus hypersecretion. IL-17E binds the 
interleukin-17B receptor (IL-17BR), which is expressed in a variety of tissues 
and is upregulated under inflammatory conditions. We have investigated the 
expression of this receptor on structural cells of the airways in addition to 
assessing the effect of IL-17E on these cells. We hypothesized that airway 
smooth muscle cells (ASMC), lung epithelial cells and lung fibroblasts express 
IL-17BR and that proinflammatory cytokines eould modulate its expression. 
The three cell types constitutively express IL-17BR mRNA and protein, and its 
expression was consistently upregulated by the proinflammatory cytokine 
TNF a. We also observed that the Th 1 type cytokine IFNy decreased IL-17BR 
expression in ASMC, we observed a similar decrease by TGFB in fibroblasts. 
IL-17E appears to have profibrotic properties, as it upregulates the expression 
of pro-collagen al mRNA in ASMC, this could suggest that it could increase 
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basement membrane thickening in vivo, a characteristic feature of airway 
remodelling. Pro-inflammatory and pro-eosinophilic cytokines su ch as 
RANTES, eotaxin, IL-8 and GM-CSF are increased in lung fibroblasts treated 
with IL-17E. In A549 lung epithelial cells, IL-17E also acts synergistically with 
TNFa to induce GROa mRNA and this effect can be inhibited by recombinant 
IL-17BR. In addition, IL-17E promoted the proliferation of bronchial epithelial 
cells isolated from biopsies taken from control and mild asthmatic donors. 
Collectively, our results show that the IL-17E receptor is consistutively present 
in structural cells of the airways and increases in the presence of TNFa. Our 
results also suggests a potential pro-remodelling and pro-inflammatory role for 
IL-17E on these cells. 
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Résumé 
L'asthme est une maladie inflammatoire des voies respiratoires qui affecte au-
delà de 2.5 à 3 millions de Canadiens. Cette condition est associée à une 
immunité de type Th2, le niveau de cytokines dominant sont de type Th2 
(interleukin (IL)-4, IL-5, et IL-13), elles sont augmentées chez les individus 
asthmatiques, ainsi que chez les modèles animaux d'inflammation des voies 
respiratoires. IL-17E (IL-25) est une cytokine nouvellement identifiée, qui 
lorsque surexprimée chez des souris, favorise l'apparition d'un phénotype 
similaire à l'asthme humain, tels que l'augmentation de l'expression de l'lL-4, 
l'IL-5 et l'IL-13, une hyperreactivitée bronchique, une augmentation des IgE, 
une éosininophilie, une hypertrophie/hyperplasie de l'épithélium, ainsi qu'une 
sécretion excessive de mucus. L'IL-17E se lie au récepteur à l'IL-17B (IL-
17BR), avec une affinité plus grande que l'lL-17B. Ce récepteur est exprimé 
par plusieurs type de tissus humains, notamment la trachée et les poumons, de 
plus, il est surrégulé dans un milieu inflammatoire. Nous avons investigué 
l'expression de ce récepteur par des cellules structurales des voies aériennes et 
des poumons, ainsi que l'effet de l'lL-17E sur ces cellules. L'expression de 
l'IL-17BR a été testée sur des cellules musculaires lisses des voies aériennes 
(ASMC), et sur des cellules épithéliales et fibroblastes pulmonaires. Nous 
avons aUSSI évalué l'effet de cytokines proinflamamtoires sur son niveau 
d'expression. Des trois types cellulaires testés, tous expriment constitutivement 
le transcript et la protéine de ce récepteur. De plus, son niveau est augmenté par 
la cytokine proinflammatoire TNF u. Au contraire, la cytokine de type Th 1, 
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IFNy, sousrégule IL-17BR chez les ASMC, et le TGF~ fait de même chez les 
fibroblastes. Nous avons noté que l'IL-17E avait des propriétés inflammatoires 
et de remodelage. Chez les ASMC, elle induit l'expression du collagène de type 
1 au niveau de l'ARNm, une composante importante de la matrice 
extracellulaire. L'IL-17E surrégule les ARNm codant pour des cytokines pro-
inflammatoires et pro-éosinophiliques tels l'éotaxine, RANTES, l'IL-8 et le 
GM -CSF dans des fibroblastes pulmonaires. Chez ces mêmes cellules, l' IL-17E 
crée une synergie en combinaison avec le TNFa, causant ainsi une forte 
augmentation de la relâche de GM-CSF. Nous notons aussi une synergie avec le 
TNFa dans l'expression de la chimiokine pro-neutrophilique GROa dans une 
lignée cellulaire épithéliale des poumons (A549). De plus, l'IL-17E semble 
promouvoir la prolifération de cellules épithéliales bronchiques isolées à patir 
de biopsies obtenues de donneurs contrôles et d'asthmatiques légers. Dans leur 
ensemble, nos résultats démontrent donc l'expression constitutive d'un 
récepteur pour la cytokine de type Th2, IL-17E, dans trois types de cellules 
structurales des poumons. Le niveau d'expression de ce récepteur est aussi 
augmenté par le TNFa. Nos résultats suggèrent aussi un rôle pro-inflammatoire 
et de remodelage potentiel pour l'IL-17E. 
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Chapter 1 - Introduction - Literature Review 
1.1 Asthma history 
The first description of asthma goes back to Greek antiquity. Asthma is derived from 
the Greek verb aazein, which means to exhale with an open mouth, to pant, to gasp 1. The 
first written account of this word was found in the Iliad written by Homer 2700 years 
ago. It is likely that it was then used to describe breathing symptoms rather than a disease 
in itself. British physician and asthma sufferer Sir John Floyer (1649-1734) also provided 
a detailed account of asthma symptoms, treatment and prevention in his Treatise of 
Asthma of 1698. He had also noted that there were several factors exacerbating asthma 
symptoms such as cold air, exercise and stress. It was only during the 19th century that 
the British physician Henry Hide Salter (1823-1871) described this condition in On 
Asthma: ils Pathology and Treatment published in 1868. He was the first to give a 
definition of asthma to the medical community, describing it as a: "paroxysmal dyspnoea 
of a peculiar character, generally periodic wilh intervals of healthy respiration between 
the attacks" 2. Interestingly, he discovered that strong black coffee could alleviate asthma 
symptoms, which later on lead to the discovery of theophylline, a molecule with 
bronchodilating activity and a similar chemical structure to caffeine. 
1.2 Asthma prevalence 
Despite our increasing understanding of this disease and efficacious treatment options, 
the number of reported cases of asthma in the last two to three decades has increased 
worldwide, especially in children. Currently about 2.5-3 million Canadians have a 
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diagnosis of asthma (8% in adults and 12% in children) and its prevalence it increasing 
(Fig 1). The general trend is of increased deaths and hospitalizations from the disease in 
all the industrialized countries of the world. Although genetic risk factors have been 
identified 3,4 and asthma certainly has a hereditary component 5-9, mutations and 
modifications of human genes that would increase susceptibility are likely to take more 
than 20-30 years to occur. Life style and environmental factors are now thought to be 
very important in the recent increased prevalence of asthma; indeed urbanization and 
pollution have been linked to increases in asthma cases worldwide 10,11. The Hygiene 
hypothesis has been proposed as an explanation for the rising cases of asthma in 
developed countries. This hypothesis suggests that the increased prevalence is caused by 
use of antibiotics, vaccination and improved hygiene 7,12. 
fil No symptoms/medication during the last 12 months 
o Symptoms/medication during the last 12 months 
12.0~--------------------------------------------------~ 
9.0 ................................. . 
6.0 ....... . 
3.0 ....... . 
94 -96 -98 -00 
Women 
94 -96 -98 -00 
Men 
94 -96 -98 -00 
Women&Men 
Source: Centre de prévention et de contrôle des maladies chroniques, Santé Canada, d'après les 
données de l'Enquête nationale sur la santé de la population, Statistique Canada. 
Fig 1. Prevalence of asthma in adults (12 years old +) from 1994 to 2000 in Canada 
(http://www.phac-aspc.gc.ca/ccdpc-cpcmc/crd-mrc/facts_asthma_f.html). 
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1.3 Asthma definition 
Asthma is a complex disease because of its mutlifactorial etiology . Allergic (atopic) 
and non-allergic (non-atopic) asthma have been described 13. Atopic asthma, also refered 
to as extrinsic asthma, is characterized by elevated levels of circulating IgE and positive 
skin tests to common allergens such as pollen, dander, house dust mite, cockroach 
antigen, etc. In non-atopic asthma, also referred to as intrinsic asthma, individuals show a 
negative skin test and have normal levels of IgE. Non-atopic asthma usually develops 
later in life with more severe symptoms. 
On the who le, asthma is a chronic disorder of the airways characterized by reversible 
airflow obstruction, airway inflammation and airway hyperresponsiveness (AHR). The 
combination of airway inflammation and tightening of the airway smooth muscle 
(bronchoconstriction) results in narrowing of the bronchi leading to the classical 
symptoms of expiratory wheeze, chest tightness, shortness of breath and cough. These 
symptoms are usually reversible either spontaneously or with treatment. A variety of 
environmental risk factors as weIl genetic predispositions combine to promote the 
development of the disease 14. Several single nucleotide polymorphisms (SNPs) have 
been associated with asthma or asthma-associated traits such as hyperresponsiveness or 
atopy 15. Asthma affects approximately 8% of the adult population and up to 20% of 
children in North America, Europe and Australia 16. The severity of the disease is highly 
variable among asthmatics ranging from mild disease with infrequent symptoms to severe 
debilitating disease with daily symptoms and daily requirements for oral corticosteroid 
therapy. Severe asthmatics comprise 10% or less of the asthmatic population, but are 
responsible for a disproportionately high fraction of the health care budget. The impact of 
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severe disease or poorly controlled disease on the individual' s quality of life is enonnous 
with high rates of absenteeism from school or work. Asthma can also be fatal and 
Canadian statistics show that approximately 20 children and 500 adults die each year in 
this country from asthma (10 deaths per week). However, with adequate treatment most 
of these deaths can be prevented. 
1.3.1 Reversible airjlow obstruction 
Airflow limitation in asthma is initially completely reversible. Airflow obstruction is 
responsible for recurrent episodes of wheeze, breathlessness, che st tightness and 
coughing. Spirometry (spirometry is a pulmonary function test that measures the volume of 
air inspired or expired as a function of time) provides an objective assessment of airflow 
limitation and is important in staging asthma severity. Classic spirometry measures the 
maximal expired volume during a forced expiration. During asthma exacerbation or once 
chronic airflow limitation is insaIled, the forced expiratory volume in 1 second (FEV1) is 
usually decreased, FEV measures the amount of air a person can exhale during a forced 
breath. The forced vital capacity (FVC), which is the total amount of air exhaled during 
the FEV test, is generally nonnal and therefore the FEVIIFVC ratio is decreased, 
consistent with airflow obstruction. FEVI is considered a central measure for classifying 
asthma severity and correlates weIl with airway diameter. In fact, it gives more 
infonnation about disease status than physical examination or symptoms reported by the 
patient. The elevated expression of certain genes in asthmatics also correlate with lower 
FEVI values, such IL-5 17 and its receptor 18, a disintegrin and metalloproteinase domain 
(ADAM) 33 or the GM-CSF receptor 19. 
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Reversible airflow obstruction is demonstrated by a reduced FEVI value (relative to 
the predicted value for the subject's height, age, weight and gender), which reverses 
following use the administration of an inhaled (32 agonist (bronchodilator). An increase in 
FEVI of ~12% following the administration of an inhaled (32 agoni st is required to 
demonstrate reversibility. However in sorne individuals with asthma, airflow obstruction 
is only partially reversible and indeed with further disease progression, may bec orne 
irreversible and is associated with permanent structural changes in the airways known as 
airway remodelling. Patients with severe airflow obstruction may need a short course of 
oral steroid therapy before they can demonstrate reversibility. In sorne cases a diagnosis 
of asthma may still be suspected even when spirometry results are normal as the nature of 
airflow limitation in patients is often periodic and variable, and FEVI values can thus be 
normal at the time it is measured. In such cases, the diagnosis may be established by peak 
flow measurements or by bronchial provocation. Peak expiratory flow rates (PEFRs) are 
generally measured and recorded by patients themselves as an indication of asthma 
control or to demonstrate reversibility of airflow obstruction. 
1.3.2 Airway hyperresponsiveness (AHR) 
Asthmatic subjects have hyperresponsive airways, meaning that their bronchi react too 
quickly and too forcefully to a given stimulus. Bronchoprovocation is a diagnostic test 
used to assess hyperreactivity of the airways. A bronchoconstrictor (histamine or 
methacholine) is aerosolized into the airways at incremental concentrations. A diagnosis 
of asthma is made if the FEVI drops by at least 20% from baseline following an inhaled 
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dose of bronchoconstrictor. The dose required to cause a 20% or more fall in FEVI is 
known as the PC20 (provocative concentration 20%). 
The exercise challenge test is another common bronchoprovocation test, which is used 
to establish a diagnosis in subjects whose asthma, is predominantly triggered by exercise 
but who have normal resting spirometry. The patient performs spirometry and then 
exercises, usually on a treadmill or exercise cycle. After the patient exercises, spirometry 
is repeated. This may be done several times, immediately after exercise and periodically, 
until there is a drop in the FEVI greater than 20% or until30 minutes have elapsed. 
1.3.3 Inflammation 
Airway inflammation correlates with the development of airway hyperesponsiveness 
(AHR) and airflow limitation. T cells and eosinophils play a primordial role in the ons et 
and maintenance of airway inflammation. Eosinophilic inflammation has long been 
considered a hallmark of asthma 20,21. However, infiltration of neutrophils into the 
airways has recently been considered to be a potential contributor to the inflammation 
present in the disease. lndeed neutrophilic inflammation in the airway has been 
demonstrated in several studies during exacerbations of asthma and in status asthmaticus 
22-26. Status asthmaticus is an intense and prolonged asthma attack that is unresponsive to 
normal bronchodilating treatment and often requires hospitalization. It has been 
suggested that the phenotype of 'severe asthma' comprises at least two different and 
distinct pathologic subtypes based on the level of eosinophils in the bronchoalveolar 
lavage (BAL) fluid. The subtype with eosinophil predominance is associated with 
increased basement membrane thickening compared to the other subtype that has little to 
no eosinophils compared to mild and moderate asthmatics25 • Physiologically, however, 
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the two subtypes of severe asthmatics behave similarly, although the eosinophil negative 
group showed a slightly lower FEVl 25. lncreased numbers ofneutrophils have also been 
reported in the BAL, endobronchial and transbronchial biopsy specimens of subjects with 
refractory asthma 25,26 compared with those with milder disease, indicating that there is 
ongoing inflammation in the airways of severe asthmatics with poor airway function 
despite very high doses of oral and inhaled steroids 27. Neutrophil numbers are similar in 
the two subgroups of severe asthma 25. 
1.4 Asthma pathogenesis 
Asthma can be described in macroscopic and microscopic terms. Morphologically, the 
lungs of individuals that have died of asthma are hyperinflated due to blockage of the 
small airways, formation of mucus plugs and thickening of the airway wall. At the 
cellular or microscopic level, the most notable changes are epithelial desquamation, 
enlargement of the smooth muscle mass area, thickening of the subepitheliallayer due to 
enhanced matrix deposition, increased numbers of fibroblasts, and infiltration of 
inflammatory cells, notably T lymphocytes and eosinophils 28. 
Clinically, the pathogenesis of asthma is characterized with increased airway 
hyperresponsiveness (AHR) and airflow obstruction, this IS manifested through 
symptoms of wheezing, breathlessness and coughing. lndividuals with asthma have 
hyperresponsive airways that narrow or constrict too much in response to a nonspecific 
stimulus. It is thought that several factors are involved in the development of AHR, 
although it is still unclear as to what causes this, though it has been shown that the degree 
of airway inflammation correlates with AHR 29. However, there is sorne debate about 
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that, sorne studies show that the degree of airway inflammation (number of inflammatory 
ceIls, especially eosinophils) does not match the severity of the disease as assessed by 
FEV1 and ARR measurements 30. Furthermore, an anti-IL-5 monoclonal antibody (mAb) 
treatment of asthmatic patients reduced blood and sputum eosinophil numbers without 
affecting their ARR 31. Interestingly, patients with eosinophilic bronchitis develop an 
eosinophil-dominated airway inflammation, yet show no evidence of asthma symptoms 
(ARR) 32. Genetic factors might also explain sorne differences between control and 
asthmatic airways, where the asthmatic smooth muscle (ASM) has a different intrinsic 
phenotype, with increased contractility and force generated compared to non-asthmatic 
ASM. Indeed, single smooth muscle cells taken from asthmatic biopsies were shown 
individually to contract more quickly and contain a greater amount myosin light chain 
kinase, a prote in associated with the contractile apparatus 33, but this is not always the 
case 34,35. Moreover, smooth muscle from asthmatics have increased force generation 
more force per cross-sectional area compared to from non-asthmatics, in addition to 
greater shortening 36. 
The inflammatory nature of asthma has been recognized for almost a century 37. 
Tissues obtained from autopsies as weIl as bronchocospic biopsies consistently 
demonstrated airway mucosal inflammation in asthmatics. The existing view is that 
inflammation leads to alteration of the structural components of the airways 38,39. On the 
other hand, there is the possibility that inflammation and structural changes are events 
that occur in parallei rather than sequentially 30,38. In lung transplantation, asthma and 
ARR can be transferred to a normal recipient receiving the lungs of a donor that had mild 
asthma, however, asthmatic recipients of non-asthmatic lungs do not develop the disease 
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40. Disease developed in recipients of "asthmatic lungs", despite being treated with the 
potent immunosuppressant cyclosporin and oral corticosteroids. 
Another pathological observation in asthma is the apparent evidence of epithelial damage 
and fragility 41 this may explain the increased shedding of epithelial cells found in sputum 
and BAL samples 42,43. Although epithelial fragility and abnormal expression of 
proliferation markers might be authentic observations 44,45, epithelial desquamation has 
been debated as an artifact of tissue manipulation 46,47. Mucus hypersecretion is 
characteristic of asthma pathology (Fig. 2) and is produced by goblet cells that are part of 
the airway epithelium as weIl as by submucosal glands. Excessive mucus secretions that 
completely plug the airways have been found post-mortem in individuals who died of 
asthma. In asthma of varying severity, the number mucus secreting ceIls are increased, 
goblet ceIls undergo hyperplasia and submucosal mucous glands show signs of 
hypertrophy 46,48-50. 
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Normal bronchiole Asthmatic bronchiole 
Fig 2. Schematic representation of a normal versus an asthmatic bronchiole. The airway 
smooth muscle excessively contracts, thus contracting the asthmatic bronchiole. The 
thickened airway wall and excessive mucus, contribute to narrowing of the lumen and 
airflow limitation ( www.nlm.nih.gov/medlineplus/ency/imagepages/19346.htm ). 
As mentioned earlier, it is thought that asthmatic airways that are subjected to chronic 
and prolonged inflammation can develop structural changes in the airway wall that can 
eventually become with time, irreversible 51. Theses changes are jointly referred to as 
airway remodelling 51. Remodelling is thought to arise from the interaction of infiltrated 
inflammatory cells with structural cells, principally through the action of cytokines. 
Possibly, the remodelling of tissues in the airways is an attempt by structural cells to 
repair damage caused by the local inflammation 52 39. In addition to what happens to the 
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epithelium, the structural changes that take place involve the thickening of the airway 
wall. This is due to an increase in smooth muscle mass, increased number of 
fibroblasts/myofibroblasts, deposition of extracellular matrix in the basement membrane 
and increased vascularization 39. This thickening, in addition to increased mucus, leads to 
a narrowing of the lumen diameter and causes restricted airflow. Severe asthmatics that 
suffer from persistent airflow limitation show greater airway wall thickening than those 
that have no airflow obstruction 53. 
1.5 Inflammatory cells in asthma 
It is weIl known that there is an influx of inflammatory cells in asthmatics airways; 
this is observed in biopsy samples from humans and also in mice models of allergic 
airway inflammation. These cells infiltrate the mucosa and come into contact with aIl the 
structural cells that compose the airways. Several different leukocyte populations 
infiltrate the airway tissue; indeed, depending on disease severity and individuals, ma st 
cells, macrophages and neutrophils can infiltrate the airway wall. However, CD4+ T 
helper 2 (Th2) lymphocytes, eosinophils and mast cells are the predominant cell types 
found in asthmatic airways. They are considered the central effector cells of this disease. 
These cells produce many different inflammatory cytokines, and express adhesion 
molecules, which initiate and maintain local airway inflammation in the airways. 
1.5.1 CD4+ T ceUs 
CD4+ T helper cells coordinate inflammation by producing several type of mediators. 
The concept of a T helper 1 (Th l) or T helper 2 (Th2) immune response originates from 
findings published two decades ago in a landmark paper that identified two subtypes of 
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mouse T helper cells 54. Thl or Th2 cells are identified by the profile of cytokine they 
secrete, moreover, these T cell subsets promote different types of immune responses. Thl 
cells produce IFNy, IL-2, IL-12 and IL-18; these are necessary for cell-mediated 
immunity and protection against intracellular pathogens. A Th2 response is necessary for 
antibody-mediated immunity against extracellular pathogens such as parasites. Th2 cells 
secrete preferentially IL-4, IL-5 and IL-13 55. These cytokines are known to promote 
mucus production IgE class switch and eosinophilia. 
The importance of the Th2 lymphocyte for the development of airway 
hyperresponsiveness, mucus production and eosinophilia was demonstrated using animal 
models of allergic airway disease 56,57. Mucus hypersecretion and eosinophilia is 
observed after allergen challenge, in mice receiving ovalbumin-specific Th2 but not Thl 
cells 58. In fact, Thl cells inhibit these events 59. Mucus secretion is still inducible by IL-4 
-/- and IL-5-/- Th2 cells to the same extent as regular Th2 cells, but absolutely requires 
the presence of IL-4Ra 60. IL-13 necessitates IL-4Ra for its signaling and has been 
shown to be critical for mucus production 61. While mucus hypersecretion and 
eosinophilia are triggered only by Th2 cells transfer, both Thl and Th2 can drive airway 
inflammation and AHR 62. 
1.5.2 Eosinophils 
Eosinophils, first named by Paul Erlich in 1879 because of intense eosin staining, are 
bilobar-nucleated cells that contain distinctive granules in their cytoplasm. The content of 
these granules are released upon cell activation or during cell necrosis. These granules are 
packed with highly basic and cytotoxic proteins, and also contain enzymes destined to 
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inflict oxidative damage to their targets. Eosinophils have long been attributed a central 
function in the pathogenesis of asthma because of their role in airway inflammation and 
remodelling. The presence of these in asthmatics was established early on, in 1860 the 
British physician Henry Salter identified binucleated cells in the sputum of his asthmatic 
patients, these were later identified to be eosinophils. Eighty-two years later, Huber and 
Kossler reported that individuals who had died of asthma had eosinophilic infiltration 37. 
The relevance of this cell in allergic airway disease has been assessed by two groups that 
generated mice devoid of eosinophils, however their findings diverge 63,64. In one type of 
eosinophil-deficient mi ce, Humbles et al. showed that allergen challenge still induced 
mucus hypersecretion and airway hyperesponsiveness, however these mice exhibited 
lesser changes associated with airway remodelling 63. Notably, after allergen challenge 
they showed less subepithelial thickening, collagen deposition, fewer proliferative ASM 
cells and a lower total ASM cell count than wild-type mice 63. Interestingly, eosinophil-
negative severe asthmatics showed much less subbasement membrane thickness than 
eosinohpil-positive asthmatics 25. These findings by Humbles et al. also concord with 
observations made in both mice and men where IL-5 was targeted. IL-5 is a crucial 
cytokine needed for eosinophil growth and differentiation. Mice which were either IL-5 
deficient or treated with an anti-IL-5 antibody to deplete eosinophils 65,66, and asthmatics 
subjects were intravenously infused with a humanized anti-IL-5 monoclonal antibody 
31,67. The mice showed a reduction in subepithelial fibrosis 65,66 and smooth muscle mass 
thickness 66. The asthmatic patients showed a decrease in the deposition of certain ECM 
proteins in the subepithelial membrane 67 but no improvement in airway 
hyperesponsiveness or FEVI 31. It is important to mention that in these patients, there 
26 
was a significant number of eosinophils remaining in the bronchial tissue even after 3 
months of treatment with the anti-IL-5 mAb 31. In contrast to these findings, the second 
type of eosinophil-deficient mice developed significantly less mucus production/goblet 
cell metaplasia and AHR after allergen challenge 64. Comparable results were obtained in 
other animal models targeting IL-5, in that they did not develop AHR following 
challenge 68,69 and were protected against airway remodelling 68. In asthma, the 
eosinophil could also serve as an antigen-presenting cell 70 as it can directly interact with 
Th2 lymphocytes to promote their expansion and the release of IL-4, IL-5 and IL-13 
through the costimulatory molecules CD80 (B7.1) and CD86 (B7.2) 71,72. 
1.5.3 Neutrophils 
Neutrophils are also known as polymorphonucleated leukocytes because of their 
segmented nucleus that contains 3-5 connected lobules. They are the most abundant of 
circulating white blood cells, and they are the first responders in the early phases of an 
inflammatory response. They have a granule-filled cytoplasm and these granules do not 
stain for hematoxylin or eosin, thus differentiating them from basophils and eosinophils. 
The neutrophils granules contain degradative enzymes (lysozyme, elastase and 
collagenase). These cells are equipped to destroy pathogens, but can also damage 
surrounding host tissue. Their role in asthma is not clearly understood, though as was 
discussed earlier in section 1.3.3, it is suggested that there are two subsets of asthma, one 
having a predominance of eosinophils, and the other neutrophils 73. Although there is a 
preponderance of literature exposing the presence of eosinophils in asthmatic bronchial 
tissue, several studies have shown the presence of increased neutrophils in the airway 
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mucosa, BAL and sputum of severe asthmatics or those undergoing asthma exacerbations 
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pulmonary disease (COPD) patients 75,76. 
1.5.4 Mast ceUs 
Aiso discovered by Paul Erlich, mast cells have unsegmented oval-shaped nuclei and 
contain several cytoplasmic granules. They also show characteristic thin protuberances of 
their plasma membrane. Mast cell precursors migrate from the bone marrow to various 
tissues su ch as the skin and airways. They participate in the innate and adaptive immune 
responses. Two types of mast cells exist, those that produce tryptase only (MCT) and 
those that make tryptase, chymase, carboxylpeptidase and cathepsin G (MeTe). Mast 
cells express the high affinity immunoglobulin E receptor (FceRI), cross-linking ofbound 
IgE by antigen induces a series of complex intracellular signaling events that activatess 
the mastocyte, and are thought to promote the release of granule content (eg.: histamine), 
cytokine gene expression (eg.: TNFa, IL-6, IL-B, IL-17E) and the production of lipid 
mediators (eg.: prostaglandin D2, leukotriene C4) 77-80. 
In asthma, a greater number of mast cells are detected within the airway smooth 
muscle, in bronchial epithelial brushings and in BAL fluid 81-83. However sorne have 
failed to see a difference in mast cells numbers in bronchial biopsies between asthmatics 
and controls 84,85. 
1.5.5 Basophils 
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Erlich first described this cell type as one that presented with cell structures stained by 
basic dyes such as hematoxylin. Like mast cells, basophils carry the FceRI and release 
histamine, however unlike mastocytes, which are found in tissue, they are almost solely 
present in peripheral blood and account for about 1 % of circulating leukocytes. Basophils 
can infiltrate tissue at sites of inflammation. They are found in higher number in 
asthmatic airway mucosal tissue than in non-asthmatics, and increase after allergen 
challenge 86-88. Moreover, these tissue-inflitrated basophils express IL-4 mRNA 87. 
J. 5. 6 Monocytes/Macrophages 
Macrophages and their blood precursors, monocytes, serve critical roles in ho st defense. 
They are an integral component of the innate immunity and are active during adaptive 
immunity. There are several types of lung tissue resident macrophages present in health; 
including peritoneal, pleural and alveolar macrophages, while, monocytes can be 
recruited to sites of inflammation. Sorne have reported an increase in macrophage 
infiltration in the bronchial mucosa of asthmatics compared to controls 89,90. Macrophages 
in asthma are apparently more activated and show less apoptosis 91,92. This cell type is 
particularly associated with other airway diseases such as COPD 75,76. 
1.6 Cytokines in asthma 
J.6. J Th2 cytokines 
Certain diseases are characterized as being either Thl- or Th2-dominant based on the 
type of cytokines observed in the tissues and/or biological fluids. Asthma is considered a 
Th2-type inflammatory disease because the levels ofthe Th2 cytokines IL-4, IL-5 and IL-
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13 in the bronchial mucosa, blood, bronchoalveolar lavage (BAL) fluid and sputum of 
asthmatic patients are often increased 18,93-104. Interestingly, these interleukins (eg.: IL-4, 
IL-5, IL-13) along with other genes (eg.: GM-CSF) coding for cytokines that may be 
important in asthma pathogenesis are located on chromosome 5q. CD4+ Th2 
lymphocytes are thought to be the principal source ofthese cytokines in asthma 96,100. 
Cytokine 
Th2 type 
IL-4 
IL-S 
IL-13 
Th1 type 
IFNy 
Proinflammatory 
TNFa 
IL-1~ 
Chemokines 
IL-8 
RANTES 
Eolaxin 
Others 
IL-11 
GM-CSF 
TGF~ 
IL-6 
Main function 
Th2 ceU differentiation, IgE synthesis 
eosinophil maturation 
eosinophil and mast ceU activation, IgE synthesis 
inhibits IgE synthesis and IgE receptor expression 
induces expression of cytokines, and adhesion molecules 
induces expression of cytokines, and adhesion molecules 
chemoaltraclant for neutrophils 
chemoaltractant for eosinophils 
chemoaltraclant for eosinophils 
pro-fibrotic 
supports eosinophil survival 
pro-fibrotic 
Band T ceU activation, enhance Th2 proliferation 
Table 1. List of sorne cytokines involved in asthma pathogenesis 
Status in asthma 
increased 
increased 
increased 
decreased, neutral or increased 
increased 
increased 
increased 
increased 
increased 
increased 
increased 
increased 
increased 
Most IL-4 cornes from CD4+ as weIl as CD8+ T ceIls, but is also found in eosinophils 
105,106, mast ceIls 106,107 and basophils. PrincipaIly, it targets T ceIls to promote Th2 
differentiation and B ceIls to induce IgE antibody production. Although T cells are 
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though to be the principal source of IL-4 in asthma 98, it also found in smooth muscle-
infiltrated ma st cells 79. Inhalation of IL-4 by patients with mild asthma results in an 
increase in AHR and eosinophil influx 108. 
Much like IL-4, CD4+, CD8+ T cens, eosinophils and mast cens secrete IL-5 106;, 
airway epithelial cens can also be a source of this cytokine 109. IL-5 is thought to be one 
of the most important mediators responsible for the eosinophilia observed in asthmatics 
110,111. Its level correlates with the number of eosinophils in the bronchial mucosa of 
asthmatics 94. Human trials using an anti-IL-5 mAb show a marked decrease in blood and 
. h'l 31 sputum eosmop 1 s . 
IL-13 cornes in large part from CD4+ Th2 lymphocytes but has been detected in mast 
cens, basophils and eosinophils. It targets B cens as well as endothelial cens to induce 
vascular cen adhesion molecule (VCAM)-1 expression, and epithelial cens and 
fibroblasts to promote mucus secretion and eotaxin release, respectively. Akin to what 
was mentioned about IL-4, while IL-13 is largely detected in T cens in asthma 98, it also 
found in smooth muscle-infiltrated mast cells 79. 
J. 7.2 ThJ cytokines 
While the majority of studies find elevated Th2-type cytokines in asthmatics, findings 
are not as consistent regarding levels ofThl type cytokines in asthma. Sorne suggest that 
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asthma is driven by a mixed Th lITh2 response as the levels of typical Th 1 cytokines can 
even be increased in asthmatics and have deleterious effects on asthma-like symptoms in 
murine models 112. Nevertheless, several studies point to the inhibitory potential of Thl 
cytokines on asthma-like features in mice models of allergic airway inflammation 113,114 
and find them downregulated in asthmatic airways 99,115. 
IFNy 
IFNy is primarily secreted by Th 1 cells and natural killer (NK) cells. IFNy inhibits IgE 
isotype switching and antagonizes IL-4-mediated expression of low affinity IgE 
receptors. It also increases the production of IL-l2, another key Thl cytokine. Increased 
IFNy in asthmatic airways might come from a viral infection, which not only exacerbate 
asthma, but also enhance IFNy production 116. On the other hand, decreased IFNy is 
possibly the result of preferential apoptosis of IFNy-producing T cells compared to IL-4-
producing ones 117. The role of IFNy in asthma pathogenesis is likely to be a complex 
one; as reflected by the observation that in asthmatics, the levels of this prototypical Th 1 
cytokine can be either unchanged 103,1l8, upregulated I03,1l9,120 or downregulated 102,121 115. 
It might, however, be beneficial to asthma pathogenesis in humans; a 3-week treatment of 
mild asthmatics with nebulized recombinant IFNy reduced the amount of airway 
eosinophils in the BAL (in 4 out of 6 patients) without promoting the influx of other 
inflammatory cells 122. In mice models of acute airway inflammation, mixed results have 
been observed. A number of studies show that IFNy-producing T cells can inhibit 
allergen-induced eosinophilia, mucus production and AHR 59,123,124 or conversely, 
enhance airway inflammation and AHR 121,125,126. 
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1.6.3 Proinjlammatory cytokines 
TNFa and IL-I B 
As asthma is an inflammatory disease, it is also characterized by increased levels of 
proinflammatory cytokines like TNFa and IL-l~ 127-129 that correlate with disease 
severity130. The primary source of TNFa are macrophages, but mast ceIls, eosinophils, 
neutrophils, T ceIls and structural ceIls also secrete it. TNFa is upregulated in the BAL of 
asthmatics who are chaIlenged with aIlergen and correlates with an increase in their 
bronchial hyperresponsiveness 131,132. TNFa acts by inducing the production of many 
cytokines, chemokines and adhesion molecules that serve to attract, activate and enhance 
the survival of leukocytes. Indeed, healthy and mild asthmatics that inhaled recombinant 
TNF a showed increased bronchial hyperresponsiveness and increased eosinophils and 
neutrophils in the sPutum 133,134. Treating severe asthmatic patients with a recombinant 
soluble TNF receptor (etanercept) significantly improved their symptoms, FEVI and 
PC20 values 130,135. 
1.6.4 Chemokines 
Chemokines are a subgroup of the larger cytokine family. They are smaIl (8-12 kDa) 
secreted proteins with chemotactic properties primarily for leukocytes. Hematopoietic 
ceIls are the source for most chemokines, although they are now being identified in 
structural cells both in vivo and in vitro. The 40+ chemokines identified so far faIl into 
four main groups based on the position of conserved cysteine residues. However, the 
majority belong to the CC or CXC c1ass of chemokines. The CC chemokines have two 
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adjacent cysteines and are involved in the chemotaxis of eosinophils and monocytes. The 
CXC chemokines share two cysteines separated by a single amino acid (X), and this 
group contains members that attract neutrophils and lymphocytes. Chemokines serve 
other roles besides chemoattraction: they have been shown to have angiogenic or 
angiostatic effects, can promote degranulation of leukocytes and mediator release. 
IL-8 (CXCL8) 
IL-8 is a member of the CXC chemokine family and is an important chemotattractant 
for neutrophils. It is produced by macrophages, eosinophils, lymphocytes as weIl as 
neutrophils themselves 136,137. In addition, IL-8 is also detected in macrophages, epithelial 
and airway smooth muscle cells from asthmatic bronchial biopsies 138,139. IL-8 is though 
to be a marker of asthma severity, as it is especially elevated in severe asthmatics and not 
in mild asthmatics I38. In patients with acute asthma exacerbation, neutrophils are 
predominantly detected and this parallels high IL-8 levels in sputum 22. 
RANTES (CCL5) 
Regulated upon activation, normal T cells expressed and secreted (RANTES), a 
member of the CC chemokine family, is chemotactic for eosinophils, T cells as weIl as 
monocytes 140-142. Originally identified in T cells 143, fibroblasts, bronchial epithelial cells 
and smooth muscle cells express this chemokine in bronchial biopsies 138,144,145. Several 
reports show that in asthmatics, RANTES prote in is increased in BAL 146 as weIl as 
RANTES mRNA in bronchial mucosa 145,147. However, one report notes no difference in 
RANTES mRNA in the BAL or RANTES prote in expression in bronchial biopsies from 
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non-asthmatic and asthmatic subjects, but shows an increase in RANTES mRNA in 
bronchial biopsies from asthmatics 144. 
Eotaxin (CCLII) 
Eotaxin is a CC chemokine involved in the recruitment of eosinophils from 
the circulation into the tissues 148. Its expression is increased in the asthmatic bronchial 
mucosa 145 and BAL and correlates with disease severity 138. It is expressed by the 
bronchial epithelium as weIl as by airway smooth muscle and infiltrated macrophages 
138,145,149 
1.6.5 Other cytokines 
IL-Il 
IL-Il is a member of the IL-6-like family and predominantly secreted by stromal 
cells. It is overexpressed in asthma 150,151 and is found in the epithelium and 
subepithelium as weIl as in eosinophils 151. IL-lI increases with disease severity and 
correlates inversely with FEVI 151. IL-Il is also associated with collagen 1 and III 
deposition in asthmatics 150 and promotes subepithelial fibrosis when overexpressed in 
murine airways 152-154. 
There are more than 30 members in the TGF superfamily. Within this superfamily is 
the TGFj3 family. Three isoforms have been identified in humans, 131, 132, and fB 155, 
though several studies only refer to TFGj3 without specifying the isoform. TGFj3 lS 
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released from inflammatory cells (T cells, eosinophils) and bronchial epithelial cells, 
fibroblasts and smooth muscle cells. TGFj3 is involved in the repair response through its 
action on matrix deposition and remodelling. Moreover, TGFj3-producing T cells are 
classified as a distinct subset called Th3 or Treg (T regulatory) because they have anti-
inflammatory properties. Indeed, T cells engineered to overexpress TGFj3 abolish airway 
eosinophilia and AHR in mice models 156. 
The biological activity of TGFj31 in vitro includes myofibroblasts differentiation and 
increased production of collagen molecules and other extracellular matrix proteins and 
therefore could participate in the subepithelial fibrosis and in the increase in the number 
of fibroblasts/myofibroblasts seen in asthma. TGFj3 is upregulated in the bronchial 
submucosa 150,157-159 and BAL 160 of asthmatic patients, and eosinophils appear to be the 
main source ofthis cytokine in the airways 157-159. 
GM-CSF 
In the context of asthma, granulocyte/monocyte-colony stimulating factor (GM-CSF) 
is the most studied of the three colony-stimulating factors (GM-CSF, Granulocyte-CSF 
and Monocyte-CSF). It cornes mainly from T lymphocytes and macrophages, though it 
has been shown that endothelial and epithelial cells, fibroblasts and airway smooth 
muscle cells can synthesize this growth factor in vitro and in vivo 129,161-165. One of its 
fu .. h· 1 f . h·l d h·l 166 167 I . . d nctIons IS to promote t e survlva 0 eosmop 1 s an neutrop 1 s ' . t IS mcrease 
in the BAL 96 and bronchial mucosa 147 from asthmatic airways and is higher in 
symptomatic versus non-symptomatic asthmatics 118. 
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IL-6 
IL-6 is produced by monocytes, T and B lymphocytes as weIl as by airway structural 
cells. IL-6 is viewed as a pleiotropic cytokine because of its many effects. It promotes B 
cell maturation, T cell activation and proliferation, has anti-tumor effects and can activate 
neutrophils 168-170. Moreover, it can promote Th2 polarization by inducing the initial 
production ofIL-4 in CD4+ T cells 171. IL-6 also induces several acute-phase proteins (C-
reactive protein, fibrinogen, etc) synthesis by hepatocytes and contributes to the systemic 
effects of inflammation. Its synthesis is strongly induced by IL-II) and TNFa. Its 
overexpression in airway epithelial cells in mi ce promotes lymphocytic cell influx but 
reduces AHR 172. Its expression is increased in the bronchial epithelium of asthmatics and 
in the BAL of symptomatic asthmatic individuals 128,173. 
1. 7 Airway remodelling 
As mentioned previously, airway remodelling is a concept that encompasses several 
structural changes within the asthmatic airways. These changes occur mostly in the large 
airways, although the small airways are also affected in more severe cases of asthma. 
MicroscopicaIly, these structural changes manifest themse1ves through the altered 
behavior of the structural cell types that compose the airways. In the remodeled asthmatic 
airway, the airway smooth muscle ceIls, fibroblasts, endothe1ial cells and the epithe1ium 
undergo noticeable changes due to intrinsic and/or extrinsic factors. Asthmatics have a 
thickened airway wall, and, patients with severe asthma show a greater thickening than 
those with mild asthma 174,175 and thicker airway walls (Fig. 2) enhance airway narrowing 
during bronchoprovocation. 
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The bronchial epithelium is subject to structural changes in asthma. Several studies 
have shown that the epithelium demonstrates signs of damage, inflammation (increased 
k· d') d d 1 dl'':' 4455176177 Th h cyto me pro uchon an a eregu ate pro l1erahve process ' , , . e p enomenon 
of epithelial shedding in asthma has been the subject of sorne dispute recently 47,49. There 
is also a noticeable increase in the number of mucus-producing goblet cells in the 
epithelium of asthmatics 178. Mucous glands are more prominent and enlarged in 
individuals with fatal asthma 179. The synthetic ability of epithelial cells in asthma is 
increased, the bronchial epithelium has been shown to generate more cytokines with 
proinflammatory and/or profibrotic properties as well as chemokines that attract T 
lymphocytes, eosinophils and neutrophils to the airway mucosa 144,180. 
Increased interstitial deposition of extracellular matrix proteins (ECM) such as 
collagen type II and V and fibronectin promotes the thickening of the basement 
membrane 181,182. Activated fibroblasts are likely the source of the ECM, and their 
number is increased in the subepithelial layer in asthmatic airways 183. Because the 
thickening occurs below the epithelium and involves increased production of fibrotic 
material, it is also referred to as subepithelial fibrosis. This phenomenon is often 
observed in cases of fatal asthma 184-186, but also in asthmatics with mild disease 182. 
Increase in smooth muscle cell mass and thickness is a typical structural change 
associated with remodelling 36,187 (Fig. 3). This fact was first reported in postmortem 
examination of patients that had died of asthma 37,179: their smooth muscle area was 
greatly enlarged in both the large and small airways. The increased mass is thought to 
occur primarily through hyperplasia and/or hypertrophy of the smooth muscle cells 
34,188,189 
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The increase in smooth muscle also appears to correlate with disease severity 138,188 
and a decrease in FEV! 138. The chronic inflammation associated with asthma is thought 
to be in part responsible for the initiation and perpetuation of airway remodelling or at 
least happens concomitantly to it 190. However, manifestations of tissue remodelling can 
happen independently of the presence of markers of allergic inflammation (ie: without 
concurrent eosinophilic infiltration) 191. For a long time, airways inflammation was 
primarily linked with infiltrated leukocytes, but we now know that structural cells are not 
solely passive responders to the inflammatory stimuli. Importantly, the synthetic ability 
(eg.: cytokine and chemokine production) of airway smooth muscle cells could make 
them a significant source of cytokines and chemokines in asthmatic airways 192. In vitro, 
airway smooth muscle cells have a strong synthetic and secretory potential, as they can 
produce large amounts of cytokines involved in inflammation and remodelling. While, 
most of the findings in this area have been done using cultured cells from airway biopsies 
the majority being from control, non-asthmatic individuals, they expose a new dimension 
to the functions of these cells in vivo. The details of the synthetic ability of ASMe, lung 
fibroblasts and epithelium will be discussed in later sections. 
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Fig.3. Asthmatic aIrways show evidence of inflammation and tissue remodelling. 
Characteristic changes are: increased number of mucus producing-goblet ceIls, increased 
deposition of collagen that thickens the basememt membrane, augmentation of fibroblasts 
numbers, the presence of infiltrated inflammatory cells such as eosinophils, mast cells 
and T cells as weIl as an increase in airways smooth muscle mass. 
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1.8 The Airway Smooth Muscle Cell 
1.8.1 Structure of the ASMC 
The airway smooth muscle (ASM) is an elongated cell and its cytoplasm filled with 
myofilaments. These filaments are composed of actin and myosin and are the primary 
components of the contractile apparatus 193. Cells are grouped in bundles and are 
physically attached to the extracellular matrix. ASMC are connected to each other via 
desmosomes (intermediate junctions) and by transmembrane glycoproteins (cadherins) 
that attach to the cytoskeleton. The smooth muscle bundles are innervated with 
parasympathetic nerve fibers. Immune cells such as mastocytes can be found within the 
smooth muscle layer 79,81. In the bronchus wall, the ASM encircles the airways as a 
broken circle, expect in the trachea where it is only present in the posterior wall and 
referred to as the trachealis muscle. 
1.8.2 Function of the ASMC 
The airway smooth musce1 cell is responsible for contracting the bronchi, this narrows 
the lumen and restricts airflow. In a treatise published in 1868, the British physician 
Henry Hyde Salter described many symptoms of asthma including bronchospams 2. The 
pathological role of the ASM in asthma is evident given its role in bronchoconstriction. 
In normal airways, ASM contraction and relaxation regulates the diameter of the airways 
and thus the passage of air. Recently ASMC have been shown to secrete a wide range of 
cytokines and chemokines as weIl as extracellular matrix components 194. 
1.8.3 Basis of ASM contraction 
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Smooth muscle cell contraction is regulated by intracellular calcium. An increase in 
intracellular calcium by a contractile agonist activates the contractile machinery. This 
increase can either come from intracellular stores or from outside the ceIl, brought inside 
by calcium channels. Elevation of free calcium within the cell activates the 
calciumlcalmodulin-sensitive myosin light chain kinase (MLCK); this leads to 
phosphorylation of the regulatory 20 kDa light chain of smooth muscle myosin (MLC20) 
located on the myosin head. This promotes the ATPase activity of the myosin heavy 
chain head, which can now form cross-bridges with actin filaments and induce cell 
contraction. Relaxation is induced by the MLC phosphatase that dephosphorylates the 
MLC20 and terminates cross-bridge cycling. Certain cytokines can affect the contractile 
response of smooth muscle cells and/or decrease its relaxation. TNFa can affect the 
contractility of ASM in isolated bronchial strips by enhancing the response to the 
spasmogen acetylcholine (ACh) 195. While it cannot modify calcium concentration on its 
own, TNFa increases the calcium concentration values of known contractile agonists 
such as bradikynin and carbachol 196. The Th2 cytokines IL-5 and IL-13 increase the 
contractile response to Ach and carbachol in isolated tracheas 197,198. On the other hand, 
they decrease the relaxation induced by isoprotenerol 197-200. This effect on smooth 
muscle relaxation is also seen with TNFa in isolated tracheas 201,202, but not in cultured 
human ASMC 203. 
1.8.4 Basis of ASM proliferation 
Hyperplasia of smooth muscle in asthmatic airways is one of the means by which the 
ASM content is thought to increase in asthma. An increase in cell number implies for the 
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most part an increase ln cell proliferation and/or a decrease in apoptosis. In animal 
models of airway inflammation, the ASM has been shown to be more proliferative and 
show a decrease in apoptosis 204-206. The observation of in vivo ASM proliferation in 
bronchial biopsies of asthmatics is not as clear 34,187,207. 
Most of the studies looking at the mechanisms behind hum an ASM proliferation were 
perforrned in vitro. Several growth factors, contractile agonists and lipid mediators 
directly induce an increase in ASMC division. These include growth factors such as 
platelet-derived growth factor (PDGF) isoforrns AB and BB, epiderrnal growth factor 
(EGF), insulin-like growth factor (IGF) and basic fibroblast growth factor (bFGF) 208. 
Other molecules induce ASMC proliferation, such as thrombin, tryptase, histamine, 
endothelin-l and serotonin 208-213. The lipid mediators thromboxane A2, and leukotriene 
D4 promote proliferation 214, while prostaglandin E2 (PGE2) inhibits growth; this effect is 
associated with an increase in cyclooxygenase-2 (COX-2) expression 215,216. Cytokines 
also act on ASMC division. For example, the profibrotic cytokine transforrning growth 
factor (TGF)-tH is known to induce ASMC proliferation 217,218. The effect of TNFa on 
ASMC proliferation is considered modest, though several report none to little effect 
219,220. TNFa has been shown to promote sorne ASMC proliferation 221 at low doses 220 
but has no effect at higher concentrations 220. TNFa also inhibits the effect of several 
mitogens on cell growth 220, possibly because TNFa can also induce COX-2 expression 
as well as PGE2 222-224. IL-l~, which also a positive inducer of COX-2 and PGE2 222-224, 
has a negative effect on ASM proliferation 225. Interestingly, the Thl-type cytokine IFNy 
226 and the Th2-type cytokine IL-4 227 have both been shown to inhibit mitogen-induced 
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proliferation of human ASMC. Conversely, IL-4 and IL-13 induced rat aortic smooth 
muscle cells proliferation, but this was inhibited by IFNy 228. 
1.8.5 The ASMe in the pathogenesis of asthma 
A key finding in remodeled asthmatic airways is that the ASM content is increased 
and correlates with disease severity. Indeed, Huber and Koessler first reported increase in 
ASM mass in 1922 36,37,229. They had shown airway cross-sections where the muscle 
mass was greater in cases of fatal asthma when compared to individuals that had died of 
other causes. In more recent times, Ebina et al. 189 performed a 3D morphometric study of 
airway smooth muscle in airways of fatal asthma cases and showed ASM hyperplasia. In 
nonfatal asthmatics, Woodruff et al. 34 and Benayoun et al. 187,188 measured increased 
ASM content. While Woodruff et al. 34 reported that hyperplasia and not hypertrophy 
was responsible for the increased ASM mass, Benayoun et al. 188 noted that ASMC in 
asthmatic biopsies were hypertrophied, an observation that was particularly salient in 
severe patients, but show no evidence of proliferation. The pathological effects of 
increased ASM mass could be attributed to augmenting normal muscle contraction, or 
induction of excessive and abnormal shortening in addition to taking up more space in the 
airways. The mechanisms that lead to increased ASM mass in asthmatics airways is not 
fully understood. Hyperplasia due to increased cell proliferation and/or decreased 
apoptosis is likely, but actually, only a few reports show this in vivo. Importantly, Roth et 
al. have shown that cultured airway smooth muscle cells from asthmatics proliferate 
more than cells from non-asthmatics 230. Recently, in vitro studies using human ASMC 
have shown that they can migrate when exposed to a chemotactic stimulus 208,231-233. 
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Additionally, it has been shown in a murine model that fibrocytes can infiltrate the 
airway mucosa after allergen challenge 234. These fibrocytes are CD34 and collagen 1 
positive: CD34 is a marker of hematopoeitic cells, while collagen 1 is seen in 
mesenchymal-type cells, such as fibroblasts or smooth muscle cells. Thus cell migration 
and fibrocyte influx have also been raised as other possible mechanisms that could 
participate in increased ASM mass 234. In recent times, the ASMC has been studied 
beyond its capacity as purely a contractile cell, indeed, ASMC can secrete several types 
of inflammatory mediators that are likely to participate in asthma pathogenesis 235. 
1.8.6 The ASMe as a proinjlammatory cell 
For a long time the airway smooth muscle (ASM) was considered a purely contractile 
tissue responding to various substances inducing contraction, however, our perception of 
this cell is rapidly changing 235. In the last decade new experimental evidence, 
particularly in vitro, has shown that this cell is capable of synthesizing a wide range of 
cytokines, chemokines and prostanoids as weIl as expressing receptors for many of them 
192. Airway inflammation has typically been associated with airway infiltrated T 
lymphocytes, eosinophils, neutrophils, mast cells and macrophages and the inflammatory 
mediators they release. However, many of the same mediators of inflammation can also 
be synthesized to varying degrees by ASMC, though the relative importance of ASMC-
derived cytokines in vivo is not fully known. Furthermore, in hum an airway biopsies, 
ASM have been shown to express certain cytokines and chemokines. 
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1.8.7 Cytokine and chemokine production by ASMC 
In vivo 
Reports of cultured ASMC producing chemokines and cytokines are plentiful. This 
phenomenon does not appear to be due to the effect of cell culturing, indeed, sorne papers 
have demonstrated that the smooth muscle in biopsies from human bronchial mucosa 
stain positively for several cytokines and chemokines. For example, in vivo the ASM 
express RANTES 138,144 eotaxin 138,149, IL-8 138, monocyte chemotactic family (MCP)-l 
236, as weIl as TGFj) 1 237. 
In vitro 
Cultured ASMC express many cytokines at baseline and their expression can be 
increased or decreased by a diverse array of stimuli. Hakonarson et al. 198 stimulated 
ASMC with human serum from non-atopic, non-asthmatic subjects and showed that 
expression for IL-2, GM-CSF, IFNy, IL-5 and IL-lO was detectable, although at very low 
level. However when ASMC were treated with serum from atopic asthmatics, cytokine 
mRNA levels were strongly increased for IL-2, IL-5, IL-lO, IL-12, GM-CSF and IFNy. 
IL-5 and IFNy prote in were also increased by atopic asthmatic serum. IL-5 protein could 
also be released by stimulation with IL-Ij), IL-lO, IL-13 or IgE 197,198. IL-4 mRNA is 
undetected in ASMC in several experimental conditions 197,198, although it detected the 
supematant after IgE treatment 238. Human ASMC also synthesize IL-13, which is 
expressed at baseline and readily upregulated by IgE 197,238. 
Proinflammatory cytokines such as TNF a and IL-I j) are known to promote the 
synthesis ofmany cytokines/chemokines. For example, they stimulate the release ofIL-6, 
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IL-8, GM-CSF and RANTES in ASMC. Moreover, IL-17A induces IL-6 and IL-8 and is 
synergistic when added to TNFa 164,239. IL-I~ and TGF~1 can increase IL-Il production, 
while combining TNFa+IL-I~ also induces IL-I~ and IL-6 mRNA. AS MC also secrete 
TGF~ that can act in an autocrine fashion on collagen 1 synthesis 240. 
ASMC release several types of chemokines. In asthma, sorne chemokines are 
increased, such as eotaxin, thymus- and activation-regulated chemokines (T ARC), 
regulated upon activation T cell expressed and secreted (RANTES), IL-8, and the 
monocyte chemotactic protein (MCP) family 144. These chemokines are also produced by 
cultured ASMC 149,225,241-244. Eotaxin, a ligand for CCR3, has received particular attention 
because it is one of the most important eosinophil chemoattractant. In ASMC, production 
of eotaxin is increased by oncostatin M (OSM) 243, IL-4 and IL-13 245, by TNFa, IL-
l~ 149 and IgE 238. IL-9 has a positive effect on eotaxin release: Gounni et al. reported 
that IL-9 alone was enough to induce eotaxin release 246, while others have shown that 
IL-9 had no effect on its own but could enhance IL-l3-mediated eotaxin secretion 247. 
RANTES, another eosinophil chemoattractant, is also increased in ASMC by TNFa and 
IL-l~, but not by IFNy. However the combination of TNFa and IFNy provided a 
synergistic effect on RANTES secretion from AS MC 241,248. ASMC also produce 
significant amounts of TARC, it selectively promotes Th2 lymphocyte migration by 
binding to CCR4, which is primarily expressed by Th2 cells and not found on Thl cells. 
Although little TARC is present at baseline and further stimulation with IL-4, IL-13, 
TNFa or IFNy does not stimulate its release from ASMC, it is grealy induced in cells 
treated with TNFa in combination with either IL-4 or IL_13244• IL-8 is probably the most 
potent chemotactic mediator for neutrophils and can act on eosinophil chemotaxix 
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through the endothelium and epithelium 249. IL-If3 and TNFa are potent inducers ofIL-8 
release, on the other hand, IL-4, IL-IO and IL-13 inhibit its synthe sis 250. TGFf3 can also 
stimulate IL-8 production in ASMC 251. 
1.8.8 Cytokine and chemokine receptors expressed by ASMC 
The action of cytokines is totally dependent on the presence of their cognate receptors 
on responding cells. ASMC can respond to several ThI, Th2 and inflammatory cytokines. 
In one of the first papers on the subject, Hakonarson et al. showed the presence of that 
certain cytokines receptors on ASMC. Sorne were constitutively expressed at baseline, 
while others were undetected, but increased after appropriate cell stimulation 198. The IL-
2R, IL-5R, GM-CSFR and IFNyR mRNA were upregulated by atopic asthmatic serum. 
IL-2R, IL-4R, IL-5R, GM-CSFR, IFNyR protein were also increased. IL-12R was 
undetected at the mRNA or protein levels. ASMC constitutively express the mRNA for 
IL-4Ra, as weIl as IL-13Ral and none to very Iittle of the common y chain 198,252. This 
y chain is an essential component of the receptors for several type of cytokines (eg.: IL-2, 
IL-4, IL-9, IL-13, IL-I5). Ligation ofthese by IL-4 or IL-13 causes signal transducer and 
activator of transcription (STAT) l, STAT6 and ERK1I2 phosphorylation 198,252. Smooth 
muscle cells also respond to IL-9 by phosphorylation of ERK 247 and release of eotaxin 
246,247 through the constitutive expression ofIL-9Ra 246. 
ASMC also express receptors for profibrotic cytokines. They carry the three 
TGFf3 receptors (TGFf3RI, TGFf3RII, and TGFf3RIII) 253 as weIl as receptors for the IL-6 
family of cytokines: there is baseline expression of IL-6R, gp130, IL-11R and OSM 
receptor mRNA 254. Function of these receptors was verified by stimulation with their 
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ligands and assessment of downstream signaling molecule activation. STAT3 was 
phosphorylated in response to IL-6, IL-Il and OSM 254. As mentioned earlier, AS MC 
respond very weIl to TNFa, these cells carry both TNFa receptors, TNFRI and TNFR2. 
TNFRI seems more abundant and is necessary for TNFa-induced activation of NF-KB 
and expression of IL-6 and RANTES 255. TNFa also induces the activation of the ERK 
and p38 pathways through TNFR 1 221. Recently, a functional IL-17R has been 
characterized on AS MC 256, IL-17 A binds this receptor and promotes the phosphorylation 
of MAPK and the release of several chemokines, including IL-8 239,256,257. 
Recently, CCR3, a receptor for eotaxin was found in cultured ASMC as weIl as by 
human smooth muscle in vivo. CCR3 mediates an eotaxin-dependent chemotaxis of 
ASMC in a Boyden chamber assay 231. 
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1.9 Bronchial epithelial cells 
1.9.1 Structure of the bronchial epithelium 
The epithelium covers the airway mucosa and within the epithelium, several celI types 
are found. There are ciliated cens, secretory cens and basal cens. In the upper airways, 
almost 80% of the epithelium is comprised of ciliated cells with a columnar shape. They 
are covered with microvilli on their apical surface. Interspaced through the epithelium are 
secretory cells, which are are much less abundant than their ciliated counterparts. Among 
them we find goblet cens, which are metabolicany active and contain large granules fined 
with mucins 49. Throughout the large airways there are submucosal glands that are lined 
by mucous and serous cens. Basal cens are smalIer in size and are found between the 
basolateral surface of columnar celIs and the basement membrane 258 and serve to anchor 
the epithelium to the basement membrane. 
Different types of adhesion complexes ho Id epithelial celIs together 258. Tight 
junctions, at the apical surface, seal adjacent columnar cens and prevent the passage of 
molecules or ions between them. Adherens junctions hold the epithelium together; these 
are made from cadherins and catenins. Desmosomes, also composed of cadherins, serve 
to bind every type of epithelial celIs tightly together, while hemidesmosomes connect 
basal cens to the extracelIular matrix of the basement membrane 258. 
1.9.2 Function of the branchial epithelium 
The airway epithelium serves several physiological functions and its constituent 
comprised of several celI types, each having particular functions. The epithelium forms a 
protective barrier between the external environment and the internaI components of the 
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bronchi and lungs. A protective layer of mucus that humidifies the inhaled air and 
prevents desiccation covers the airways epithelium 48,259. The ciliated epithelial cells are 
responsible for mucocilliary clearance of pathogens and debris trapped in the mucus 
48,259. The goblet cells compose 10% of the normal epithelium, but can become much 
more abundant in chronically irritated airways and lead to increased mucus secretions 
49,50. Mucus secretions are made up of 90% water and 10% of proteins, carbohydrate and 
lipids. The proteins in mucus include mucins, a group of heavily glycosylated proteins, 
that are 50%-90% carbohydrate by weight 259. Mucins are exceptionally large molecules 
ranging from 3 to 23 million daltons. So far, 19 different mucin genes (MUC) have been 
identified in humans 48. In the airway lumen, mucus is mixed with inflammatory cells and 
sloughed epithelial cells and can enhance airway narrowing and thus airflow limitation 48. 
The airway epithelium is far from being only a structural entity; epithelial cells have 
very potent secretory abilities. They express cytokines, chemokines, lipid mediators, 
adhesion molecules, ECM proteins and gases 260. Sorne of these are constitutively 
expressed by the airway epithelium, while others need the action of a specific stimulus to 
be detected 260. 
1.9.3 The branchial epithelial cell in the pathogenesis of asthma 
In asthma, the bronchial epithelium is subject to both structural and functional 
changes. Indeed, bronchial epithelial damage and denudation have been shown in early 
post-mortem studies of asthmatics, and later using biopsy samples of the airways 
analyzed by light and electron microscopy 261. Epithelial damage and desquamation in 
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asthmatic airways has been long-held as an important pathological feature of this disease. 
This phenomenon may be associated with disease severity: sorne authors have observed 
more epithelial disruption in more severe cases of asthma 262. Amin et al. found that there 
was no difference in epithelial integrity between control subjects and non-atopic 
asthmatics, whereas atopic asthmatics showed much greater epithelial damage 55. Another 
group showed epithelial damage in both atopic and non-atopic asthmatics compared to 
controls 261. Also degree of epithelial integrity might also not be associated with asthma 
severity, mild asthmatic showed less epithelium than individuals with severe disease 188. 
However, this could be attributed to the effect of corticosteroids treatment on increased 
epithelial survival and proliferation 176. Certain researchers have attributed the occurrence 
of epithelial desquamation as being an artifact caused by tissue handling and/or 
processing 46,47,49. 
Interestingly, a greater number of activated eosinophils and T lymphocytes are found 
in areas of epithelial damage in asthmatic bronchial biopsies 55. Activated eosinophils 
release potent cytotoxic proteins su ch as major basic protein (MBP) or eosinophil 
cationic prote in (ECP), which have been shown to cause direct damage to bronchial 
epithelial cells in vitro 263. 
Activated T cens release TNFa and IFNy. TNFa, can induce pro-apoptotic processes 
in epithelial cens 264. AIso, IFNy is known to increase TNFa responsiveness by 
upregulating the TNF receptor 265. Cultured bronchial epithelial cens exposed to T cens 
and eosinophils undergo significant apoptosis, and this is effectively inhibited using 
blocking antibodies to TNFa and IFNy 263. This finding was correlated with biopsy data 
showing increased apoptosis as assessed by TUNEL (Terminal deoxynucleotidyl 
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Transferase Biotin-dUTP Nick End Labeling) staining in the bronchial epithelial cells of 
mi Id asthmatics. Other experimental studies have shown that the amount of desmosomes 
is decreased in bronchial epithelial cell cultures exposed to TNF a and IFNy 266. 
Desmosomes are cellular structures critical for cell-to-cell adhesion 266, and are decreased 
in asthmatic bronchial tissue 261. This is thought to facilitate epithelial cell detachment. 
The asthmatic epithelium is subject to other structural changes associated with 
remodelling, such as an increase in goblet cell numbers 261. This occurs through 
hyperplasia 178,267 and also metaplasia 268,269 of columnar epithelial cells into mucus-
secreting cells 178,267. 
Deregulated expression of proliferative and apoptotic markers is a well-documented 
aspect of bronchial epithelial cell biology in asthma 45,176. Vignola et al. did not detect 
differences in epithelial apoptosis between control and asthmatic subjects 44. However, 
they have shown that the epithelium of asthmatics expresses more of the anti-apoptotic 
protein Bc1-2 (B-cell lymphoma 2) than normal epithelium, thus possibly enhancing its 
survival. Staining for proliferating cell nuc1ear antigen (PCNA) showed similar scores for 
the epithelium in control and untreated asthmatics. However, markers of epithelial 
survival (Bc1-2) and proliferation (PCNA) of corticosteroid-treated asthmatics were 
significantly higher than in the epithelium from control or untreated asthmatics. 
Proliferation of the bronchial epithelium is increased in allergen-challenged asthmatics 
(mi Id atopic) and correlates with the number of activated eosinophils 270. 
1.9.4 Cytokine and chemokine production by epithelial cells 
In vivo 
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Many different cytokines are detected in the bronchial epithelium, and their expression 
can be increased or decreased in asthma. The epithelium of asthmatic airways shows 
increased expression of the CD4+ T cell chemotactic cytokine IL-16, the profibrotic 
cytokines IL-6, IL-Il and TGF(31, the chemokines eotaxin, RANTES, stem cell factor 
(SCF), TARC, monocyte chemotactic protein (MCP)- 3 and -4 and IL-8, and the growth 
factor GM-CSF 55,145,151,271-275, but shows decreased expression of IL-18 276. Certain 
cytokine and chemokine receptors are increased in asthma in the bronchial epithelium. 
This is the case for the IL-4Ra which is increased in atopic asthmatics 277, the stem cell 
factor (SCF) receptor, c-kit, and IL-9Ra are also increased in asthmatic epithelium 
101,275,278 
In vitro 
Cultured bronchial epithelial cells express a large range of cytokines and chemokines. 
They release eosinophil chemotactic proteins such as RANTES and eotaxin and the 
neutrophil chemoattractants GROa and IL-8. Epithelial cells are also a source of 
cytokines such as IL-Il and TGF-(31 and colony-stimulating factors like G-CSF and GM-
CSF. Cytokine production in several cell types including epithelial cells is potently 
inhibited by dexamethasone, a very potent synthetic corticosteroid often used in in vitro 
experiments. 
Like ASMC, epithelial cells are an important source of eotaxin; its expression can be 
induced by TNFa, IL-4 and IL-13 279,280 as well as by in vitro rhinovirus infection 28I. 
They also synthesize RANTES which is increased by TNFa, IL-I(3 and IFNy 282,283. 
Moreover infection of epithelial cultures with rhinovirus, influenza A or the respiratory 
syncytial virus (RSV), a common cause of respiratory infection in infants and children, 
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causes RANTES synthesis 284-286. RANTES is also detected in the sputum of children 
undergoing a viral asthma exacerbation 287. This suggests an active role for RANTES in 
viral defense as it is chemotactic for leukocytes and promotes their recruitment to sites of 
inlammation. MCP-4 is upregulated in epithelial cells after treatment with IL-4, TNFa, 
and IL-l~ 279. Epithelial cells also appear to have a basal expression of TARC which, 
unlike in ASMC, is upregulated by IL-4 and IL-B, though much greater levels are 
obtained when these cytokines are combined with either TNFa or IFNy 272. 
GM-CSF is thought to contribute to the survival of eosinophils and neutrophils within 
the mucosa 165-167,288. Indeed, GM-CSF produced in the supematant of bronchial 
epithelial cells prolongs the survival of cultured eosinophils and neutrophils 167. Cultured 
epithelial cells produce constitutive GM-CSF 161 and its expression is upregulated by 
proinflammatory cytokines and respiratory viruses such as RSV, but this upregulation is 
corticosteroid sensitive. TNFa, IL-4 and dust mite allergen (Der p, from the house dust 
mite Dermatophagoides pteronyssinus) induce GM-CSF release 289. IL-l~ induces the 
gene transcription and release of GM-CSF in A549 pulmonary epithelial cells and 
primary bronchial epithelial cells. However, IL-4 and IL-13 inhibit its expression in A549 
cells through a transcriptional mechanism 290. 
Epithelial cells can also be a source of G-CSF, interestingly, G-CSF can enhance the 
survival and activation of neutrophils in vivo 167 and TNFa-induced G-CSF production 
by the immortalized human bronchial epithelial cell line BEAS-2B is not inhibited by 
dexamethasone 291. Notably, corticosteroid treatment does not affect neutrophil numbers 
in vivo as it does with eosinophils. 
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Bronchial epithelial cells are a very important source of neutrophil attracting 
chemokines. While they produce constitutive levels of IL-8 161,292, several types of 
inflammatory stimuli are potent at increasing its synthesis and release such as IL-4, IL-
13, IFNy, IL-17 A, TNFa, viruses, bacteria and allergen 289292293 281. Pathogens rapidly 
induce IL-8 synthesis in the host, and because of this, neutrophils are usually the first 
responders on a site of inflammation. Indeed, RSV quickly increases IL-8 mRNA 
synthesis by BEAS-2B 294. Similarly, rhinovirus infection of A549 epithelial cells yields 
a potent upregulation of IL-8 message in as little as an hour, although in these cells, IL-8 
protein levels continue to rise for as many as four days 295. Epithelial cells produce other 
cytokines of the same family, namely GROa and epithelial-derived neutrophilic peptide 
(ENA-78), that are upregulated proinflammatory by cytokines 293 and serve to 
chemoattract neutrophils. 
Bronchial epithelial cells constitutively express IL-6, but it is strongly upregulated by 
TNFa and IL-lf3, but also by IL-17A and in vitro viral infections. IL-lI, which shares 
several properties with IL-6 296 is increased in epithelial cells by viruses, IL-17 A, IL-l f3 
and TGFf3 296-298. Bronchial epithelial cells are themselves capable of expressing TGFf3 
299,300 and its release is inhibited by IFNy 300. Cultured bronchial epithelial cells can also 
produce another member of the TGF family, TGFa, which is present at baseline in cells 
from normal and asthmatic donors. It is increased by TNFa, allergen, IL-4 and IL-13 but 
only in asthmatic cells 301. TGFa binds the epithelial growth factor receptor (EGFR) and 
induces fibroblast proliferation as well as goblet cell differentiation. 
1.9.5 Cytokine and chemokine receptors expressed by branchial epithelial cells 
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Although bronchial epithelial cells are known to respond to various cytokines, direct 
demonstration and characterization of their putative receptors has not been systematically 
performed. Bronchial epithelial cells express receptors for the IL-4, IL-9, IL-13 289,302, IL-
6 302 and IL-lO 303. Like in ASMC, chemokine receptor characterization in bronchial 
epithelial cells is a recent endeavor. They express CXCRI and CXCR2 304 which are 
receptors for both IL-8 and GROa, CCR3 305 as well as CXCR3 that binds CXCL Il 
(interferon-gamma inducible T cell alpha chemoattractant or I-TAC), a chemoattractant 
for activated T cells 306. 
1.10 Lung fibroblasts 
1.10.1 Structure of the lungjibroblast 
Lung fibroblasts are cells of mesenchymal origin. In the airways, they are present in 
the connective tissue underlying the epithelial layer and are an integral structural cell. 
These cells are thin and elongated and form a sheath around the basement membrane 307. 
1.10.2 Function of the lungjibroblast 
The primary function of fibroblasts is to maintain integrity of supporting tissues by a 
constant slow turnover of components of the extracellular matrix; they are also associated 
with wound repair 307. Indeed, active fibroblasts secrete factors that are involved in 
wound healing, inc1uding deposition of extracellular matrix proteins (ECM). Under 
physiological conditions, the ECM serves several functions: it provides structural support 
by acting as a scaffold, and separates the epithelium and endothelium from other 
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structures 308. The ECM also affects cellular function, such as adhesion, spreading, 
growth and gene expression. 
1.10.3 Lung fibroblasts in the pathogenesis of asthma 
In asthmatic airways, ECM such as type l, III and V collagen and fibronectin derived 
from subepithelial fibroblasts contribute to the thickening of the subepithelial reticular 
layer. lncreased deposition of ECM is thought to happen partly because there are more 
fibroblasts. lndeed the increased number of subepithelial fibroblasts in asthmatics is one 
of the characteristics of airway remodelling. In fact, this increase correlates with the 
thickness of the reticular layer 309. However, it was shown that cultured non-asthmatic 
fibroblasts survived longer and proliferated more than asthmatic fibroblasts 310 . In 
asthma, bronchial epithelial cells are thought to interact with the underlying fibroblasts 
and promote their proliferation and ECM synthetic ability. Conditioned media of bovine 
bronchial epithelial cells enhances bronchial fibroblast proliferation and co-culturing 
these two cell types also increases fibroblast proliferation 311. 
Certain cytokines can affect the behavior of fibroblasts by either promoting their 
proliferation, or their ECM synthetic ability and thus contributes to features associated 
with airway remodelling. Bronchial epithelial cells are a source of the potent profibrotic 
cytokine TGF~l 312. This cytokine plays a role in the in vitro proliferation of human 
fibroblasts and the production of collagen l and III as well as fibronectin 313. 
TGF~l, 2 and 3 have been reported to be proliferative for lung fibroblasts at low 
concentrations but is inhibitory at higher concentrations 314, yet others have reported no 
effect on proliferation 311. Furthermore, TGF~ 1 enhances fibroblast growth factor (FGF)-
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induced proliferation of fibroblasts by upregulating FGF receptors 315. TGF~l and 
TGF~3 also inhibit the action of metalloprotease-2 (MMP-2), a collagen degrading 
enzyme, and increase the expression of tissue inhibitor of metalloprotease (TIMP)-l 313. 
Importantly, TIMP-l happens to be increased in the BAL ofasthmatics 316, and TGF~l is 
1 d · h h Il'' 1 d 1 f' . fl . 157160 upregu ate III uman ast ma as we as III amma mo e s 0 alfway III ammatlOn ' . 
The proinflammatory cytokines TNFa and IL-l~, which are increased in the airways of 
asthmatics 128,317,318, affect the proliferation of fibroblasts and the synthesis of certain 
ECM. Several reports show that TNF a and IL-l ~ inhibit collagen 1 synthesis in several 
cell types 319-322, but can increase the production of other ECM 323_ Data from human 
fibroblasts show that TNF a and IL-l ~ can also inhibit their proliferation, however, others 
have found that TNFa promotes proliferation and collagen 1 production in mouse 
intestinal myofibroblasts 324. A possible reason for this discrepancy might be in the use of 
human lung 323 versus murine intestinal fibroblasts 324. Inflammatory cells are thought to 
interact directly with structural cells III the alrways and enhance the 
inflammatory/remodelling response of these cells. Indeed, human lung fibroblasts co-
cultured with eosinophils will synthesize more fibronectin and TIMP-l mRNA 325 which 
can contribute to subepithelial fibrosis. IL-4 and IL-13 promote the proliferation of lung 
fibroblasts 326-328, sorne report that these cytokines have no profibrotic effect 327, however, 
IL-4 has been shown to increase collagen 1 in primary lung fibroblasts 329. OSM, a 
member of the IL-6 family, has been shown to decrease apoptosis and Illcrease 
proliferation oflung fibroblasts in addition to enhancing collagen 1 synthesis 330. 
1_10_4 Cytokine and chemokine production by lungfibroblasts 
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In vivo 
Most in vivo studies that stain human biopsy tissues to investigate expression of 
cytokines will assess expression in easily recognizable structural tissues such as the 
epithelium, smooth muscle and endothelium, although in several studies the submucosal 
layer is also positively stained and is the location for airway fibroblasts 236,271. Using 
antibodies to both eotaxin and a fibroblast marker (Ab-l), Wenzel et al. demonstrated 
that bronchial biopsies from severe asthmatics show more eotaxin-positive fibroblasts 
than nonnal 331. 
In vitro 
Fibroblasts have the potential to directly participate in atrway inflammation and 
fibrosis because they can release several types of immune mediators. Much like ASMC 
and bronchial epithelial cells, the majority of this type of data is derived from in vitro 
experiments. Nevertheless, this points to an active inflammatory role for these cells, 
which eventually could lead to the initiation and/or support of existing airway 
remodelling. Microarray analysis of nonnal human lung fibroblasts treated with the Th2 
cytokine IL-13 revealed that genes like MCP-I and IL-6 were among the most 
upregulated 250. IL-6 has been shown, in a transgenic mice model, to promote 
subepithelial fibrosis 172. The chemokine MCP-I, a ligand for CCR2, has been implicated 
in lung fibrosis, also, CCR2 -/- mi ce are protected against pulmonary fibrosis 332. This 
phenomenon might be in part explained by the fact that CCR2 -/- airway epithelial cells 
suppress fibroblast proliferation to a greater extent than CCR2+/+ airway epithelial cells 
333 
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In response to several types of cytokines, fibroblasts can generate large amounts of 
chemokines like IL-8, eotaxin and RANTES that are responsible for attracting 
inflammatory cells to the bronchial mucosa, as well as, factors like GM-CSF 162 that 
support their survival within mucosal tissue. These chemokines could contribute to 
initiating and/or maintaining chronic inflammation in asthmatic airways. Lung fibroblasts 
secrete IL-8 in response to IL-l7A, TNFa, and TGFj31 331,334,335. In contrast, IL-13 
inhibits IL-8 release in fibroblasts 331, though it enhances its secretion in normal and 
asthmatic bronchial epithelial cells 289. IL-l 7 A and TNF a have also been shown to 
induce IL-6 334. In addition, lung fibroblasts, like other airway structural cells, are 
important sources of eotaxin. Fibroblasts stimulated with TNFa, IL-4 and IL-13 produce 
eotaxin 331,336. TNFa in combination with either IL-4 or IL-13 creates a synergistic effect 
on eotaxin release 336. IFNy has no effect alone, but suppresses TNFa-induced eotaxin 
336. AIso, TGFj31 and IL-13 together show a strong synergy on eotaxin production 331. 
COllectively, it appears that inflammatory conditions in association with a Th2 milieu 
(lL-4, IL-13) favors the synthesis of eotaxin and thus eosinophil recruitment. 
RANTES is detected at constitutive levels in cultured fibroblasts, and like most 
chemokines, it is strongly induced by TNFa. Stimulation with IFNy or IL-4 has no effect 
on RANTES. Unlike what is seen with eotaxin, the combination of TNFa plus IL-4 does 
not further enhance the expression of RANTES. Instead of the inhibitory effect on 
TNFa-induced eotaxin, IFNy produces a synergistic effect when combined with TNFa 
on RANTES synthesis and release 336. In an unstimulated state, supernatants from human 
lung fibroblast have monocyte chemokinetic activity, mediated through GM-SCF, TGFj3, 
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MCP-I and leukotriene B4, but not by RANTES 337. Though MCP-I is produced by 
fibroblasts, MCP-3 or MCP-4 are undetected in the supematant 336. 
1.10.5 Cytokine and chemokine receptors expressed by lungfibroblasts 
Little data is available in the literature on actual expression of particular cytokine 
receptors by human lung fibroblasts. Both isoforms of the TNFa receptor (TNFRI and 
TNFRII) are expressed on the surface of fibroblasts 338,339 and their expression is lower in 
fibroblasts obtained from fibrotic lungs as compared to controllungs 339. IL-4Ra as weIl 
as both the signaling (IL-13RaI) and the decoy IL-13 receptor (IL-13Ra2), are expressed 
by human nasal and lung fibroblasts 340, though only IL-13Ra2 is increased by both 
TNFa and IL_4 34o. IL-I7R is also present on these ceIls 338. 
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1.11 The interleukin-17 family 
Interleukin-17, now caHed IL-17 A, is the founding member of a relatively novel 
family of cytokines. Since its discovery, five other members of this family have been 
identified: IL-17B, IL-17C, IL-17D, IL-17E (IL-25) and IL-17F. Members of the IL-17 
family are synthesized as monomers, and secreted as glycosylated homodimers held 
togetherby disulfide bonds (Fig. 4). AH IL-l7's share four conserved cysteines (Fig. 5A), 
necessary for the formation of a cysteine knot held together by disulfide linkages. These 
cysteines are thus essential for the 3D structure of the protein (Fig. 4). Interestingly, the 
growth factor superfamily also has a cysteine-knot conformation held by six cysteine 
residues, and resembles the one found in IL-17 members 341,342. 
AH IL-l7's are located on different chromosomes (Table 2) with the exception of IL-
17A and IL-l7F, which are both found in tandem on human chromosome 6p12. Among 
the IL-l7's, IL-17F shares the highest level of homology with IL-l7A (55%), then IL-
17B (29%), IL-17D (25%), IL-17C (23%) and IL-17E with the least similarity (17%). 
Sorne of the IL-l7' s might even play a role in the pathogenesis of airway and lung 
diseases such as nasal polyps, asthma and cystic fibrosis, in which levels of IL-17 A 
and/or IL-17F are increased 150,297,343,344. 
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Fig.4 AlI members of the IL-17 family adopt a similar 3-dimensional structure because of 
the disulfide bonds that are created through their 4 conserved cysteine residues. (A) 
Structure of the IL-17F monomer. (B) Structure of the IL-17F homodimer. (C) Structure 
of nerve growth factor has similarities to IL-17F. 
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Fig. 5: Alignement of the amino acid (aa) sequences of the IL-17 family members, The four 
cysteine residues that form the disulide bonds are conserved in aIlIL-17's, they are highlighted 
in bold (in rectangles). Sequences were aligned using ClustalW (A). Phylogenetetic analysis of 
the aa sequence reveal their relatedness Tree construction was performed using the online 
SATCHMO method (8). 
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1.11.1 Interleukin-17A 
This interleukin was first identified in 1993 by subtractive cDNA library screening. 
This library was generated using cDNA from mouse T cell of various sources. The new 
gene was termed cytotoxic T lymphocyte associated antigen 8 (CTLA8) as it was 
specifically expressed in cytotoxic T cells activated with PMA and ionomycin. Rouvier et 
al. found that the amino acid sequence of CTLA8 was 56.8% identical to the 13th open 
reading frame (ORF) of the T cell trophic herpervirus, Herpesvirus saimiri, also called 
HSV13 345. Both recombinant HSV13 and CTLA8 induce the activation of NF-kB and 
the secretion of IL-6 in fibroblasts. In 1995 Yao et al. also described IL-17 A in activated 
CD4+ memory T cens from peripheral blood and proposed to name CTLA8 as IL-17 A 
and HSV13 as viral IL-17 (vIL-17). The newly identified cognate receptor for IL-17 A 
was hence referred to as IL-17R. Later, data from mice and human stimulated memory 
CD8+ T lymphocytes demonstrated production of IL-17 A. 
IL-17 A is on the whole a product of activated T cens as it is noticeably absent from 
resting T lymphocytes. T lymphocytes are the primary source of IL-17 A although it has 
been detected in eosinophils and neutrophils 297,346. The biological relevance of 
eosinophils and neutrophils as a source of IL-17 A is uncertain since the release of IL-17 A 
in the supematant of either has not been measured 297,346. IL-23, a cytokine primarily 
secreted by dendritic cens, is a strong stimulus for IL-17 A production in cultured CD4+ 
T lymphocytes. T cens from IL-23-deficient mice can still make IL-17 A, although to a 
lesser extent 347. In line with this observation, T cens stimulated in vitro only through the 
TCR with an anti-CD3 antibody secrete IL-17 A without the need for exogenous IL-23 or 
presence of dendritic cens, although addition of IL-23 enhances IL-17A production 348. 
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IL-17 A does not appear to be particularly associated with the Thl or Th2 subsets of T 
cells as it has been found in both lineages 349-352. Recently, two groups identified a 
distinct subset of CD4+ T cells that produce IL-17A 353,354. They showed that IL-23 was 
critically important in the development of a newly identified T celllineage called ThIL-17 
(or Tw I7). Interestingly, the prototypical Thl and Th2 cytokines (lFNy and IL-4) inhibit 
the development of the ThIL-17 lineage. 
C tokine Len th aa Size kDa Chromosome Homolo to mouse Rece tor 
IL-17A (CTLA8) 155 35 6p12 62 IL-17R 
IL-17B 180 41 5q32-34 88 IL-17BR 
IL-17C 197 40 16q24 83 unidentified 
IL-17D 202 52 13q12.11 78 unidentified 
IL-17E (IL-25) 161 34 14q11.2 81 IL-17BR 
IL-17F ML 1 153 44 6 12 77 IL-17R? 
Table 2: IL-17 family members 
J.JJ.2 Potential raie of IL-J7 A in asthma 
Under physiological conditions, IL-17 A is present at low levels in the airways 355 but 
increases during inflammation or in airway diseases such as asthma 150,297, though its role 
in normal and asthmatic airways is still unclear. In asthma, it is likely to participate in 
maintaining or enhancing airway inflammation and promoting fibrosis. IL-17 A is 
increased in asthmatic bronchial mucosa, sputum and in BAL 297,356. In addition, blood 
eosinophils from asthmatics express more IL-17 A protein than control subjects 297,357 and 
this correlates with increased airway hyperreactivity 357. IL-17 A is considered to have 
profibrotic properties because it can induce the release of IL-6 and IL-Il from airway 
fibroblasts 297 and epithelial cells 334. 
Overexpression of IL-6 in murine epithelial cells of the airways causes subepithelial 
fibrosis and increased collagen deposition 172. IL-Il transgenic animaIs share a similar 
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phenotype to the IL-6 transgenic mlce, both develop fibrosis below the basement 
membrane and show increased deposition of collagen 1 and III. In asthmatics airways, 
both IL-Il and IL-17 A are upregulated and their expression correlates with disease 
severity 150. Their expression in control and mi Id asthmatic subjects are similar, whereas 
it is much higher in moderate-to-severe asthmatics 150. This suggests that IL-17 A is 
involved in a more severe form of the disease, which is characterized by neutrophilic 
infiltration. The presence of higher IL-Il and IL-17 A levels in the airways of these 
patients is also associated with an increased deposition of collagen 1 and III 150. Notably, 
a 2-week course of oral corticosteroids decreased IL-17 A levels, but not collagen 1 or III 
150. IL-17 A as well as IL-6 also appear involved in mucin production by bronchial 
epithelial cells in vitro as both can induce an increase in MUC5AC and MUC5B mRNA 
358. In these ceIls, IL-17 A increased the MUC5B gene partly through IL-6. Interestingly, 
the Th2 cytokines IL-4, IL-5, IL-9 and IL-13 did not increase either mucin gene. 
Although there are 19 mucin genes characterized so far, MUC5AC and MUC5B are the 
major gel-forming mucins 267. Moreover, there was significant increase in mucus 
production in the aiways of IL-17 A transgenic mice 353. Collectively these results suggest 
that IL-17 A could participate in asthma pathogenesis through increased neutrophilic 
infiltration, fibrosis and mucus production. 
1.11.3 Biological effect of1L-17A 
IL-17 A is known to induce the activation of several proinflammatory transcription 
factors and cytokines 359. IL-17A activates NF-kB and API as weIl as members of the 
MAPK and Jak/STAT pathways in many types of cells 360-364. The induction oflL-6 and 
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IL-8 production were the first biological effects associated with IL-17A 359,365,366. Later, 
IL-17 A was shown to promote the expression of other neutrophil chemoattractants of the 
CXC chemokine family besides IL-8, such as growth related oncogene (GRO)-u and 
granulocyte chemotactic protein (GCP)-2 367,368. In human bronchial epithelial cells IL-
17A induces IL-6 and IL-8 through p38 and ERK 363. Similarly, GROu and GCP-2 
release is dependent on p38 but inhibition of the ERK or the calcineurin pathways has no 
effect 368. 
Considering the ability of IL-17 A to increase neutrophil activating and chemotactic 
cytokines, it is no surprise that it causes a potent neutrophilia in vivo 367,369 and their 
migration in vitro 369, but this effect can be effectively blocked using antibodies against 
IL-8 or KC (murine analogue of human GROu) 367,369. IL-17A on its own had no 
chemotactic abilities for neutrophils in vitro 369. IL-17 A also has proangiogenic properties 
in vivo and in vitro. In vitro it induces vascular endothelial growth factor (VEGF) in 
mouse lung fibroblasts, and chemotaxis of endothelial cells 370,371. IL-17 A promotes 
angiogenesis in rat comea and enhances tumor survival through increased blood vessel 
formation 370,372,373. IL-17 A also promotes the release of the growth factors granulocyte-
colony stimulating factor (G-CSF) and granulocyte/monocyte-colony stimulating factor 
(GM CSF) 163359374 d d' l' .. . 375 - "an can me late granu opoelsls ln mlce . 
1.11.4 Cooperation of IL-17 A with other cytokines 
An important aspect of IL-17 A biology is its ability to synerglze with other 
inflammatory mediators and it is suggested that the primary function of this cytokine is to 
amplify or enhance an existing inflammatory reaction 376,377. 
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The combination of IL-17A with the CD40 ligand (CD40L) 378 or with the 
proinflammatory cytokines TNFu, IL-If) or IFNy can induce a potent synergistic effect 
with respect to the release of several cytokines, chemokines and growth factors such as 
IL-8 IL-6 GROu G-CSF and GM-CSF 164,293,334,344,364,379-381 complement pathway , , , , 
proteins C3 and factor B 382 or expression of the adhesion molecule (ICAM)-l 383. Many 
reports attribute this synergism to increased mRNA stability of transcripts like IL-6, IL-8 
and GROu 367. In ASMC, IL-17A on its own fails to induce IL-6, however it increases 
the level of TNFu-induced IL-6 but not of IL-If). In this report, the synergistic 
mechanism does not occur through increased transcription of the IL-6 gene, as assessed 
by a promoter activity assay, but through enhanced stabilization of the IL-6 mRNA 
transcript by IL-17A 164. Cooperation between IL-17A and TNFu does not only occur at 
the post-transcriptional level, as observed with mRNA stabilization: there is evidence of 
enhanced gene transcription as well 380. IL-17 A can also synergize with IFNy. Although 
there is less data the mechanism behind this particular synergistic effect, overall, the data 
shows similar results than with TNF u. Combination of IL-17 A +IFNy enhances the 
production ofIL-6, IL-8, GROu and GM-CSF as weIl as ICAM-I in bronchial epithelial 
cells and keratinocytes 351,352,384. 
While there is plentiful evidence that IL-17A combines well with TNFu to create a 
potent synergistic end result, sorne have reported that IL-17 A can antagonize the action 
ofTNFu. IL-17A can suppress TNFu-induced CCL27 expression 385 as well as VCAM-I 
surface expression 338. Other reports show that IL-17A is effective at bloc king TNFu- or 
IFNy-induced RANTES expression in a variety of cell types 338,379,383,386. 
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1.11.5 The IL-17A receptor 
The interleukin-17 A receptor (IL-17R) is structurally unrelated to any other cytokine 
receptor. IL-17R is a type 1 transmembrane receptor (single pass through the cell 
membrane) that mediates the signaling of IL-17 A and possibly IL-17F 342,387. It was first 
c10ned in 1995 by using HSV13 as bait for screening by flow cytometry a cDNA library 
expressed by a murine T cell line (EL4) 365. Later the human IL-17R was c10ned using a 
probe based on the murine IL-17R sequence 388. Only very recently has the configuration 
of the IL-17R been studied and identified 387. The majority of cytokine receptors belong 
to one of four families. 
An important aspect of cytokine receptor biology is the status of the receptor 
molecules before ligand binding. Sorne receptor subunits come preassembled, while in 
other cases, the receptor dimerizes upon ligand binding. Recent data shows that the 
functional IL-17R contains at least two identical subunits preassembled in the cell 
membrane before IL-17 A binding 387. Affinity binding experiments show that 
recombinant IL-17A has a low affinity for its receptor 342,388, yet low concentrations (0.1-
lOng/ml) of IL-17 A can elicit a biological response suggesting that there are maybe 
other subunits to the IL-17R. Knowledge of the signal transduction events that follow IL-
17 A binding is for the most part limited to downstream events such as the activation of 
NF-kB or the phoshorylation p38, JNK and ERK 239. 
Work performed by Schwandner and colleagues revealed the importance of the TNF 
receptor-associated factor (TRAF) 6 in promulgating the IL-17A signal to NF-kB and 
JNK 389. Using murine embryonic fibroblasts (MEF) deficient in TRAF6, they showed 
that, both IL-1~ and IL-17A, but not TNFa, were unab1e to initiate IKK or NF-kB 
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activity and JNK phosphorylation. However, IL-l ~ and IL-17 A initiated activation of 
NF-kB and JNK in TRAF2 -/- cens, similar to wild-type. TNFu-induced activation of 
NF-kB and JNK was reduced in TRAF2-/- cens. The presence TRAF6 is also required 
for IL-17A-mediated IL-6 production, ICAM-l expression 389 and activation of the 
cytokine-induced neutrophil chemoattractant (CINC) promoter 362. 
IL-17R most likely mediates the destructive effect of IL-17 A in rheumatoid arthritis, a 
chronic inflammatory disease of the joints. IL-17 A is increased in the synovial fluid of 
patients with rheumatoid arthritis 390-392, and promotes destruction of human articular 
cartilage explants 342,393. Moreover, increased IL-17R expression is associated with this 
condition in humans, as cens isolated from the synovium of arthritic patients show higher 
levels of this receptor. To further support this, mice lacking the IL-17R show no cartilage 
destruction, fewer infiltrating cens and a decrease in proinflammatory cytokines 394. The 
increased IL-17 A levels observed in asthma and cystic fibrosis 150,297,344 could act via the 
IL-17R expressed in the human airways by ASM bundles 256 and the bronchial epithelium 
344. Furthermore, the airway epithelium expresses IL-17R primarily on its basolateral 
surface 344, possibly as the source of IL-17 A cornes from tissues and cens below the 
epithelium, such as infiltrating T cens. McAllister et al. cultured human bronchial 
epithelial cells in an air-liquid interface and treated them with IL-17 A on either their 
apical or basolateral surface. After 24 h, the basolateral media was tested for GROu or G-
CSF, and only cens treated with IL-17A on the basolateral surface showed any 
upregulation ofthese cytokines 344. 
While IL-17 A and its receptor are deleterious in a disease such as arthritis, they are a 
critical component of innate immunity. The necessity of IL-17R in ho st defense against 
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various types of pathogens is evident in IL-17R knockout animaIs. The lack of IL-17R 
has a dramatic effect on the survival of mice infected with Klebsiella pneumoniae, 
Candida albicans or Toxoplasma gondii 395-397. Because IL-17A is a potent inducer of 
several neutrophil chemoattractants such as IL-8, GROu, CINC and MIP-2, IL-17R-/-
animaIs have greatly impaired neutrophils influx in response to infection. 
1.11.6 lL-17 A receptor regulation 
Little data is available on the in vitro regulation of IL-17R expressIOn. IL-17R 
expression is upregulated by treatment with TNFu in colonic fibroblasts but not in human 
chondrocytes or synovial fibroblasts 398. IL-17R is unaffected by IFNy in bronchial 
epithelial cells or keratinocytes 351,384. IL-17 A and IL-4 also have no effect on IL-17R 
expression in keratinocytes 351. 
1.11.7 Interleukin-17B 
IL-17B has been mostly detected at the mRNA level in the pancreas, stomach and 
small intestines. Unlike IL-17 A, IL-17E, and IL-17F, it is undetected in either resting or 
stimulated CD4+ T cells. IL-17B cannot induce IL-6 in human foreskin fibroblasts but 
promotes TNFu as weIl as IL-Ij3 release from the monocytic ceIlline THP-I 399. 
1.11.8 lnterleukin -17C 
IL-17C is one of the least studied IL-I7's. Similar to IL-17B, it is undetected in either 
resting or stimulated CD4+ T cells. Itcannot induce IL-6 in human foreskin fibroblasts 
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but induces both TNFa and IL-lj3 release from THP-l cells 399. Also, a human IL-17C 
adenoviral construct promotes neutrophilia in mice 400. 
1.11.9 Interleukin-17D 
Besides IL-17 A, IL-17E and IL-17F, little has been published on the expreSSIon, 
regulation or function of the other IL-17's. IL-17D is present in several tissues, but is 
most strongly expressed in skeletal muscle, brain, heart and lung. Cellularly, IL-17D 
mRNA is detected in resting CD4+ and CD 19+ cells 401. Much like IL-17 A or IL-17E, 
IL-17D induces the release of IL-6, IL-8 and GM-CSF by hum an umbilical cord 
endothelial cells (HUVEC) and activates NF-kB in 293 epithelial cells 401. This suggests 
that IL-17 A, D and E share similar intracellular signaling events. So far, a unique feature 
of this cytokine is that it inhibits division of myeloid progenitors in vitro. Granulocyte-
monocyte, erythroid and multipotential progenitor cells derived from human bone 
marrow and treated with IL-17D showed a reduction in the formation of colony forming 
units (CFU) 401. 
1.11.10 Interleukin-17F 
IL-17F is the last IL-17 to have been identified, it also the most closely related to IL-
17 A in terms of amino acid sequence and biological activity 402. Moreover both genes are 
located in tandem on human chromosome 6p12. IL-17F mRNA is observed in 
unstimulated human mast cells and in activated in ThO, Thl, Th2, PMBC and basophils 
402. It is undetected in monocytes and unstimulated CD8+ T cells, but its expression is 
highly induced by PMA +ionomycin in CD4+ T lymphocytes 342,402. As with IL-17 A, IL-
17F promotes the secretion of IL-6 and IL-8 by human fibroblasts 342, induces IL-6, IL-8, 
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G-CSF, GM-CSF, GROa and MCP-l in human pnmary bronchial epithelial cells 
344,402,403 and can synergize with TNFa to induce greater amounts of certain of these 
cytokines 344. The synergy of IL-17F with TNF a is mediated by both TNFRI and TNFRII 
344. Similar to IL-17A in the case ofTNFa-induced RANTES, IL-17F can also have an 
inhibitory action on G-CSF and GM-CSF release induced by TNFa by lung endothelial 
cells 163,404. IL-17F also increases ICAM-l surface expression in epithelial cells 402. The 
receptor for IL-17F has not been formally identified; it appears however that it can signal 
through IL-17R. A blocking antibody against IL-17R prevents the upregulation of G-
CSF, GROa and MCP-l 344. While the majority of the data recorded for this cytokines 
have been from in vitro experiments, it has been shown that IL-17F is increased in certain 
diseases such as asthma and cystic fibrosis 344,402, thus implicating this cytokine in their 
pathogenesis. 
1.11.11 Interleukin-17E 
IL-17E, also known as IL-25 78,400,405-408, is structurally related to the other members 
of the IL-17 family, but shares the least sequence homology. This could account for its 
distinct biological effects in vivo. In fact, phylogenetic analysis of aIl six IL-I7's shows 
IL-17E to be the most divergent (Fig. 5B). Several regions of IL-17E, ncluding the four 
characteristic cysteine residues, are conserved across mammalian orthologs, which 
suggests their importance in proper function of this cytokine (Fig. 6B). The gene for IL-
17E spans 3.6 kb and is located in hum ans on chromosome 14q 11.2; this chromosomal 
region is linked to skin prick reactivity 409. 14ql1.2 also contains the gene for mast cell 
chymase and a certain restriction site polymorphism associated with eczema 410. 
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The IL-17E gene contains 2 exons that yie1d a 1.36 kb message and the open reading 
frame encodes a 177 amino acid (aa) protein. The mature protein contains 145 residues 
after the 32 aa-signal peptide is cleaved. So far, nothing is known of the transcriptional 
regulation of this cytokine, though, IL-17E is like1y to be regulated at the post-
transcriptional leve1 as the 3' -untranslated (UTR) region of its mRNA molecule contains 
several instability sequences 411 (Fig. 6A). This sequence motifis 5'-AUUUA-3' and was 
first identified in the 3' -UTR of the human GM-CSF mRNA by Shaw and Kamen 411. 
These pentamers are also known as Shaw-Kamen sequences. Their presence induces 
mRNA instability and acce1erates its decay. Shaw-Kamen sequences are often found in 
messages coding for cytokines, cytokine receptors, growth factors and oncogenes. 
Constitutive tissue expression of IL-17E is limited, the highest leve1s being observed 
in testes, while levels of expression are low to moderate in the lungs and trachea 412. In 
vitro, IL-17E is expressed by human Th2-polarized T lymphocytes 408, murine bone 
marrow-derived mast cens stimulated with IgE 78 and by mouse alveolar macrophages 
406. The first evidence of IL-17E in vitro production shows that it is undetected in naïve 
CD4+ T cens and only Th2 polarized lymphocytes can express IL-17E mRNA 408. IL-
17E message is observed in unstimulated murine bone marrow-derived mast cens but its 
expreSSIOn mcreases after IgE crosslinking 78. Interestingly, in addition to Th2 
lymphocytes making IL-17E 78,408, unpolarized ThO cens express it at baseline; 
expression is higher in both lineages when stimulated with anti-CD3 78. The BAL fluid of 
rats treated with titanium oxide particles show elevated IL-13 and IL-17E; both cytokines 
are also upregulated in cultured alveolar macrophages from these animaIs 406. 
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A 
B 
CTCAAGTCACTCCCTAAAAAGACAGTGGAAATAAATTTGAATAAACAAAACAGGCTTGCTGAAAATAAAA 
TCAGGACTCCTAACCTGCTCCAGTCAGCCTGCTTCCACGAGGCCTGTCAGTCAGTGCCCCACTTGTGACT 
GAGTGTGCAGTGCCCAGCATGTACCAGGTCAGTGCAGAGGGCTGCCTGAGGGCTGTGCTGAGAGGGAGAG 
GAGCAGAGATGCTGCTGAGGGTGGAGGGAGGCCAAGCTGCCAGGTTTGGGGCTGGGGGCCAAGTGGAGTG 
AGAAACTGGGATCCCAGGGGGAGGGTGCAGATGAGGGAGCGACCCAGATTAGGTGAGGACAGTTCTCTCA 
TTAGCCTTTTCCTACAGGTGGTTGCATTCTTGGCAATGGTCATGGGAACCCACACCTACAGCCACTGGCC 
CAGCTGCTGCCCCAGCAAAGGGCAGGACACCTCTGAGGAGCTGCTGAGGTGGAGCACTGTGCCTGTGCCT 
CCCCTAGAGCCTGCTAGGCCCAACCGCCACCCAGAGTCCTGTAGGGCCAGTGAAGATGGACCCCTCAACA 
GCAGGGCCATCTCCCCCTGGAGATATGAGTTGGACAGAGACTTGAACCGGCTCCCCCAGGACCTGTACCA 
CGCCCGTTGCCTGTGCCCGCACTGCGTCAGCCTACAGACAGGCTCCCACATGGACCCCCGGGGCAACTCG 
GAGCTGCTCTACCACAACCAGACTGTCTTCTACCGGCGGCCATGCCATGGCGAGAAGGGCACCCACAAGG 
GCTACTGCCTGGAGCGCAGGCTGTACCGTGTTTCCTTAGCTTGTGTGTGTGTGCGGCCCCGTGTGATGGG 
CTAGCCGGACCTGCTGGAGGCTGGTCCCTTTTTGGGAAACCTGGAGCCAGGTGTACAACCACTTGCCATG 
AAGGGCCAGGATGCCCAGATGCTTGGCCCCTGTGAAGTGCTGTCTGGAGCAGCAGGATCCCGGGACAGGA 
TGGGGGGCTTTGGGGAAAGCCTGCACTTCTGCACATTTTGAAAAGAGCAGCTGCTGCTTAGGGCCGCCGG 
AAGCTGGTGTCCTGTCATTTTCTCTCAGGAAAGGTTTTCAAAGTTCTGCCCATTTCTGGAGGCCACCACT 
CCTGTCTCTTCCTCTTTTCCCATCCCCTGCTACCCTGGCCCAGCACAGGCACTTTCTAGATATTTCCCCC 
TTGCTGGAGAAGAAAGAGCCCCTGGTTTTATTTGTTTGTTTACTCATCACTCAGTGAGCATCTACTTTGG 
GTGCATTCTAGTGTAGTTACTAGTCTTTTGACATGGATGATTCTGAGGAGGAAGCTGTTATTGAATGTAT 
AGA~TCCAAATAAATATCTTTa!ILAAAAATGAAAAAAAAAAAAAAA 
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MRGQPRLGENSSLISLFLQVIAFLAMVMGTHTY--------SHWPSCCPSKG-YPSEELL 51 
--------------------IVFLVMAMGTHTLNFRIRKDCTHWPNCCPSKRQDPTHEWL 40 
KRERETLPRMDSKISEFLQLTGILVVALGTQALNLRLRRDYNHHHRGCCHQGQGFSEEWL 60 
:*.::**:: '* '* ** 
KWSSASVSPPEPLS-------HTHHAESCRASKDGPLNSRAISPWSYELDRDLNRVPQDL 
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KRDTVLKFPGETTS-------LTHHPESCKASEDGPLNSRSISPWKYELDRDLNRLPQDL 
QRNSVPSTLLQVSSNLQVPNI EVSKPFKCQASRDGPLNSRAI SPWKYVLDRDENRLPQDL 
: .. *:* •. *******:.*** '* .*** **:***. 
YHARCISLQTGSHMDPLGNSVPLYHNQTVFYRRPCH--GEEGTHRRYCLERRLYR 
YHARC SLQTGSHMDPMGNSVPLYHNQTVFYRRPCH--GEQGAHGRYCLERRLYR 
YHARC SLQTGSHMDPRGNSELLYHNQTVFYRRPCH--GEKGTHKGYCLERRLYR 
YHARC SLQTGSHMDPRGNSELLYHNQTVFYRRPCH--GKKGTHKGYCLERRLYR 
YHARC SLQTGSHMDPRGNSELLYHNQTVFYRRPCH--GKKGNHKGYCLERRLYR 
YHARC SLQTGSHMDPLGNSELLYHNQTVFYRRPCP--GEQGAPDGYCLEQRLYR 
YHARC NLRSGHDIDYRGNSELLWHNQTVFYRRPCHGHGEQQGSDCYYLEPRTYL 
****** **:.*::*.:* .*. *:*********** *:: * ** * '* 
VSIPRVMA S PRMMA 
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Fig. 6: (A) Human IL-17E cDNA sequence. Start and stop codons are highked bold; Shaw-Kamen 
sequences (ATITA) are underlined (B).Comparison of the different mammalian homologues of IL-17E. 
The four cysteine residues (in rectangles) that form the disulide bonds are conserved accross ail species 
aligned. Identicalresidues are marked with a star; residues that share the same side chain type are marked 
by two dots; residues that have different side chain type are marked by a single dot. Numbers appearing at 
right refer to the last amino acid on that line. Sequellces were aligned using ClustalW. 
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1.11.12 Bialagical effect aflL-17E 
IL-17E has distinct biological properties not reported for the other IL-I7' s, as IL-17E 
induces elements of allergic asthma and a Th2-type phenotype in mice 400,408,413,414. Using 
diverse strategies of IL-17E overexpression, three independent groups showed similar 
findings 400,408,413,414. Their primary results show that the mice develop eosinophilia, 
increased serum IgE and increased Th2-type cytokines (IL-4, -5, and -13). In addition, 
mice receiving intranasal recombinant IL-17E show production of mucus (positive 
periodic acid shiff staining) by the airway epithelium. Detailed accounts of the main 
findings are summarized in Table 3. The increase in Th2 cytokines appears specific to IL-
17E, as it is not observed in animaIs overexpressing either IL-17A 353 or IL-17F 415. 
Using various knockout mi ce or blocking antibodies, Fort et al. and Hurst et al. showed 
the necessity of IL-4, IL-4Ra, IL-5 or IL-13 in IL-17E-mediated eosinophilia, gene 
expression, histological changes and serum antibody production 400,408. While IL-4 -/- and 
IL-4Ra -/- mice given IL-17E still developed eosinophilia 400,408, such mice did not 
produce elevated IgA, IgE and IgG1 levels 408. IL-13-/ - animaIs administered IL-17E had 
no detectable BAL fluid eosinophils 400 and less blood eosinophils than wild-type 408. IL-
13 is also necessary for much of the IL-17E-mediated increase in IL-4 and IL-5. Lack of 
IL-4 does not affect elevated circulating eosinophils in mice infused with IL-17E. In 
contrast, eosinophilia is totally dependent on IL-5, and an IL-5 blocking antibody 
effectively prevents eosinophilia in IL-17E-treated mice 400,408. Interestingly, mice 
lacking IL-4Ra or IL-13 were protected against the tissue changes caused by IL-17E, 
though IL-4Ra KO mice still developed eosinophilia and had higher levels of IL-4, IL-5 
and IL-13 than WT 400,408. Interestingly, histological changes are maintained in IL-17E-
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treated RAG (recombination-activating gene) KO mi ce which lack mature Band T cells, 
and while lymphocyte deficiency totally prevents IL-4 production, IL-5 and IL-13 levels 
are still increased in these mice, but to a somewhat lesser extent than in WT 408. 
Although eosinophils are the predominant inflammatory cell observed in blood and 
tissue in all mice models overexpressing IL-17E, sorne have reported a rise in 
neutrophils. Mice given recombinant IL-17E only show BAL fluid eosinophilia and no 
neutrophilia, while mice receiving an adenoviral construct of IL-17E showed both. As 
neutrophil recruitment is not observed in mi ce receiving the control adenoviral construct 
(Ad-GFP), the authors suggest that IL-17E promotes this effect because of adenoviral 
infection 400. In addition to eosinophilia, mice expressing either a human or mouse IL-
17E transgene also report increased circulating neutrophils 413,414. Moreover, in vitro, IL-
17E induces IL-8 production, a potent neutrophil chemoattractant. Collectively, the 
evidence also supports a role for IL-17E in neutrophil recruitment. The cell types 
responsible for producing the elevated levels ofIL-4, IL-5 and IL-13 and thus mediating 
eosinophilia in the IL-17E mice models have yet to be identified. RAG KO mi ce could 
not produce IL-4 when given recombinant IL-17E, suggesting that cells of a lymphocytic 
lineage make the IL-4 408. Although, in vitro stimulation of a~TCR+CD4+ T cells or 
CDI9+ B cells with IL-l7E failed to induce IL-4, authors further suggested the role of 
yô TCR+CD4+ T cells and NK-T cells as a source for this cytokine 408. Nevertheless, IL-
17E can still promote eosinophilia in mice without lymphocytes, NK or mast cells 400 and 
induces IL-5 and IL-13 from cells of a non-lymphocyte, non-NK and non-granulocyte 
origin 400,408. While T cells, basophils and mast cells are primarily associated with IL-5 
and IL-13 secretion, other cell types have been shown to produce these cytokines 109,238. 
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Together, these results show that IL-4 production is lymphocyte-dependent, but not the 
expression of IL-5 and IL-13. The pathologies observed in the tissues occur without 
lymphocytes and require IL-13 and IL-4Ra, while eosinophilia is dependent on IL-5. IL-
17E is also very important for developing the proper Th2 immunity against parasitic 
infections. Recently, using IL-17E knockout mice, this cytokine was shown to be of 
critical importance in eradicating helminth infection 416,417 
IL-17E induces the release of several cytokines and chemokines from vanous 
structural cells as well as activating the MAPK and NF-kB pathways. The biological 
action of IL-17 A and IL-17E overlap as both promote the production of IL-6 and IL-8, 
NF-kB activation and phosphorylation of ERK1I2, p38 and JNK. AIso, both these IL-
17's necessitate the presence ofTRAF6 for proper signaling 389,405. 
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Method of Pathologies and Inflammatory Increased cytokines 
overexpression histological changes ceUs Lung Liver Kidney Spleen Stomach S.1. Blood 
Purified 1L17E Splenomegaly, eosinophils n.d. IL-S IL-S IL-13 IL4 IL-13 n.d. 
protein (i.p.) hyperplasia/hypertrophyJ (blood. spleen IL-13 IL-13 IL-13 
(Fort et al.) mucus production of lungs) 
lung and GI tract 
epithelium. Increased IgE 
levels 
Purified 1L17E Hyperplasia/mucus eosinophils IL-S n.d. n.d. n.d. n.d. n.d. n.d. 
protein (i.n.) of lung epithelium. (blood. spleen IL-13 
(Hurst et al.) lungs) IFNy 
Eotaxin 
AdenoviraIIL-17E eosinophilsl IL4 n.d. n.d. n.d. n.d. n.d. n.d. 
construct (s.e.) neutrophils IL-13 
(Hurst et al.) (lungs) Eotaxin 
hlL -17E transgene Splenomegaly, eosinophilsl n.d. n.d. n.d. n.d. n.d. n.d. IL-2 
(Kim etaI.) Iymphadenopathy, neutrophilsJ IL4 bone marrow myeloid lymphocytes IL-5 
hyperplasia. B œil (blood) G-CSF 
hyperplasia (CD19+). Eotaxin 
Increased IgE IFNy levels 
mIL-17E transgene Jaundice, growth eosinophilsJ IL4 IL4 IL4 n.d. n.d. n.d. IL-5 
(Pan et al.) retardation. Liver: neutrophilsJ GROu TNFu GROu IL-13 
fibrosis,severe (blood) IL-10 G-CSF G-CSF TNFu 
periportal inflammation, IFNy IFNy IL-10 G-CSF 
adenomatous hyperplasia ICAM1 
of bilde duels, hypertrophy 
of bile duct epithelium. 
Lung: inflammation and 
hyperplasia of bronchiole 
epithelium. Increased IgE 
levels 
n.d.: not detennined; i.p.: intraperitonneat; i.n.: intranasal: S.e.: subcutaneous; S.I.: small intestines. Cytokines: IL: interleukin; 
IFNy: interferon gamma; G-CSF: granulocyte-colony stimulating factor; GROu: gro\\1h related oneogene alpha; 
ICAM 1: intercellular adhesion molecule 1. 
Table 3. Overview of the biological changes observed III mice treated with or 
overexpressing IL-17E. 
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1.11.13 The IL-17E receptor (IL-17BR) 
IL-17BR is the second receptor of the IL-17 family to be identified 412,418,419. 
Identification of this novel receptor was made by screening expressed sequence tags 
(EST) databases for IL-17R homologs. In human it is mapped to chromosome 3p21, a 
region found to harbor several deletions in breast, lung and renal carcinomas 420-422 and is 
the most frequently deleted region in chronic myeloid leukemia 423,424. As with IL-17R, it 
is a single transmembrane receptor that shares similar position and amino acid sequence 
of its transmembrane domain 419. Structurally, IL-17BR has a much shorter cytoplasmic 
tail than the unusually long one of IL-17R. AIso, IL-17BR is thought to encode a soluble 
form, a feature not known to exist with IL-17R. The full-Iength IL-17BR mRNA is 
encoded from Il exons spanning approximately 20 kb, it contains the co ding region for 
the 22 amino acid (aa) transmembrane region on exon 10 (IL-17R has a 21 aa 
transmembrane domain). The soluble form of the receptor is though to arise from 
retention of intron 8 during transcription, yielding a longer IL-17BR message. The 
retained intron contains an in-frame stop codon that halts translation and produces a 
truncated version of the receptor lacking the transmembrane domain. Another notable 
difference between the two receptors is the affinity for their ligands, the binding kinetics, 
of IL-17 A for IL-17R shows a dissociation constant value (KI) of 74 nM, whereas it is 
only of 1.1 nM for IL-17E for IL-17BR 342. This indicates that an almost 10-fold greater 
concentration of IL-17 A is necessary to bind IL-17R than is necessary for IL-17E to bind 
IL-17BR. 
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IL-17BR is expressed in a wide variety of human tissues, the highest mRNA content 
being found in the kidneys 412,418,419. The receptor also shows constitutive expression in 
the lungs and trachea 412. At the cellular level, IL-17BR is present in various murine and 
human leukocytic celllines as weIl as in sorne human epithelial cancer cell lines 412,419. 
IL-17BR binds IL-17B and IL-17E, but shows a greater affinity for IL-17E 342,412. IL-
17BR is also known as IL-17Rhl 412 and Evi27 419. The murine ortholog ofthis receptor, 
initially identified as Evi27, is a common integration site for retroviral integration in 
BHX2 murine myeloid leukemias 425. Only one report is available on IL-17BR 
regulation. Gratchev et al. showed that human monocytes and monocyte-derived 
dendritic cells express IL-17BR 426. In this study, the baseline measurement of the 
receptor is unclear, but the combination of IL-4 and TGFB for monocytes and IL-I0 for 
dendritic cells are strong stimuli in increasing IL-17BR mRNA. Similar to findings in 
ASMC 427, IFNy appears to decrease both IL-17BR message and protein in monocytes 
426. TNFa is an effective inducer of IL-17BR expression in both ASMC and lung 
fibroblasts 427,428. 
While data in the literature concerning the signaling components associated with IL-
17BR is very limited, IL-17E is known to activate NF-kB in several cell type 405,407,412. It 
was suggested that IL-17E might signal through one of the TNF receptor-associated 
factor (TRAF) molecules because IL-17 A is dependent on TRAF6 for NF-kB and JNK 
activation 389. Indeed, TRAF6 is also necessary for NF-kB activation by IL-17E as 
assessed using TRAF6 -/- mouse embryonic fibroblasts (MEF) 405. IL-17BR associates 
specifically with TRAF6, not TRAF2 or TRAF5, to convey the signal to the NF-kB 
pathway. In addition, IL-17E activates ERK, p38 and JNK phosphorylation 
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independently ofTRAF6. IL-17E also activates p38 and JNK in human eosinophils 407. In 
MEF, TRAF6 is necessary for the induction of IL-6, TGFf), G-CSF and TARC mRNA 
after IL-17BR ligation 405. In contradiction with the Th2 nature of IL-17E and the 
necessity of TRAF6 for sorne of its signaling, TRAF6 knockout mice develop a Th2-type 
inflammation 429. Anti-CD3 and anti-CD28-stimulated CD4+ T cells from TRAF6-/-
mice secrete similar amounts of IFNy as wild-type, but inordinately higher quantities of 
IL-4, IL-lO and TGFf) 429. However, levels of IL-5 or IL-13 were not assessed in these 
mice. In addition, lack of TRAF6/NF-kB signaling might not adversely affect IL-17E-
induced Th2 cytokines, as IL-4, IL-5 and IL-13 secretion can be mediated by other 
signaling pathways 430. Since TNFa is also increased in the transgenic animaIs 41\ and as 
TNFa upregulates IL-17BR in ASMC and lung fibroblasts 427,428, it is possible that it is 
responsible for the elevated IL-17E receptor expression. AIso, in vitro data from 
eosinophils suggests that IL-17E itself may also increase expression of IL-17BR 407. 
Interestingly, IL-17BR expression is upregulated in IL-17E transgenic mice 413,414. 
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1.12 Rationale 
IL-17E promotes a Th2-type inflammatory response in mice and has been shown in 
vitro to be produced by Th2 lymphocytes as weIl as mast cells, two celIs types that are 
known to infiltrate the bronchial mucosa of asthmatics. Little is known about the biology 
of IL-17E on human cells because most data generated so far have been in mice models. 
IL-17E is an important target of study in the context of human asthma since it induces 
asthma-like features in mice. The importance of airway structural cells in the 
participation of asthma has been weIl identified. However their exact contribution to 
airway inflammation remains to be elucidated. Thus, understanding their interaction with 
cytokines important in asthma pathogenesis is crucial. 
1.13 Hypothesis 
We hypothesized that structural cells of the alrways would express the IL-17E 
receptor, and that the levels of expreSSIOn could be modulated by Thl, Th2 or 
proinflammatory cytokines. Secondly, we hypothesized these structural cells would 
respond to IL-17E via IL-17BR by generating mediators and effects important to to 
asthma pathogenesis, such as cytokines and chemokines that support airway 
inflammation, deposition of components of the extracellular matrix and promoting 
cellular proliferation. 
1.14 Aims 
1.14.1 General Aims 
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The general aim of this thesis was to clarify the link between IL-17E and structural 
cells of the airways. We wanted to assess the presence of the Il-17E receptor (IL-17BR) 
in cultured airway structural cells as weIl as in human bronchial biopsies. In addition, we 
examied the biological effect of IL-17E on these cells in vitro. 
1.14.2 Specifie Aims 
1. To assess the presence of IL-17BR on airway smooth muscle in sections of biopsies 
taken from human bronchial tissue. Then examine its expression in cultured airway 
smooth muscle cells as well as its modulation by various types of cytokines. If the 
receptor was to be present, evaluate the effect of IL-17E on the production of components 
of the extracellular matrix. 
2. To investigate the presence of the IL-17E receptor on lung fibroblasts and evaluate the 
effect of this cytokine on the production of mediators that promote allergie airway 
inflammation. 
3. To examine the presence of IL-17BR on the epithelium in sections of biopsies taken 
from human bronchial tissue. Following that, to investigate its expression in cultured lung 
epithelial cells as weIl as its modulation by various types of cytokines. To compare levels 
of IL-17BR between bronchial epithelial cells isolated from asthmatics vs. cells from 
control donors. If the receptor was to be present, evaluate the effect of IL-17E on the 
production of inflammatory cytokines and chemokines as weIl as it role in epithelial 
proliferation. 
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Chapter 2 - Materials and Methods 
2.0 Summary of experimental design 
To address the questions put forward in our hypothesis, three different studies were 
perfonned. We cultured three different types of airway structural cells (airway smooth 
muscle cells, fibroblasts and epithelial cells) for this purpose of studying the presence of 
the IL-17E receptor as well as the effect of IL-17E on these cells in vitro. Initially we 
used primary airway smooth muscle cells from non-asthmatic donors; these were purified 
from lung resected tissue and characterized as smooth muscle ceUs. We also used airway 
sections from biopsies to assess the in vivo presence of IL-17BR on airway smooth 
muscle ceUs. For in vitro experiments, we used recombinant human cytokines to 
stimulate the ceUs in culture and assess expression of IL-17BR by experiments involving 
real-time peR, western blot, laser capture microdissection, immunohistochemistry and 
immunofluorescence. 
Secondly, primary lung fibroblasts were commercially obtained and were tested for 
the presence of IL-17BR on by immunofluorescence, western blot and real-time peRo 
We then treated the fibroblasts with recombinant human IL-17E and measured by real-
time peR and enzyme-linked immunosorbent assay (ELISA) chemokine production. 
FinaUy, we used lung epithelial ceUs in which we assessed the presence of IL-17BR 
by western blot and real-time peRo We then treated the epithelial ceUs with recombinant 
human IL-17E and measured their proliferative response by radioactive thymidine uptake 
and production of chemokines by real-time peR. 
87 
2.1 Materials 
This section mentions the commercial and non-commercial sources for the materials 
used in the experiments performed in this thesis. Smooth muscle Growth medium was 
purchased from Cambrex (East Rutherford, NJ, USA). LabTek chamber slides were 
bought from Nalgene Nunc (Naperville, IL, USA). Human recombinant cytokines, rhIL-
17BR:F c, mouse monoclonal anti-IL-17BR and isotype antibodies were obtained from 
R&D Systems (Minneapolis, MN, USA). QuantiTect SYBR Green PCR kit, RNeasy 
mini and micro kit extraction columns, HiSpeed Maxi plasmid kit, the QIAquick PCR 
purification kit and the Endo-free Maxiprep kit were purchased from Qiagen 
(Mississauga, ON, Canada). CXCL8 and GM-CSF ELISA kits were obtained from 
Biosource International (Camarillo, CA, USA). Trypan Blue dye, Superscript II, Taq 
Platinum polymerase, PCR primers, 100 bp DNA ladder and restriction enzymes were 
obtained from Invitrogen (Burlington, ON, Canada). Bradford assay reagent and Western 
blot precision plus molecular weight standards were purchased from Bio-Rad 
(Mississauga, ON, Canada). Donkey anti-mouse HRP-conjugated secondary antibody, 
oligo(dT)12-18 primer, RNAguard, Hybond-P polyvinylidene fluoride (PVDF) 
membrane, ECL Plus, and X-ray films were purchased from Amersham Pharmacia 
Biotech (Baie d'Urfé, QC, Canada). The LightCycler real-time PCR, the minicomplete 
protease inhibitor cocktail tablets were bought from Roche Diagnostics (Laval, QC, 
Canada). pGEM-T, pGL3 and pRL-TK plasmids and the Dual luciferase assay were 
purchased from Promega (Madison, WI, USA). Pharmacological inhibitors (U0126, 
SB203580, and SP600125, resuspended in dimethyl sulfoxide - DMSO), dexamethasone 
21-phosphate di sodium salt (resuspended in water) and Fast Red were purchased from 
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Sigma-Aldrich (Oakville, ON, Canada). The specific IKK2 inhibitor, AS602868, was a 
generous gift from Dr. Ian M. Adcock (National Heart and Lung Institute, Imperial 
College London). Alexa Fluor 555 labelled goat antimouse IgG was obtained from 
Molecular Probes (Eugene, OR). Universal Blocking Solution and mouse alkaline 
phosphatase anti-alkaline phosphatase (APAAP) were bought from Dako, (Mississauga, 
ON, Canada), Gill modified hematoxylin was from Surgipath (Winnipeg, MB, Canada). 
The BX51 Olympus epifluorescence microscope attached to a CooISNAP-Pro color 
digital camera was purchased from Carsen Group (Markham, ON, Canada). The Cap-
Sure Macro LCM Caps and the PixCelI II System were obtained from Arcturus 
(Mountain View, CA, USA). The GeneAmp high fidelity PCR enzyme mix was obtained 
from Applied Biosystems (Foster City, CA, USA). The antibody array was obtained from 
RayBiotech (Norcross, GA, USA). AlI sequencing reactions were performed at McGilI's 
University Genome Centre. 
2.2 General techniques 
Several of the techniques used in this thesis were performed across all three main projects 
and will be included in this section. 
2.2.1 RNA extraction 
Total RNA was isolated from (i) cultured ASMC and (ii) ASMC bundles from human 
airway biopsies (see 2.2.9 section) using RNeasy mini and micro kit extraction columns, 
respectively. The columns are composed of a specially engineered silica membrane that 
captures and holds the RNA. The frozen samples in RL T buffer are thawed out and an 
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equal volume (350 ul) of 70% ethanol is added to each tube to promote selective binding 
of RNA to the RNeasy column. This serves to acidify the solution and helps the RNA to 
bind the silica membrane. Buffers are used to wash away residual proteins and other 
impurities. RNA is eluted from the extraction columns using 35 ul RNAse-free water and 
then quantified using spectrophotometry. 
2.2.2 Complementary DNA (cDNA) preparation 
cDNA is obtained by reverse transcribing RNA into DNA using a reverse transcriptase 
enzyme. We used 500 ng of total RNA from cultured airway smooth muscle to generate 
the cDNA. As messenger RNA (mRNA) is characterized by having a tail containing 
several non-coding adenosines (poly A tail), a synthetic primer composed of 
complementary thymidines (oligodT) that will initiate the reverse transcription reaction. 
This mix of RNA, and oligodT is heated at 65°C for 5 min in order to linearize the RNA 
molecules by undoing secondary structure formation. The mix is then quickly chilled on 
ice. 20 ul of a master mix composed of water, reverse transcription buffer (250 mM Tris-
Cl, 375 mM KCI and 15 mM MgClz), 0.1 M dithiothreitol (DTT), dNTPs (dATP, dTTP, 
dGTP and dCTP), 40 units of ribonuclease inhibitor (RNasein), and 40 units of 
SuperScript II reverse transcriptase is then added to then RNA and the reverse 
transcription reaction was performed at 42C for 1 h. The enzyme is inactivated by heating 
the reaction for 15 min at 70°C. The cDNA is then stored at -20°C until used as a 
template for PCR. 
2.2.3 Real-time quantitative PCR (QPCR) 
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Real-time QPCR was used to detennine the expression of several genes of interest at 
the mRNA level. Real-time QPCR was done using the LightCycler system from Roche. 
The PCR reaction is done in a 20 III volume containing 7 III water, 1 III cDNA, 0.3 IlM of 
each primer, and 10 III of2X QuantiTect SYBR Green PCR Master Mix. The QuantiTect 
SYBR Green master mix contains HotStartTaq DNA polymerase, PCR buffer, dNTPs 
and the SYBR Green dye. The SYBR Green dye is used to quantify the generation of 
ampli cons in the PCR reaction in real-time, it intercalates in the minor groove of double-
stranded DNA, but cannot bind single-stranded DNA. Hence, the amount of double-
stranded DNA in a PCR reaction correlates with the amount of SYBR Green dye bound, 
thus generating more fluorescence. The LightCycler uses a diode to excite the SYBR 
Green dye and a fluorescence detector to measure the resulting signal. 
The PCR reaction is perfonned in a glass capiUary that pennits very rapid and 
efficient air-induced heating and cooling. 
AU primers used in this thesis were designed to span at least one intron and, in the 
case of IL-17BR, to include the region encoding the transmembrane domain. Designing 
primers that cover at least one intron avoids co-amplification of genomic DNA. Relative 
quantification of the genes was achieved by constructing standard curves using seriaI 
dilutions of PCR amplicons of the gene in question. PCR was employed to amplify the 
genes of interest from structural ceU cDNA, AU PCR amplicons were purified using the 
QIAquick PCR purification kit and specificity of the amplified products was assessed by 
gel electrophoresis, then quantified by spectrophotometry. A 10-fold dilution series 
ranging from 10 -1 to 10-10 ng/Ill of each amplicon was then prepared in Tris-HCl pH 
8.0. Relative quantification of gene expression was perfonned using the LightCycler 
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software. The software calculates a standard curve from the known concentrations in 
ng/ul vs. the Ct values (crossing point) and uses this curve to compute the concentrations 
by interpolating the Ct values of the experimental samples. 
Gene name Sequence .\mplicon size 
Sense: 5'- TGCTGACGCTTGATGAGAAG -3' 
S9 .. __ ._N __ . __ ... NH.· __ · .. ··,_. ____ ·_· ____ · ____ ._ •.• _· _________ . __ • __ , 
Antisense: 5'- CGCAGAGAGAAGTCGATGTG-3' 
307 bp 
Sense: 5'- AACAGGCGTCCCTTTCCCTCTGGA -3' 
IL-17BR .... _ .... _._.-._ .... _ .. _ .._-_._._. __ .... __ .. _ ... __ ._.--_ ... _._-------_ .. __ ........ _._---------_._--
Antisense: 5'- TTCTTGATCCTTTCGTGCCTCCAC -3' 
141 bp 
Sense: 5'- CTGGTCCCCAAGGCTTCCAAGG -3' 
Pro-collagen al ....... __ ..... _-_ ........ _ .... _ ... _ ...... _ ..... _-------_ .. --_._ ...... __ ._----_. __ ._------------- 478 bp 
Antisense: 5'- CTTCACCCTT AGCACCAACAGC -3' 
Sense: 5'- GAATTGGAGACCCAACCAGCC -3' 
Versican -_. __ ._------_ .................. _ ..... _ .. _---_._-_. __ ._--............... _------_ ... _-----------_._-_ .. _---_._----... 300bp 
Antisense: 5'- GGTATAGCCCATCTTCCATTTCC -3' 
Sense: 5'- CCTGGTTGAGCTGGATCTGT -3' 
Lumican .. __ .. _. __ ...... __ ....... _-_ .... _.-... _ ..... _--_ ..... _-......... __ ._----_ ... _--_._-----.. _._--_ .. _._ ... _._. __ .. 194 bp 
Antisense: 5'- TGGTTTCTGAGATGCGATTG -3' 
Sense: 5'- GAAAGCTTGCCTCAATCCTG -3' 
GROa .. _ .... __ ._ ........ __ .-......... __ ._ .. -.. _. __ ._--_ .... _---_._ .... _-_._ ... _-----------_ .. _-_. __ . 194 bp 
Antisense: 5'- CATTAGGCACAATCCAGGTG -3' 
Sense: 5'- GCAGAGGGTTGTGGAGAAG-3' 
IL-8 (CXCL8) -_ .. _ .. __ .. __ . __ ._ .... _-------_._ .. _-_._._-_ .... __ .. _-----_._ ... _---_._--_. __ ... _--_.-
Antisense: 5'- TCTTGTATTGCATCTGGCAAC-3' 
169 bp 
Sense: 5'- GGTACATCCTCGACGGCATC -3' 
IL-6 ......... _ ...__ ._--_ ........ __ ._--_ .. _ ..... _-----_ .. _---_.--------_._---_ ... _- 79bp 
Antisense: 5'- GCCTCTTTGCTGCTTTCACAC-3' 
Eotaxin Sense: 5'- GGGCCAGCTTCTGTCCCAAC -3' 
..... _-_ ...... __ .. _ .. _----_. __ .... _. __ .... _ ... __ ... _---------------- 225 bp (CCLll) Antisense: 5'- TT ATGGCTTTGGAGTTGGAGATTT -3' 
Sense: 5'- CCAGCCACTACAAGCAGCAC-3' 
GM-CSF 
Antisense: 5'- GGGATGACAAGCAGAAAGTCC -3' 
112 bp 
RANTES Sense: 5'- TCCAACCCAGCAGTCGTC -3' 
(CCL5) Antisense: 5'- CAAGAGCAAGCAGAAACAGG -3' 
162 bp 
Table 4. List of primers used for real-time peR 
2.2.4 Western blotting 
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Western blot was used to detect IL-17BR protein after treatment of ASMC with TNFa 
and IFNy. After cytokine stimulation, the media was removed and the cells were rinsed in 
ice-cold PBS and incubated in lysis buffer (150 mM NaCI; 10 mM Tris-HCl pH 7.4; 1 
mM EDTA; 1 mM EGTA; 1 % Triton X-100; 0.5% NP40, 100 mM sodium fluoride; 10 
mM sodium pyrophosphate; 2 mM sodium orthovanadate) containing a mini-complete 
protease inhibitor cocktail tablet for 30 minutes on ice. Cell extracts were collected from 
the bottom of each wells and clarified at 14,000 x g at 4°C for 20 minutes to remove cell 
debris. Prote in concentration was determined using the Bradford assay. 10 Jlg of prote in 
was then resolved by one-dimensional 10% sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis (SDS-P AGE) and transferred to Hybond-P polyvinylidene difluoride 
(PVDF) membranes. Blocking of membranes was carried out using 5% bovine serum 
albumin (BSA) in Tris-buffered saline (TBS) containing Tween-20 (TBS-T) (0.05% 
Tween-20, 10 mM TBS, pH 7.5) for 2 h at room temperature. Blots were incubated 
overnight at 4°C with either 0.5 Jlg/ml of mouse monoclonal anti-IL-17BR antibody or 
with anti-IL-17BR preincubated with a 10 molar excess of rhIL-17BR:F c chimera for 2 h 
at room temperature. After washing, membranes were treated with horseradish 
peroxidase (HRP)-conjugated anti-mouse secondary antibody for 1 h at room 
temperature. After washing, signal was developed using reagents from the ECL Plus kit 
that con tains a substrate for the HRP enzyme that is converted to a chemiluminescent 
signal. Chemiluminescence was detected by exposing the membranes to an X-ray film. 
2.2.5 Immunojluorescence 
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Immunofluorescence was used to visualize IL-17BR expression by cultured ASMC 
and lung fibroblasts. To do so, cells were grown to 50-60% confluence in LabTek 
chamber slides. These chamber slides offer 8 plastic chambers glued on top of a glass 
slide and permit 8 different conditions on the same slide. The slides were briefly rinsed in 
room temperature PBS, then fixed in a 4 % paraformaldehyde solution for 20 min at 
room temperature and washed again in PBS for 5 min before drying ovemight. Fixed 
slides were stored at -80°C until use. When processed, the slides were first incubated 
with a solution of 50 ~M NH4CI for 30 min, followed by blocking in 20% normal goat 
serum. Slides were then exposed ovemight to a solution of mouse anti-human IL-17BR 
(5 ~g/ml), or isotype matched control antibody. Slides were extensively washed and 
incubated with a 1/750 dilution of goat anti-mouse IgG labeled with the Alexa Fluor 555 
dye. After 555 nm light excitation, the Alexa Fluor will emit fluorescence at 565 nm, 
visible as orange-red. Cell nuclei are visualized by staining with Hoechst 33342 (2 
~g/ml); this dye stains nucleic acids and emits blue fluorescence (461 nm) after 
ultraviolet-light excitation. Slides were examined with a BX51 Olympus epifluorescence 
microscope attached to a CooISNAP-Pro color digital camera. 
2.2. 6 Immunohistochemistry of sections from branchial biopsies 
Immunohistochemistry was performed on sections of major airways from 6 mi Id 
asthmatic subjects. Paraffin-embedded sections were deparaffinized and heat-induced 
antigen retrieval was performed using 10 mM citrate buffer. Slides were then extensively 
washed in PBS, blocked for 30 min in Univers al Blocking Solution and incubated 
ovemight at 4°C with 25 uglml murine anti-human IL-17BR, or IgG2B isotype control, 
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antibodies. Sections were subsequently washed twice m TBS pnor to 45 minute 
incubation at room temperature with rabbit anti-mouse Ig followed by mouse alkaline 
phosphatase anti-alkaline phosphatase (AP AAP). The reaction was developed using Fast 
Red. Tissue was then counterstained with Gill modified hematoxylin and examined by 
light microscopy. Images were acquired with the BX51 microscope. 
2.2.7 Statistical analysis 
Data are expressed as means ± standard deviation. Analysis of Variance 
(ANOVA) followed by a Student's T test was performed on a minimum of3 independent 
experiments whenever statistical analysis was used. ln sorne cases the differences 
between groups were detected using the Kruskall-Wallis test. The Mann-Whitney U test 
was performed after the Kruskall-Wallis test when appropriate. A p value of <0.05 was 
considered significant. 
2.3 Airway smooth muscle eell-specifie experiments 
2.3.11salatian and culture afhuman branchial ASMe 
Primary human airway smooth muscle cells (ASMC) were obtained from mam 
bronchial airway segments (0.5-1.0 cm diameter) in pathologically uninvolved segments 
of resected lung specimens using isolation methods described previously (17, 46). Cells 
were then seeded at a density of 105 cells/cm2 and grown at 37°C in Smooth Muscle 
Growth medium. At confluence, primary human ASMC exhibited spindle morphology 
and a hill-and-valley pattern characteristic of smooth muscle in culture. In cultures up to 
passage 5, over 90% of the cells at confluence retained smooth muscle-specific a-actin, 
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SM22, and calponin protein expression, and were able to mobilize intracellular Ca 2+ in 
response to acetylcholine. Growth rate (detennined by cell number) of ASMC from aIl 
lung resection donors was similar to that reported previously for AS MC cultures from 
healthy human transplant donors. MorphologicaIly, the ASMC from lung resection 
don ors and from healthy human transplant donors were indistinguishable. Cell viability 
was always above 95% as assessed by Trypan Blue dye exclusion. ASMC were cultured 
in commercially available media containing 5 % fetal bovine serum (FBS), insulin, 
human fibroblast growth factor, hum an epidennal growth factor and gentamycin sulfate 
and amphotericin-B. 
2.3.2 Cel! stimulation 
ASMC were grown in 6 or 12-well dishes. At confluency, cells were serum-starved 
for 24 h before stimulation to allow the cells to reach a quiescent state. Recombinant 
human cytokines (TNFa, IL-4, IFNy or IL-17E) were added for various times and at 
different concentrations. We also used phannacological inhibitors (table 5) that target the 
three main mitogen activated kinase (MAPK) pathways, namely extracellular-regulated 
kinase (ERK), p38 and c-Jun-N-tenninal kinase (JNK) as weIl as the NF-kB pathway. 
These inhibitors help to distinguish the pathway(s) necessary by which a specific 
stimulus conducts its observed effect(s); in this case the stimuli are TNFa and IFNy. NF-
kB is a proinflammatory transcription factor that regulates several immune response 
genes. NF-kB activation is an important downstream effect of TNFa signaling. ASMC 
were therefore pre-treated with the phannacological inhibitors 1 h prior to addition of 
TNFa or IFNy. For RNA extraction, cells were lysed and homogenized directly from the 
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wells using 350 ul RL T buffer supplemented with ~-mercaptoethanol. The RL T buffer is 
a guanidine isothiocyanate solution (RLT buffer) containing ~-mercaptoethabol, which 
provides a denaturing and RNAse-free environment. Lysates were stored at -80°C until 
RNA extraction. 
Pharmacological inhihitor Function 
U0126 
SB203580 
SP600125 
AS602868 
Prevents phosphorylation of ERKI and ERK2 by inhibiting MEKI 
and MEK2 431 
Inhibits the phosphorylation of p38 432 
Inhibits the phosphorylation of c-Jun by inhibiting JNK 433 
Inhibits IKK2 and prevents IkB phosphorylation and degradation, 
and therefore NF-kB activation.434,435 
Table 5. List of pharmacological inhibitors used and their target. 
2.3.3 Laser capture microdissection of ASMe bundle 
Laser capture microdissection (LCM) is a technique that originated at the National 
Institutes of Health (NIH) 436,437 and allows for the removal of specific areas or cell-types 
from sectioned tissue preparations. The removed tissue can be used for RNA, DNA and 
even prote in extraction and analysis. To assess the presence of IL-17BR mRNA in airway 
smooth muscle cells in vivo, LCM was performed on sections of the airways taken from 
biopsies of mi Id asthmatic patients in order to selectively remove smooth muscle bundles. 
Slides were completely air-dried and desiccated to prevent the activation of endogenous 
RNase in the tissues. LCM of smooth muscle bundles was performed using the PixCell II 
System with the following parameters: laser diameer, 15 !lm; pulse duration, 1.5 
milliseconds; and amplitudes, 80 to 90 milliWatts. The interval between staining of slides 
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and completion of microdissection was 1 to 2 hours. After samples were captured on 
Cap-Sure Macro LCM Caps, cells were lysed with RLT lysis buffer (Qiagen RNeasy kit), 
and samples were stored at -80DC until RNA extraction (Fig. 8). 
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Fig. 8. Overview of laser capture microdissection (LeM). (A) A cap with a thermoplastic 
membrane is placed above the tissue of interested and pulses of low energy infrared laser 
activates the adhesiveness of the membrane and captures cells or cellular structure of 
interest which can then be lifted off the slide. The cells that were transferred to this 
membrane can then be processed for RNNDNA extraction. (B) Actual example of a 
human airway biopsy stained with hematoxylin, where a smooth muscle bundle is 
captured and lifted off the slide. 
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2.3.4 Antibody array 
Antibody arrays are small nitrocellulose membranes on which capture antibodies that 
recognize several types of target proteins (cytokine, chemokines, phosphorylated 
proteins, etc) are spotted. They allow for the comparison of supematants, cell or tissue 
extracts, serum, etc, from different sources or treatments and gives information on 
possible increase or decrease of proteins represented on the membrane. 
In our experiment, we used a commercial antibody array (RayBio) that contains 42 
different cytokine and chemokine capture antibodies spotted in duplicate on membranes. 
ASMC were treated with either vehicle or IL-17E (30 ng/ml) for 24 h. Supematants were 
collected and incubated with the antibody array ovemight at 4°C to allow for the 
cytokines and chemokines in the supematant to bind the capture antibodies on the array. 
Membranes were rinsed and incubated with a cocktail of biotin-Iabeled detecting 
antibodies (the cocktail contains antibodies against all 42 cytokines and chemokines 
represented on the array) ovemight at 4°C. Membranes are then incubated with an HRP-
conjugated streptavidin and incubated with ECL+. Chemiluminescence was detected 
using X-ray film. Dot intensity was quantified using the free ImageJ software from the 
National Institutes of Health (http://rsb.info.nih.gov/ij/). 
2.4 Primary lung fibroblast-specific experiments 
2.4.1 Growth ofprimary lungfibroblasts 
Normal primary hum an lung fibroblasts (CCD-8Lu) were obtained from the American 
Type Culture Collection (ATCC). These fibroblasts were isolated from a single non-
asthmatic 48 yr old male donor that deceased of cerebral thrombosis. Lung fibroblasts 
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were grown in Dulbecco's Modified Eagle Medium (DMEM) that was supplemented 
with the essential amino acid L-glutamine, penicillinlstreptomycin and 10% FBS. 
2.4.2 Cel! stimulation 
Lung fibroblasts were grown III 6-well dishes. At confluency, cells were serum-
starved for 24 h before stimulation to allow the cells to reach a quiescent state. Various 
cytokines (TNFa, TGF~I, IL-17E) were added for various times. Since IL-17E is often 
synergistic in combination with TNFa in the production of certain cytokines, we also 
combined IL-17E and TNFa. Supematants from certain conditions were kept for ELISA 
analysis. For RNA extraction, cells were harvested directly from the wells using 350 ul 
RLT buffer supplemented with ~-mercaptoethanol. Lysates were stored at -80°C until 
RNA extraction. 
2.4.3 ELISA: measurement ofGM-CSF and IL-8 (CXCL-8) release 
Sandwich ELISA is a very sensitive method by which to measure the release of certain 
mediators such as cytokines or chemokines in supematants of cultured cells. The 
sandwich tenn cornes from the fact that the molecule being detected is held between the 
capture antibody and the detection antibody. This method was used to measure IL-8 and 
GM-CSF in the supematants of lung fibroblasts treated with IL-17E, TNFa, IL-17E in 
combination with TNFa or in those receiving no stimulation. After 48 hours of 
stimulation, fibroblast supematants were collected and centrifuged to rem ove residual 
cells. Samples were stored frozen at -80°C until quantification by using commercially 
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available ELISA kits specifie for hum an GM-CSF and CXCL8 (lL-8). ELISA are 
performed in a 96-well plate format. 
The capture antibody coats the bottom of the wells. The wells are blocked using a 
solution of BSA for 3 h at RT. Blocking solution is removed and wells are rinsed then 
100 ul of supematant is incubated in the wells for 1 h at R T . Wells are washed thoroughly 
and incubated with the detection antibody that is coupled to biotin molecules for 1 h at 
RT. After washing, a solution of streptavidin conjugated to HRP is added for another 
hour at RT. Wells are washed once more and then incubated with the HRP substrate, 
TMB blue for approximately 20-30 min at RT until the development of a clear blue color. 
This reaction is stopped by addition of IN HCI, a plate reader reads the color intensity 
and calculates with the help of a standard curve the amount of cytokine of interest in 
pg/ml in each weIl. The detection limits were 3 pg/mL for GM-CSF and 5 pglmL for 
CXCL8. 
2.4 Lung epithelial cell-specific experiments 
2.4.1 Growth of the lung epithelial cel/line A549 
The lung alveolar epithelial cellline A549 were obtained from the A TCC, these cells 
were isolated from lung carcinomatous tissue from a 58-year-old male. A549 cells are a 
widely used cell model in lung and respiratory research. Cells were maintained in al: 1 
mix of DMEM and FI2 media that was supplemented with the essential amino acid L-
glutamine, penicillin/streptomycin and 10% FBS. 
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2.4.2 Isolation and growth ofprimary bronchial epithelial cellsfrom control and mild 
asthmatic donors 
These epithelial cells were isolated from bronchial biopsies of mild asthmatic and non-
asthmatic subjects as reported previously 438. Volunteers aged between 20 to 35 years 
were recruited from the Asthma Clinic at the Laval Hospital (Quebec, QC, Canada). The 
ethics committee of Laval Hospital approved the study and all subjects gave written 
informed consent. The asthmatic subjects were diagnosed according to the American 
Thoracic Society criteria 439 (methacholine PC20< 8 mg/ml) and used only inhaled fh-
agonists on demand. Their mean FEV I was 85 ± 3.1 % and mean PC20 was 4.0 ± 2.2 
mg/ml. None used inhaled or systemic corticosteroids. All asthmatics were non-smokers 
atopics and had skin test positive for house dust mite. Control subjects (mean FEV I = 
98.2 ± 5.1 and mean PC20=99.4 ± 1.2 mg/ml) were non-atopics and non-smokers with no 
history of asthma or systemic diseases. Bronchial biopsies were obtained by 
bronchoscopy from asthmatic and normal subjects and epithelial cells were isolated from 
bronchial biopsies as reported previously 440 and characterized by immunofluorescence 
and flow cytometry using anti-cytokeratin, anti-vimentin, and a mouse anti-human 
fibroblast antigen Ab-1 (CD90/Thy-1) antibody (Calbiochem) that showed no cross 
reactions with epithelial cells, endothelial cells, smooth muscle cells or many other cell 
types 441. This characterization confirmed the purity of our bronchial cell culture. Primary 
epithelial cells from donors were grown in DMEM/F12 (3:1) supplemented with 10% 
FBS, 10 ng/ml epithelial growth factor (EGF), 5 /lg/ml insulin, 5 /lg/ml transferrin, 2x1O-
9 M T3, 0.4 /lg/ml hydrocortisone, 10-10 M cholera toxin. Cells from control, non-
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asthmatic individuals are labeled as BNE (bronchial normal epithelial) and cells isolated 
from mild asthmatics are labeled as BAE (bronchial asthmatic epithelium). 
2.4.3 Cell stimulation 
A549 cells were grown in 12-well dishes. At confluency, cells were serum-starved for 
24 h before stimulation to allow the cells to reach a quiescent state. Various cytokines 
(TNFa, IL-17 A, IL-17E) were added for various times and at different concentrations. 
Since IL-17E is often synergistic in combination with TNFa in the production of certain 
cytokines, we tried to block that effect by using the recombinant IL-17E receptor (IL-
17BR). Accordingly, IL-17E (50 ng/ml) was pre-incubated with rhIL-17BR:Fc fusion 
prote in for 2 h at RT prior to adding with TNFa to A549 cells. As control we also 
performed the same experiment using IL-17A. For RNA extraction, cells were harvested 
directly from the wells using 350 ul RL T buffer supplemented with ~-mercaptoethanol. 
Lysates were stored at -80°C until RNA extraction. 
Primary bronchial epithelial cells from donors were grown III 6-well dishes. At 
confluency, cells were serum-starved for 24 h before stimulation to allow the cells to 
reach a quiescent state. Cytokines (TNFa, IL-17E) were added for various times and 
doses. Stimulations were done for 4 or 24 h. Cells were detached and cell pellets were 
immediately lysed in 350 ul RL T buffer. All extracts were kept at -80°C until processing. 
2.4.4 Assessment of A549 cell proliferation by radioactive thymidine incoporation 
The effect of IL-17E on proliferation of A549 cells was measured by radioactive 
thymidine uptake. The initiation of DNA repli cation is a sign of cell division. To assess 
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it, radioactive thymidine is placed in the media where it enters the cells and is used by the 
DNA replication machinery in place of regular endogenous thymidine. An increase in 
radioactive signal emission correlates with increased incorporation of radioactive 
thymidine in the cell's DNA and an indicator of cell proliferation. For this experiment, 
A549 cells were plated in 96-well dishes at 3000 cells per weIl and allowed to adhere 
ovemight in complete media (DMEM/F12 + 10% FBS). Cells were rinsed twice in 
starving media, (DMEMIF 12 without FBS) and starved for 48 h. After starving, media is 
replaced with fresh starving media containing IL-l7E (50 ng/ml) or 2% FBS (positive 
control) and stimulated for 24 h. Cells were pulsed with 0.5 ",Ci 3H-thymidine/well for 
the last 5 hours of the 24 h stimulation period. After incubation, wells were rinsed once 
with lx DPBS and incubated for 15 min with trypsin to detach the cells and stored at -
80DC. Cells were harvested onto glass filter mats (Wallac, PerkinElmer Life Sciences, 
Boston, MA, USA) with a semiautomatic cell harvester (Micro96 hervester, Skatron 
Instruments, Sterling VA, USA). 3H-thymidine incorporation was measured by liquid 
scintillation counting (1450 MicroBeta Tri1ux, Wallac) and expressed as counts per 
minute (CPM). 
2.4.5 Assessment ofBNE and BAE cel! proliferation by bromodeoxyuridine incorporation 
The effect of IL-17E on proliferation of BNE and BAE cells was assessed by uptake 
of the synthetic thymidine analog bromodeoxyuridine (BrdU). ELISA was used to 
measure total cellular BrdU incorporation. For this experiment, BNE and BAE cells were 
plated in 96-well dishes at 10 000 cells per well and allowed to adhere ovemight. Cells 
were serum-starved for 24 h and then stimu1ated with either media or IL-l7E (50 ng/ml) 
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for 48 h. Afterwards, 10 ul of BrdU labeling solution was added to each weIl and 
incubated for 2 h. Cells are rinsed and fixed and BrdU is detected by using an anti-BrdU 
antibody. 
106 
Chapter 3 - ResuUs 
3.1 Expression and function of the IL-17E receptor on human airway 
smooth muscle cells. 
3.1.1 Introduction 
Interest in the interleukin (IL )-17 family has been stimulated by the publication of 
data suggesting that its founding member, IL-17 A, may contribute to the pathogenesis of 
conditions su ch as cancer, multiple sclerosis, arthritis, lupus and asthma 
150,297,391,392,442,443 The expression of this cytokine is significantly upregulated in the 
airways of subjects with moderate-to-severe asthma 150. IL-17 A is proinflammatory in 
nature and is produced primarily by activated memory CD4+ T lymphocytes, and does 
not appear to be particularly associated with either the Th1 or Th2 subset of these cells 
349,351. It has now been demonstrated that IL-17 A is produced by a particular lineage of 
CD4+ T cells called Th17 or ThIL-I7 353,354,444. IL-17 A is especially potent at synergizing 
with IL-If) or TNFa to induce production of cytokines such as IL-6, IL-8 and GM-CSF 
163,164,334,344,364,380. Among the six members of the IL-17 family, the homodimer IL-17E, 
also known as IL-25, is unique in that it is able to elicit protypical Th2 responses such as 
peripheral and lung eosinophilia, increased serum IgE, increased respiratory tract mucus 
production, as weIl as the induction of IL-4, IL-5 and IL-13 gene expression 400,408,413,414. 
Recent in vitro experiments have shown that Th2 cells, mast cells and macrophages 
produce IL-17E 78,406,408. This cytokine binds to the interleukin-17B receptor (IL-17BR) 
418 also known as IL-17Rh1 412 and Evi27 419, and is expressed in a variety of human 
tissues including the lung 412,418. IL-17E activates NF-KB and stimulates IL-8 production 
107 
on binding to IL-17BR in two hum an renal carcinoma ceIllines, TK-IO and 293 412. It 
also induces p38 and JNK phosphorylation in eosinophils 407, 
Airway smooth muscle cells (ASMC) are responsible for the airway narrowing of 
asthma. However, their role is not limited to this action, rather, they appear to play an 
active role in the pathogenesis of this condition through various mechanisms including 
airway remodelling. ASMC have been shown to express receptors for a variety of 
cytokines and chemokines, including the IL-17 A receptor 256, and respond to their 
cognate ligands by releasing other proinflammatory mediators and extracellular matrix 
(ECM) proteins 192,308. One of the characteristic features of remodelling is the increased 
deposition of ECM, in particular collagen l, III, V, and proteoglycans. We hypothesized 
that ASMC harboured IL-17BR and that proinflammatory cytokines could modulate its 
expression. We also assessed the potential of IL-17E to induce expression of ECM 
components. Here, we provide data showing the presence of the IL-17E receptor, IL-
17BR, in ASMC in vivo and in vitro, as weIl as its modulation by TNFa and IFNy. We 
also show that there was increased expression of pro-collagen al and lumican mRNA 
increased in these cells in response to IL-17E. Taken together, these data suggest the 
involvement of IL-17E and its receptor in the initiation and/or perpetuation of airway 
remodelling in asthma. 
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3.1.2 Results 
3.1.2.1 IL-17ER is expressed by culturedprimary human ASMe. 
In order to determine whether human cultured ASMC constitutively expressed 
ILl7BR at the mRNA and prote in levels, we analysed unstimulated cells by RT-PCR, 
Western blot and immunofluorescence. The RT -PCR data illustrated that IL-17BR was 
constitutively expressed in all our human ASMC sources as shown in Fig. lA. Western 
blot analysis from the same ASMC demonstrated basal expression oflL-17BR (Fig. lA). 
To confirm the specificity ofthe anti-IL-17BR antibody, we incubated it with rhIL-17BR, 
when this was applied to the Western blot membrane, no signal was detected, thus 
confirming the specificity of the 55 kDa band observed (Fig. 3.1.4.1A). 
Immunofluorescence also revealed receptor protein expression by primary cultured 
ASMC (Fig. 3.1.4.1C and D). Compared to isotype control, specifie fluorescent staining 
was observed on the cell membrane, as well as in the cytoplasm. 
3.1.2.2 IL-17ER mRNA and protein expression are increased by TNFa and decreased by 
IFNy. 
We wanted to investigate whether IL-17BR expression could be regulated by TNF a 
and IFNy. Real-time PCR and Western blot were used to evaluate receptor modulation by 
these cytokines. TNFa upregu1ated IL-17BR in ASMC (Fig 3.1.4.2A). A time course of 
the effect of TNFa shows a rapid peak expression for both mRNA and protein after 4 h 
(Fig. 3.1.4.2A). Furthermore, we observed a concentration-dependent effect of TNFa on 
IL-17BR message and protein levels after 4 h stimulation (Fig. 3.1.4.2B). Levels of IL-
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17BR appeared to reach a plateau at lOng/ml TNF a at the mRNA level. In contrast, 
treatment of cells with IFNy resulted in a decrease in the expression of IL-17BR mRNA 
and protein (Fig. 3.1.4.2B). IL-17BR mRNA showed an early tendency for 
downregulation by IFNy, however, the maximal inhibitory effects for mRNA and protein 
were reached after 12 h. IFNy also inhibited the receptor's expression at the mRNA and 
protein levels in a concentration-dependent manner (Fig. 3.1.4.2B) up until 10 ng/ml, the 
100 ng/ml concentration did not further inhibit the receptor. 
3.1.2.3 Th2 cytokines do not affect IL-17BR expression in ASMe 
We wished to assess whether IL-17BR expression was sensitive to the prototypical 
Th2 cytokines IL-4 and IL-B. These cytokines had no noticeable effect on the receptor 
in ASMC after 4 or 24 h of stimulation (Fig. 3.2.4.3). In the same conditions the Thl 
cytokine IFNy induced a significant downregulation of IL-17BR mRNA. 
3.1.2.4 Effect of pharrnacological inhibitors on IL-17BR expression 
As previously illustrated (Fig. 3.2.4.2 and 3.2.4.3), TNFa-induced a robust increase 
III IL-17BR mRNA, and although upregulation of IL-17BR mRNA by TNFa was 
strongest at 4 h, the receptor remained induced after 24 h. This time point was used to 
study the effects of TNFa plus, either IFNy For dexamethasone. Addition of increasing 
concentrations of IFNy to TNF a-treated cells abrogated IL-17BR expression in a 
concentration dependent fashion (Fig 3.1.4.4A). The addition of the synthetic 
corticosteroid dexamethasone to TNFa-stimulated ASMC caused an ev en greater 
reduction in expression of IL-17BR message (Fig 3.1.4.4B). Inhibition of the NF-kB 
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pathway with AS602868 produced a marked inhibition of IL-17BR expression with a 
similar potency to that of dexamethasone (Fig 3.1.4.4C). The JNK inhibitor SP600125 
caused a partial decrease in IL-17BR message (Fig 3.1.4.4C). The inhibitor of ERK 
phosphorylation, UO 126, appeared to produce sorne inhibition of IL-17BR expression, 
although this effect was only significant at the concentration of 1 ~M. The p38 
phosphorylation inhibitor SB203580 showed no effect (Fig 3.1.4.4C). Of note, the fold 
increase values observed with TNFa+DMSO compared to DMSO were less than those 
observed with TNFa al one as compared to medium (Fig 3.1.4.2A). This may be related 
to an effect of DMSO on ASMC. The inhibitory effect of IFNy on IL-17BR expression 
was reversed by U0126 in a concentration-dependent manner (Fig. 3.1.4.4D). Treatment 
with SB203580 and SP600125, had no significant effect on this parameter (Fig. 
3.1.4.4D). 
3.1.2.5 IL-17E stimulates ECM mRNA expression in ASMe. 
Cells were stimulated with either 100 ng/ml IL-17E or equivalent in vehicle (4 mM 
HCl! 0.1 % BSA) for 4, 24 and 48 h and analyzed for their expression of ECM 
components such as pro-collagen al, lumican and versican mRNA. Of the ECM tested, 
pro-collagen 1 was the most increased by IL-17E. Statistically significant data points 
showed that pro-collagen al was on average 1.6 fold upregulated after 24 h and 1umican 
was 1.2 fold increased after 4 h (Fig. 3.1.4.5) when compared to vehicle-treated cells at 
their respective time points. Pro-collagen al appeared to remain elevated after 48 h of 
stimulation, but was not significant (p = 0.054). 
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3.1.2.6 IL-17BR is expressed by airway smooth muscle in vivo 
We investigated IL-17BR expression in vivo, using immunohistochemistry on 
airway biopsies obtained from 6 different asthmatic donors. Positive staining was evident 
in the smooth muscle layers (Fig. 3.1.4.6B) demonstrating the relative abundance ofthis 
receptor in the airways. No staining was observed using isotype control antibody (Fig. 
3.1.4.6A). We confirmed in vivo expression of IL-17BR by laser capture microdissection 
of ASMC bundles from suitable biopsies (n=3). cDNA obtained from these 
microdissected tissues were analyzed by real-time PCR and showed that the IL-17BR 141 
bp amplicon was present in laser-captured ASMC bundles (lanes 1-3). Cultured ASMC 
were used as a positive control (Fig. 3.1.4.6C). Non-specific bands observed below 100 
bp correspond to primer-dimers (lanes 1 and - ctrl). 
3.1.2.7 IL-17E promotes cytokine release by ASMe 
The supematant of control- or IL-17E-treated ASMC was evaluated for cytokine 
production using an antibody array (Fig. 3.1.4.7A). There are 42 different cytokines 
represented in duplicate on the antibody array. The quantified signaIs showed that IL-6, 
IL-8, IL-IO, grow-related oncogene (GRO)-a and GM-CSF were upregulated by IL-17E 
in ASMC (Fig. 3.1.4.7B). 
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3.1.3 Figures 
A 
B 
234 
Figure 3.1.4.1. IL-17BR is expressed in cultured airway smooth muscle cells. IL-17BR 
mRNA (A) and protein (B) are constitutively expressed by cultured ASMC from different 
donors (n=4). Specificity of the 55 kDa band in the western blot was assessed using 
ASMC protein extract from donor 1 incubated with anti-IL-17BR preincubated with 
rhIL-17BR. Detection of IL-17BR in cultured ASMC was performed by 
immunofluorescence usmg an Alexa Fluor 555-labelled antibody. (C) 200X 
magnification of the staining obtained with the isotype control or (D) anti-IL17BR 
antibody. 
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Figure 3.1.4.2. Time and concentration dependent effect of TNFa and IFNy on IL-
17BR mRNA and protein expression in ASMe. Cells were starved for 24 h before 
treatment with cytokines, cDNA and protein sarnples were analyzed by real-tirne PCR 
(bar graphs) and Western blot (insets). A) Tirne and B) concentration-dependent 
expression of IL-17BR rnRNA and protein in ASMC in response to TNFa. C) Tirne and 
D) concentration-dependent, expression of IL-17BR rnRNA and protein in ASMC 
after treatment with IFNy. RNA was extracted at stated tirne and concentration and 
reverse-transcribed. cDNA was analyzed by real-time peR, and data are represented as 
the rnean of 3 to 5 independent experirnents ± SD (*p<O.05). Western blots shown are 
representative of 3 independent experirnents. 
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Figure 3.1.4.3. Effect of Th2-type cytokines on IL-17BR rnRNA expression in 
ASMe. Cells were starved for 24 h and treated with 10 ng/ml IL-4, IL-13, or IFNy. RNA 
was extracted at 4 and 24 h and reverse-transcribed. cDNA was analyzed for IL-17BR 
levels by real-time PCR. Data represent the mean of 3 to 6 independent experiments ± SD 
(*, p<O.05;** p<O.Ol). 
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Figure 3.1.4.4. Effect of various inhibitors on IL-17BR expression. ASMC were 
starved for 24 h pnor to stimulation and then treated with cytokines. Cells were 
stimulated 24 h with TNFa (10 ng/ml) and increasing concentrations of A) IFNy or B) 
dexamethasone. C) ASMC were stimulated 4 h with TNFa (10 ng/ml) and increasing 
concentrations ofMAPK (U0126, SB203580 and SP600125) or IKK2 (AS = AS602868) 
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inhibitors. D) ASMe were stimulated 24 h with IFNy (10 ng/ml) and increasing 
concentrations of MAPK inhibitors. Effect of the solvent (DMSO, 0.2%) was tested for 
the equivalent volume used in the highest inhibitor concentration (20 !-lM). RNA was 
extracted after 4 or 24 h. RNA samples were reverse-transcribed and cDNA was analyzed 
for IL-17BR levels. Data are expressed as the mean of 3 to 4 independent experiments ± 
SD (*p<0.05; **p<O.OI; # =significantly different from media or DMSO, t= significantly 
different from TNFa or IFNy alone). 
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Figure 3.1.4.5. Effeet of IL-17E on the expression of ECM rnRNA in eultured 
ASMC. Cells were starved for 24 h and treated with 100 ng/ml IL-17E or its vehicle (4 
mM HCl/O.I % BSA) and RNA was extracted at 4, 24 and 48 h. RNA samples were 
reverse-transcribed and cDNA was analyzed for pro-collagen al, lumican and versican 
levels. Real time PCR data represents the mean of 4-8 independent experiments ± SD. (* 
p <0.05; **p<O.OI). 
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Figure 3.1.4.6. Expression of IL-17BR in vivo. IL-17BR is expressed at the protein 
level as assessed by immunohistochemistry. Representative staining of a human airway 
biopsy showing positive immunoreactivity in smooth muscle layers. 200X magnification 
of an airway biopsy treated with the isotype control (A) or the anti-ILI7BR (B) antibody 
followed by AP AAP detection. Expression of IL-17BR mRNA in ASMC bundles 
obtained by laser capture microdissection (lanes 1-3). Cultured ASMC were used as a 
positive control (C). 
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Figure 3.1.4.7. IL-17E induces the release of cytokines from ASMe. (A) ASMC were 
treated with vehic1e or 30 ng/ml IL-17E for 24 h, supernatants were incubated with a 
cytokine antibody array. Signal was developed by X-ray autoradiography. (B) Cytokines 
increased by IL-17E as assessed by antibody array and expressed as the quantified dot 
intensity of IL-17E membrane over control membrane. 
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3.1.4 Discussion 
We report for the first time the expression and modulation of the IL-17E receptor in 
a primary structural cell type. We show here that IL-17BR is expressed in vitro by 
primary ASMC and in vivo in airway biopsies with predominant staining in smooth 
muscle layers. Previous reports show that dendritic cells, leukocytes and sorne structural 
celllines express this receptor 419,426. Interestingly, a functional IL17R has recently been 
described on airway smooth muscle cells 256. IL-17BR and IL-17R share partial amino 
acid homology but bind different IL-17 family members, IL-17BR binds IL-17E and to a 
lesser extent IL-17B but not IL-17, or IL-l 7 C 412. To date, there has been only one report 
describing the modulation of IL-17BR 426. The authors found that IL-4, -10, and -13 
upregulated IL-17BR mRNA in hum an dendritic ceIls, although the report of baseline 
levels of the receptor is unclear 426. In ASMC, IL-4 and IL-13 did not have any effect on 
the constitutive expression of IL-17BR. However, our data shows that IL-17BR message 
and prote in were readily upregulated by TNF a, an effect observed for IL-17R in human 
colonic myofibroblasts 364. Preliminary bioinformatic analysis of the IL-17BR promoter 
region revealed several NF-KB binding sites, which could account for the TNFa-induced 
upregulation of the IL-17BR transcript we observed. TNF a is a weIl known inducer of 
NF-KB in ASMC. Consequently, we evaluated the effect of AS602868, a specifie 
inhibitor of the IKB kinase 2 (IKK2), important for TNFa-mediated NF-KB activation. 
As expected, inhibition ofNF-KB led to a marked reduction ofTNFa-induced IL-17BR 
mRNA. IL-17BR expression is also corticosteroid sensitive, as demonstrated by the 
potent inhibition of TNFa-induced IL-17BR by dexamethasone. Besides activating the 
IKB kinase (IKK) pathway, TNFa can tum on the main MAPK signalling cascades 
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including, p42/44, p38 and c-Jun N-terminal kinase (JNK). The effect of inhibiting JNK 
was less drastic than with either dexamethasone or AS602868, SP600125 reduced TNFa-
induced IL-17BR levels to baseline. Taken together, our data show NF -KB and to a lesser 
extent JNK play a role in the induction of IL-17BR by TNF a. Most likely, NF -KB causes 
a direct transactivation of the IL-17BR promoter. 
IFNy reduced the constitutive expression of IL-17BR, a finding also observed in 
dendritic cells. Furthermore, the increase in IL-17BR transcript induced by TNFa could 
be antagonized at the mRNA level by the addition of IFNy. The mechanism by which 
IFNy downregulates IL-17BR is unknown; IFNy has been shown to target gene 
expression at different levels. IFNy downregulates IL-4-induced IgE and IL-4R as weIl as 
collagen 1 expression by mechanisms involving transcriptional suppression, and 
posttranscriptional inhibition mediated by increased mRNA degradation. The IL-17BR 
promoter sequence displays two potential IFNy response elements (lgRE) that bind Y-
Box-l, previously shown to be responsible for IFNy-mediated collagen 1 a2 
downregulation. Furthermore, the 3' -untranslated region of the mouse and human IL-
17BR transcript contain 3 and 2 Shaw-Kamen motifs (5' AUUUA-3'), respectively. This 
pentamer motif was previously shown to be present in several immediate early genes, 
such as cytokines, cytokine receptors, and oncogenes, and conf ers instability to mRNAs 
411. Indeed, we have preliminary data suggesting that IFNy accelerates IL-17BR mRNA 
decay when added to actinomycin D treated ASMC. Collectively, these observations hint 
at the possible downregulation of IL-17BR by IFNy via possible IgRE elements present 
in its promoter and/or through an increase in mRNA decay. Besides the traditional 
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Jak/STAT pathway involved in IFNy signaling, this cytokine has been shown to activate 
ERK 1/2 and p38 in sorne cell types, such as cardiac myocytes, macrophages, glioma 
ceIls, hum an bronchial epithelial cells and hum an vascular smooth muscle cells. IFNy can 
also induce ERK 1/2, and JNK phosphorylation in ASMC (data not shown). It has also 
been reported that IFNy can induce, through JAK2, the activation of Raf-l, an upstream 
kinase involved in ERK phosphorylation. Moreover, the MEK inhibitor U0126 can 
abrogate IFNy induced gene expression in the RA W murine macrophage cell line. 
Accordingly, preincubation of ASMC with the MAPK inhibitor U0126 totally reversed 
the IFNy mediated IL-17BR downregulation. Inhibition of p38 or JNK phosphorylation 
had no significant effect. This suggests that IFNy exerts its inhibition at least through the 
MEK-ERK pathway. 
Shi et al. found that IL-17BR mRNA was significantly upregulated in a murine 
model of intestinal inflammation 418, a condition characterized by elevated TNFa levels 
in humans. In asthma, TNF a is increased in the airways and is linked to disease severity 
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published data shows that levels of this cytokine are either increased, decreased or 
unchanged in asthma and upregulated in subjects treated with corticosteroids. Airways 
exposed to increased TNF a and decreased IFNy concentrations could thus favor IL-17BR 
expression in vivo by smooth muscle. This phenomenon could modulate their sensitivity 
to IL-17E released by airway-infiltrated Th2 cells and/or mast cells. Accordingly, mi ce 
that were administered either recombinant IL-17E or an adenoviral IL-17E construct, 
developed a robust eosinophilic infiltration of the airways and stimulated the release of 
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the Th2 cytokines IL-4, IL-S, and IL-13 400,408,413,414. IFNy inhibits Th2 cells and Th2 
cytokine release as well as eosinophilia in sensitized mice after exposure to allergen and 
could therefore antagonize the effects of IL-17E. Indeed, one of the positive effects of 
increasing IFNy in asthmatic patients, through allergen immunotherapy, could be the 
reduction of IL-17BR expression on ASMC and other cell types and the subsequent 
reduction of IL-17E bioactivity in vivo. One of the hallmarks of remodelling is the 
increased deposition of ECM proteins in the airways 308. We wanted to investigate 
whether IL-17E was potentially involved in airway remodelling and for this, evaluated 
production of extracellular matrix (ECM) components by ASMC after stimulation with 
IL-17E. Reports have shown that cultured ASMC can produce matrix proteins such as 
collagen l, versican, and decorin 308. In addition, IL-17 A has been associated with an 
increased deposition of type 1 collagen in the airways of moderate to severe asthmatics 
150, but it is thought that IL-17 A could induce collagen 1 deposition indirectly through the 
induction of the profibrotic cytokines IL-6 and IL-Il which have been shown to enhance 
collagen and tissue inhibitor of metalloprotease (TIMP)-l production 297,353. Moreover, 
IL-17 A transgenic mice, showed increased deposition of collagen in the subepithelium of 
bronchioles. IL-17E has also been shown to induce IL-6 production in eosinophils and 
human cartilage 393,407. Interestingly, IL-17BR ligation promotes TGFj31 mRNA 
production by murine embryonic fibroblasts, a known profibrotic cytokine 405. 
Primary ASMC cultured in the presence of IL-17E showed increased mRNA 
expression for lumican, and especially collagen al (60% increase approximately). For 
comparison, TGF -131, an inducer of collagen al, produced a 150% increase in collagen al 
124 
mRNA (data not shown). In contrast, IFNy, a known inhibitor of collagen al synthesis 
led to a 40-50% decrease in pro-collagen al mRNA (data not shown). Similar values 
were found in the literature regarding collagen al mRNA modulation by TGF-j31 and 
IFNy in fibroblasts and hepatic stellate cells. This initial finding implies that IL-17E 
could participate with other Th2 and profibrotic cytokines and contribute to airway 
remodelling observed in asthmatics. 
Altogether, our results provide initial insight into the in vitro and in vivo expression as 
weIl as the in vitro regulation of the IL-17E receptor and a potential mechanism of action 
of this novel cytokine on ASMC. Further work is necessary to better understand the 
mechanisms that lead to the modulation of IL-17BR in ASMC by TNFa and IFNy 
respectively. Moreover, it would be of considerable interest to assess if IL-17E and IL-
17BR are overexpressed in asthma, an area of ongoing research in our laboratory. 
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3.2 Expression and function of the IL-17E receptor on human 
epithelial cells. 
3.2.1 Introduction 
Interest in the interleukin (IL )-17 family has been stimulated by the publication of 
data suggesting that its founding member, IL-17 A, may contribute to the pathogenesis of 
conditions such as multiple sclerosis, arthritis and asthma 150,297,390,392,445. Indeed, the 
expression of this cytokine is significantly upregulated in the airway mucosa, sputum and 
BAL fluid of asthmatics 150,297. IL-17 is proinflammatory in nature and is produced 
primarily by activated memory CD4+ and CD8+ T lymphocytes. In fact, the main source 
of IL-17 cornes from a newly identified CD4+ T ceIllineage that is neither Th 1 or Th2, it 
is termed Th-17 (ThIL_ I7) 353,354_ IL-17 is especiaIly potent at synergizing with IL-l ~ or 
TNFa to induce production of cytokines such as IL-6, IL-8 and GM-CSF. Among the six 
members of the IL-17 family, the homodimer IL-17E, also known as IL-25, is unique in 
that it is able to elicit protypical Th2 responses such as peripheral and lung eosinophilia, 
increased serum IgE, increased respiratory tract mucus production, as weIl as the 
induction of IL-4, IL-5 and IL-13 gene expression 400,408,413,414. Recent in vitro 
experiments have shown that IL-17E is produced by Th2 ceIls 408, mast ceIls 78 and 
macrophages 406. IL-17E binds to the interleukin-17B receptor (lL-17BR) also known as 
IL-17Rhl 412 and Evi27 419. IL-17BR is expressed in a variety ofhuman tissues including 
the lung and trachea 412 and in vitro by human monocytes, dendritic ceIls, primary lung 
fibroblasts and airway smooth muscle ceIls 426-428. In cultured ceIls, IL-17E activates NF-
KB 405,412, upregulates IL-6, IL-8, TARC, TGF-~I, G-CSF and GM-CSF production 
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393,405,407,412,414,428. It also induces ERK, p38 and JNK phosphorylation in eosinophils and 
in mouse embryonic fibroblasts 405,407. 
Epithelial cells are an integral component of the alrways and serve as a 
physiological barrier. Besides its structural nature, the epithelial cell is also a source of 
potent mediators of inflammation that may be involved in asthma pathogenesis and 
remodeling 446. In has been shown that the bronchial epithelium of asthmatics express 
several cytokines and chemokines as well as cytokine receptors. In asthma, there is 
evdicence of epithelial damage and increased proliferation 44,446. Moreover, cultured 
primary and transformed bronchial epithelial cells show evidence of increased 
proliferation in the presence ofTh2 cytokines such as IL-4 and IL-13 289,446. 
This study focuses on IL-17E, a novel Th2 cytokine capable of inducing allergic 
asthma-like characteristics in mice 400,408,413,414. Interestingly, these mice show evidence 
of bronchial epithelial hypertrophy and hyperplasia 408,414. However this might not be 
unique feature of IL-17E, intratracheal IL-17F gene transfer into mice causes goblet cell 
hyperplasia in small and large airways 415 and IL-17 A transgenic mice have hypertrophic 
epithelium in the bronchus and bronchioles 353 . Moreover, IL-17E induces several types 
of cytokines and chemokines other thanthe Th2 type in vivo 413,414. So far, human lung 
epithelial cells have not been shown to carry a functional IL-17E receptor. In addition, it 
is not known wether IL-17E can act directly on epithelial cells to induce gene expression 
or proliferation. Here, we show for the first time that human epithelial cells constitutively 
express the IL-17E receptor. Similar to data obtained with human primary lung 
fibroblasts and airway smooth muscle cells 427,428, TNFa increases the basal expression of 
IL-17BR in pulmonary (A549) and primary bronchial epithelial cells. Additionally, 
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treating bronchial epithelial ceIls with IL-17E promotes their proliferation. We show also 
that IL-17E can synergize with TNFa to induce greater levels of the GROa chemokine, 
and that this effect is completely abrogated by incubation with the recombinant receptor 
to IL-17E (IL-17BR). 
3.2.2 Results 
3.2.2.1 IL-17BR is constitutively expressed by epithelial cells and is upregulated by TNFa 
Real-time PCR was performed on cDNA obtained from A549, airway smooth muscle 
ceIls (ASMC), primary lung fibroblasts and T ceIls. AlI ceIl types show a basal level of 
IL-17BR expression at the mRNA level (Fig. 3.2.3.1A). To determine protein expression 
of IL-17BR, western blot was performed on ceIl lysates of A549, and human bronchial 
epithelial ceIls. The fuIllength isoform at 55 kDa is present in these ceIls (Fig 3.2.3.1B). 
Moreover, IL-17BR mRNA is increased by TNF a in A549 pulmonary epithelial ceIls (lO 
ng/ml TNFa for 4 h). 
3.2.2.2 Trend towards synergism between IL-17E and TNFa on GROa mRNA. 
The expression of GROa and IL-6 was measured by real-time PCR in A549 cells that 
were treated with IL-17 A, or IL-17E al one or in combination with TNF a (Fig. 4). IL-17E 
had little to no effect on GROa transcript level, by comparison, IL-17 A induced a 3.3 
fold increase and TNFa, induced a 4.6 fold increase in GROa. While not as potent as the 
combination oflL-17A and TNFa (~22 fold increase, data not shown), there was a noted 
synergistic effect between IL-17E and TNFa (~7.3 fold increase) on GROa levels. By 
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incubating IL-17E with its recombinant receptor (lL-17BR:F c) we couid abrogate the 
effect caused by IL-17E and retum the GROa levels to those ofTNFa al one (4.6 fold for 
TNFa and 4.8 fold for IL-17E+TNFa+IL-17BR:Fc). To confirm specificity of IL-17E 
for its receptor, IL-17BR:F c was also incubated with IL-17 A but had no consequence on 
GRO message (22 fold for IL-17A+TNFa and 21.9 foid for IL-17A+TNFa+IL-
17BR:Fc, data not shown) (Fig. 4). 
3.2.2.3 TNFa increases expression of IL-I 7BR mRNA in primary bronchial epithelial 
cells 
Similarly to A549 cens, human bronchial epithelial cens isolated from non-asthmatic 
and mild asthmatic donors that were treated with TNFa (10 nglml) for 4 h showed an 
increased in their expression of the IL-17BR transcript. Baseline expression of IL-17BR 
mRNA in bronchial epithelial cens from mild asthmatics appear higher compared to 
control cens, but this difference is not statisticany significant (p=O.13) (Fig. 3.2.3.3). 
Moreover, TNF a induced a much greater upregulation of IL-17BR message in control 
cens (~4.5-fold) than in asthmatics cens (~1.8-fold) when compared to media-treated 
cens. 
3.2.2.4 IL-I7E fails to enhance TNF a-induced GROa or IL-6 in primary bronchial 
epithelial cel/s. 
Primary bronchial epithelial cens were treated with media al one, IL-17E, TNFa or a 
combination of IL-17E and TNFa. Levels of GROa were assessed by real-time peRo 
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Message for either cytokine were not increased by IL-17E, but as expected, 
TNF a induced both in the bronchial epithelial cells. However, addition ofIL-17E did not 
appear to further enhance the transcript levels for either GROa or IL-6. Unexpectedly, 
cens from asthmatic donors (BAE) were practically unresponsive to TNFa treatment, in a 
similar fashion to results obtained for IL-17BR in BAE (Fig. 3.2.3.3). 
3.2.2.5 IL-17E induces branchial epithelial cell proliferation. 
IL-17E was tested for its ability to induce cellular proliferation on A549 and primary 
bronchial epithelial cells (Fig 3.2.3.6) 48 h-serum starved A549 cells were stimulated 
with media, IL-17E, or PDGF -bb (lOng/ml) as positive control. Although IL-17E-treated 
cells show a trend towards increased proliferation, results did not reach statistical 
significance. However, the proliferative response of BNE and BAE after IL-17E 
treatment was more robust. We observed an increase in proliferation in both BNE and 
BAE cens, however the response to IL-17E as well as to the positive control (TNFa) was 
Stronger in asthmatic-derived epithelial cells with an almost 50% increase in BrdU 
incorporation compared to media-treated cells. 
3.2.2.6 IL-17BR is present on human airway epithelium. 
Immunohistochemistry was performed on section of human airways to assess the 
presence of IL-17BR in bronchial epithelial cens (Fig. 3.2.3.7). Sections were treated 
with an anti-IL-17BR antibody or a matched isotype control antibody. There was a 
positive staining throughout the epithelium for IL-17BR. The signal was considered 
specific, as the isotype antibody did not stain the tissue. Constitutive expression of IL-
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17BR rnRNA was also verified by LCM and is expressed in the tested donors (Fig. 
3.2.3.7C). 
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3.2.3 Figures 
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Figure 3.2.3.1. IL-17BR is constitutively expressed by several cell types, including 
epithelial cells and is upregulated by TNFa. (A) PCR for IL-17BR using cDNA from 
various cellular sources. (B) Western blot showing the IL-17BR 55 kDa band in A549 
epithelial cells and in primary bronchial epithelial cells (BEC). (C) IL-17BR levels by 
real-time PCR in A549 cells treated for 4 h with 0, 1 or 10 ng/ml TNFa (n=2-3 ± SD). 
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Figure 3.2.3.3. IL-17E synergizes with TNFa to indu ce GROa, but not IL-6. A549 
cells were serum-starved for 24 h then stimulated with media, IL-17 A (50 ng/ml), IL-17E 
(50 ng/ml), TNFa (1 ng/ml) or in combination for 24 h. The cytokine mixture (IL-
17E + TNF a) was also preincubated with recombinant human IL-17BR:F c (2 ug/ml) for 2 
h prior to adding to the cells. RNA was extracted and reverse transcribed to cDNA. 
GROa and IL-6 expression was assessed by real-time peR. Data is expressed as meanS± 
SD of 3-4 independent experiments. 
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Figure 3.2.3.4. The proinflammatory cytokine TNFa increases expression of IL-
17BR mRNA in bronchial epithelial cells. Primary bronchial epithelial cens from non-
asthmatic (bronchial normal epithelial - BNE; n=5) and mi Id asthmatic donors (bronchial 
asthmatic epithelial - BAE; n=5) were cultured and treated with TNFa (10 ng/ml) for 4 
h. RNA was extracted and reverse transcribed to cDNA. Level of IL-17BR was assessed 
by real-time peR. Results are values ofmean± SD. * p<O.05 for TNFa-treated BNE cens 
vs. media-treated BNE cens. Ribosomal protein S9 was used as the housekeeping gene 
(see Materials and Methods). 
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Figure 3.2.3.5. IL-17E fails to enhance TNFa-induced GROa or IL-6 in primary 
bronchial epithelial cells. Primary bronchial epithelial cells from non-asthmatic 
(bronchial nonnal epithelial - BNE; n=6) and mild asthmatic donors (bronchial asthmatic 
epithelial- BAE; n=5) were cultured and treated with media, IL-l7E (50 ng/ml), TNFa 
(lOng/ml) or in combination for 24 h. RNA was extracted at the indicated time and 
concentration and was reverse transcribed to cDNA. Level of GROa and IL-6 was 
assessed by real-time PCR. Results are values of mean± SD. * p<0.05; ** p<O.Ol vs. 
media-treated cells. 
135 
!!!. 
~ 180 
W160 
z 
IX! 140 
'0 120 
c 
,g1oo 
~ 80 ~ 
e 60 
0-
ë 40 
~ 20 
CIl 0 
"-
ln 
= 250 ~ 
W 
« 200 
IX! 
'0 
c 150 
0 
:+:l 
~ 100 ~ 
e 
0- 50 
ë 
CIl 
e 0 CIl 
"-
204 
)( 2.0 
III 
~ 1.6 
c 
~ 1.2 
ni 
BNE 
BAE 
~ 0.8 ' 
.. 
III 004 
0.0 
Media Il-HE TNFu 
** 
Media Il-HE TNFa 
A549 
Media IL-17E PDGF-bb 
Figure 3.2.3.6. IL-17E has a positive effect on bronchial epithelial cell proliferation. 
BNE and BAE cens were serum starved for 24 h then treated with media, IL-17E (50 
nglml) or TNFa (1 nglml) as positive control for 48 h. Proliferation of BNE and BAE 
cens was measured by BrdU incorporation and assessed by ELISA. A549 cens were 
serum-starved for 48 h and treated with media, IL-17E (50 ng/ml) or PDGF-bb (10 
nglml) as a positive control. cens were pulsed with 0.5 ~Ci 3H-thymidine/wen (25 
~Ci/ml) for the last 5 h of stimulation (n=3 ± SD). CPM values for media-treated A549 
cens ranged from 6700 to 11900. Results of IL-17E in A549 cens did not reach statistical 
significance. * p<0.05; ** p<O.OI vs. media-treated cens. 
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Figure 3.2.3.7. IL-17BR is expressed by human airway epithelium. IL-17BR is 
expressed at the protein level as assessed by immunohistochemistry. Representative 
staining of a human airway biopsy showing positive immunoreactivity in smooth muscle 
layers. 200X magnification of an airway biopsy treated with the isotype control (A) or the 
anti-IL-17BR (B) antibody followed by AP AAP detection. Expression of IL-17BR 
mRNA in airway epithelium obtained by laser capture microdissection from biopsies (C). 
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3.2.4 Discussion 
We have shown that IL-17E in vitro, in addition to inducing cytokines such as IL-6, 
IL-8, GM-CSF, and MCP-l; can promote the proliferation of bronchial epithelial cells. 
This finding is in agreement with epithelial and goblet cell hyperplasia observed in IL-
17E transgenic mice or mice treated with IL-17E 408,414. We also report that human 
epithelial cells carry a functional IL-17E receptor. Expression of this receptor (IL-17BR) 
is widely distributed among tissues, including the lung and trachea. In addition, cells of 
both a structural and immune nature express IL-17BR 419,426. By comparison, IL-17R also 
shares a broad tissue and cellular distribution, and is expressed by cultured bronchial 
epithelial cells and human lung epithelium 344. As with IL-17 A, IL-17E is more restricted 
in its expression, as their production has only been mostly observed in immune-type cells 
78,297,353,354,406,408. In vitro, Th2 cells, alveolar macrophages and mast cells produce IL-17E 
78,406,408. Several groups have studied the effect of elevated levels of IL-17E in mice, 
either through an IL-17E transgene or by treating them with an adenoviral expression 
construct or intranasaVintraperitoneal administration of the recombinant cytokine. 
Collectively, their data shows that IL-17E promotes a Th2-type response in these animaIs 
400,408,413,414. The data presented in this study demonstrates the presence of the IL-17E 
receptor in cultured bronchial- and lung-derived epithelial cells as well as in the bronchial 
epithelium from human biopsies tissue; this suggests that epithelial cells can respond to 
IL-17E. 
Of the six IL-17 family members, IL-17E shares the least amino acid homology with 
IL-17 A, nevertheless, both share sorne biological activity: they activate NF -kB, induce 
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the profibrotic cytokine IL-6, 297,393,407,447 are associated with collagen 1 production 427 or 
deposition, 150 induce IL-8 239,297,412 and GM-CSF 364,428. The combination oflL-17A with 
TNF u provides a potent synergistic effect in the production of several growth factors, 
chemokines and cytokines, similarly, human lung fibroblasts treated with IL-17E in 
addition to TNFu had enhanced GM-CSF production 428. As expected, the combination 
oflL-17A and TNFu induces a very strong effect on GROu and IL-6 mRNA production. 
IL-17E on its own is not as potent as IL-17 A, it fails to upregulate IL-6, but lightly 
induces GROu. However, while not as potent as IL-17 A + TNF u, IL-17E has a 
synergistic effect with TNFu on the induction of IL-6 and GROu transcripts. The 
synergistic effect between IL-17E and TNFu was partIy abrogated by the recombinant 
IL-17E receptor (IL-17BR:F c). Preincubating IL-17 A with IL-17BR:F chad not effect on 
GROu or IL-6 expression, confirming its specificity for IL-17E. The similarities between 
IL-17 A and IL-17E biology might be explained by comparable intracellular events. 
Although there are differences in the size and amino acid composition of their respective 
receptors, both ligands can induce ERK and p38 phosphorylation 360,405,407,447 and require 
the presence of the adaptor protein TNF receptor-associated factor (TRAF) 6 for proper 
signaling to NF-kB and JNK 389,405. 
Data regarding the effect of IL-17 A on in vitro cellular proliferation is conflicting and 
could be due to differing cell types. Recently, IL-17A was shown to induce proliferation 
of tracheal epithelial cells 448, however, sorne show no effect on A549 cells 370 and can 
even be anti-proliferative on primary human intestinal epithelial cells 449. IL-17 A also 
appears to play a role in tumor cell growth and apoptosis 370,373,443,449. IL-17 A promotes 
the growth of different human non-small cell lung cancer (NSCLC) cell lines in SCID 
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mice. Interestingly, IL-17 A had anti-apoptotic properties on the tumors generated by the 
NSCLC celllines Sq 19 and A549 370. In line with our observation that IL-17E promotes a 
proliferative phenotype, the murine B cell line Ba/F3 expressing the IL-17E receptor 
proliferated when cultured with supematant from a mouse myeloma cell line (X63) 
engineered to produce IL-17E 405 and support the B cell hyperplasia noted in one of the 
IL-17E transgenic mice models 413. 
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3.3 Expression and function of the IL-17E receptor on human lung 
fibroblasts 
3.3.1 Introduction 
Asthma is a chronic inflammation of the alrways and is characterized by the 
Illcrease III expressIOn of Th2 cytokines such as IL-4, IL-5 and IL-13, mucus 
hypersecretion, fibrosis eosinophil accumulation in aIrway tissues, and in allergie 
asthmatic increased IgE synthesis. IL-17E (IL-25), a newly characterized member of the 
IL-17 family, induces in mice several features typical of human asthma. Mice treated 
with or overexpressing IL-l7E show increased expression of IL-4, IL-5 and IL-13, 
circulating IgE, mucus production, promotes a strong eosinophilia 400,408,413,414 and in 
sorne models, neutrophilia as weIl. Thus IL-17E is suggested to play an important role in 
allergie airway disease. Eosinophilia has long been considered a hallmark feature of 
asthma, the cytokines eotaxin, RANTES, IL-8 and GM-CSF are involved in regulation of 
eosinophil attraction and maintenance in the bronchial mucosa, aIl of which are 
upregulated in asthmatics. These tissue-infiltrated eosinophils are thought to play an 
important role in this disease because they are a source of proinflammatory and 
profibrotic cytokines, such as TNFa and TGFj3l. 
ln vitro, production of IL-17E has been shown in hum an Th2 lymphocytes, murine 
mast cells exposed to IgE and rat airway macrophages stimulated with titanium oxide 
particles. IL-17E is also constitutively found at the mRNA level in human lung and 
tracheal tissue. This cytokines is a ligand for the interleukin-17B receptor (IL-17BR) also 
known as IL-l7RhI 412 and Evi27 419. IL-l7B also binds IL-17BR but with less affinity 
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than IL-17E 342,412. This receptor is expressed in a variety ofhuman tissues inc1uding the 
trachea and lung 412. In vitro, human macrophages and dendritic cells have been shown to 
express IL-17BR 426. Like many proinflammatory cytokines such as IL-17 A and TNF a, 
IL-17E activates NF-kB and the members of the mitogen-activated protein kinase 
(MAPK) pathway 405,407,412. IL-17E can induce IL-6, G-CSF, IL-8 in murine fibroblasts, 
human articular cartilage, and a renal epithelial cellline 393,412,414. It can also promote the 
release ofIL-6, MIP-la and IL-8 from cultured human eosinophils 407. 
Because structural cells of the airways are a potent source of cytokines and chemokines 
both in vivo and in vitro, they are now regarded as important effector cells in the 
pathogenesis of airway diseases. Cultured primary pulmonary fibroblasts constitutively 
express IL-17BR and produce mediators involved in allergic airway disease in response 
to IL-17E. IL-17E induces synthesis ofIL-8, GM-CSF, RANTES and eotaxin. Moreover, 
TNFa and TGF~l have the ability to modulate IL-17E bioactivity on human lung 
fibroblasts, maybe in part through increased or decreased IL-17BR expression. 
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3.3.2 Results 
3.3.2.1 Human lungjibroblasts constitutively express IL-17BR: modulation by TNFa and 
TGFfJ1. 
Immunofluorescent staining of unstimulated fibroblasts shows constitutive expression of 
IL-17BR (Fig. 3.3.3.lA). Similarly, western blot analysis demonstrates that fibroblasts 
ceIl lysates contain de fuIl-Iength protein at 56 kDa (Fig. 3.3.3.lB), as weIl as other 
previously demonstrated isoforms, thought to represent secreted and glycosylated 
variants 419. The chimeric protein IL-17BR:Fc was used as a positive control and the 
expected band at 75 kDa was detected (Fig. 3.3.3.lB). Real-time PCR analysis showed 
that fibroblasts express IL-17BR mRNA at baseline. The IL-17BR transcript was strongly 
upregulated in ceIls stimulated with TNF a at 4 or 24 h, with the maximal effect observed 
after 4 h (Fig. 1 C). On the other hand, TGFj3l-stimulated ceIls showed a decrease in their 
expression of the receptor's mRNA at both 4 and 24 h of stimulation, but reached greatest 
inhibitory effect after 24 h (Fig. 3.3.3.lC) 
3.3.2.2 IL-17E increases mRNAfor IL-8 (CXCL8), RANTES (CCL11), eotaxin (CCL5) 
andGM-CSF. 
Fibroblasts were stimulated with either 50 ng/ml IL-17E or its vehic1e (4 mM 
HCI+O.l % BSA) for 4 or 24 h. Real-time PCR was used to assess mRNA levels for IL-8 
(CXCL8), RANTES (CCLII), eotaxin (CCL5) and GM-CSF. Although these cytokines 
were detected in vehic1e treated ceIls, IL-17E upregulated their transcript levels (1.5- to 
3-fold) after 4 and 24 h of stimulation. However, cytokine increase reached statistical 
significance only at the 24 h time point (Fig. 3.3.3.2). IL-8 (CXCL8) and GM-CSF 
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message were the most sensitive to IL-17E with an almost 3-fold increase over vehicle 
(Fig, 3.3.3.2C, D). 
3.3.2.3 Trend towards synergism between IL-I7E and TNFa on GM-CSF and CXCL8 
mRNA production. 
Levels of IL-8 (CXCL8), RANTES (CCLII), eotaxin (CCL5) and GM-CSF mRNA 
were measured on fibroblasts that were treated with either IL-17E, TNFa or in 
combination. TNFa strongly induced these cytokines, especially at 24 h (Fig. 3.3.3.3). 
The combination of IL-17E and TNFa had no noticeable effect on CCL5 and CCLll 
transcript levels at either incubation times. IL-I7E appeared to induce a synergistic effect 
on the amount ofGM-CSF (2-fold for IL-17E and 118-fold for TNFa versus I76-fold in 
combination; Fig. 3.3.3.3C) and CXCL8 (464-fold for TNFa and 666-fold for IL-
17E+TNFa; Fig. 3D), both at 24 h, however the differences between the TNFa and 
TNF a+ IL-17E groups did not reach statistical significance. 
3.3.3.4 TGFpI decreases production of CCLII but in creas es CXCL8 production in IL-
17E-treated cells. 
Levels of IL-8 (CXCL8), RANTES (CCLll), eotaxin (CCL5) and GM-CSF mRNA 
were measured on fibroblasts that were treated with either IL-I7E, TGFp 1 or in 
combination. In contrast to TNFa, TGFpl did not upregulate CCL5 or CCLll mRNA 
(Fig. 3.3.3.4A, B). GM-CSF mRNA was modestly increased after 24 h with TGFp1; 
however, it had a much stronger effect on CXCL8 expression at 4 and 24 h (Fig. 
3.3.3.4C, D). The combination of IL-17E and TGFp1 induced a transient (only at 4 h) 
144 
decrease in GM-CSF rnRNA. Likewise, CCLII rnRNA was downregulated by IL-
17E+TGF~I cornpared to IL-17E alone at 24 h (Fig. 3.3.3.4A). Conversely, IL-17E 
increased a TGF~ l-rnediated upregulation of CXCL8 expression, especially at 24 h (Fig. 
3.3.3.4D). 
3.3.3.5 Trend towards synergism between IL-1lE and TNFa on GM-CSF and CXCL8 
release from lung fibroblasts. 
ELISA was used to rneasure levels of GM-CSF and CXCL8 in the supematants of 
cells treated with IL-17E alone or in cornbination with TNFa for 48 h. Low levels of 
GM-CSF and CXCL8 were detected in unstirnulated fibroblasts. IL-17E induced a slight 
increase in the secretion ofboth cytokines, although it was not statistically significant. As 
expected, TNFa induced GM-CSF and CXCL8 release and this effect appeared to be 
accentuated by addition of IL-17E (Fig. 3.3.3.5). However, differences between TNFa 
alone and TNFa+IL-17E are not statistically significant. 
3.3.3.6 IL-1lE is present in human airways. 
The expression of IL-17E in hurnan asthrnatic airways was done by 
irnrnunohistochernistry of bronchial biopsy tissue. Mainly inflarnrnatory cells, sorne with 
eosinophil-like rnorphology stained positive for IL-17E in the bronchial subrnucosa (Fig. 
3.3.3.6). Moreover, the sarne tissue revealed eosinophil infiltration as assessed by 
positive MBP staining. 
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3.3.3 Figures 
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Figure 3.3.3.1. Expression of IL-17BR in human lung fibroblasts. (A) IL-17BR 
immunofluorescent staining in cultured lung fibroblasts (left panel). Negative control 
experiment using an isotype-matched control primary antibody is shown in right panel. 
Magnification: x200. (B) Detection of IL-17BR expression by Western blot in fibroblast 
lysates (lane 2) in parallel with the purified control fusion protein F c/IL-17BR (lane 1). 
Results are representative of a minimum of 3 experiments. (C) Expression of IL-17BR 
mRNA, as quantified by real-time PCR in fibroblasts stimulated with vehicle, TNFa or 
TGFb 1. IL-17BR levels were normalized over those of the housekeeping gene S9, and 
values are expressed as a fold increase compared with vehicle-treated cells. Values are 
means ± SEMs of 3 to 5 experiments. *P<O.05 compared with vehicle-treated fibroblasts 
at the same time point. 
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Figure 3.3.3.2. Effect of IL-17E on the expression of tibroblast-derived mediators. 
Serum-deprived lung fibroblasts were stimulated with IL-I7E or its vehicle and (A) 
CCLII (B), CCL5 (C), GM-CSF (D), and CXCL8 mRNA levels were evaluated. Results 
are presented as a fold increase compared with vehicle-treated cells at the same time 
point. Values are means ± SEMs of 6 experiments. *P<O.05 compared with vehicle-
treated fibroblasts. 
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Figure 3.3.3.3. Effect of TNFa and IL-17E on the expression of cytokines in lung 
fibroblasts. Fibroblasts were stimulated with IL-17E or its vehicle, alone or in 
combination with TNFa, and (A) CCLII (B), CCL5 (C), GM-CSF (D), and CXCL8 
mRNA levels were quantified. Results are expressed as fold increase over values 
obtained with vehicle-treated cells at the same time point. Values are means ± SEMs of 3 
to 7 experiments. *P<O.05 compared with IL-17E-treated cells at the same time point. 
Differences between TNFa alone and TNFa+IL-17E are not statistically significant. 
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Figure 3.3.3.4. Effect of the combination of TGF~ 1 and IL-17E on the expression of 
cytokine expression in fibroblasts. Fibroblasts were stimulated with IL-17E or its 
vehicle, al one or in combination with TGF~l, and mRNA levels of (A) CCLll (B), 
CCL5 (C), GM-CSF, and (D) CXCL8 were quantified. Results are expressed as a 
percentage of the value obtained in vehicle-treated cells at the same time point. Values 
are means ± SEMs of 3 to 6 experiments. *P<O.05 compared with IL-17E-stimulated 
cells and tP<O.05 compared with TGF~I-treated cells at the same time point. 
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Figure 3.3.3.5. Effect of IL-17E and TNFa on cytokine release by fibroblasts. 
Fibroblasts were stimulated for 48 hours with IL-17E or its vehicle, with or without 
TNFa. (A) GM-CSF and (B) CXCL-8 were quantified in supernatants. Values are 
expressed as means ± SEMs of 3 to 6 experiments. *P<0.05 compared with vehicle and 
tP<0.05 compared with IL-17E-treated cells. Differences between TNFa alone and 
TNF a+ IL-17E are not statistically significant. 
150 
Figure 3.3.3.6. Expression of IL-17E in asthma. (A) Immunohistochemistry for IL-17E 
and (B) major basic protein (MBP) was performed on bronchial biopsies of subjects with 
asthma to identify eosinophils. Representative staining experiments are shown. 
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3.3.4 Discussion 
Little is know about the biology of IL-17E in alrway diseases such as asthma, 
however, its Th2 nature leads us to believe that it could indeed play a role in this disease. 
This report demonstrated for the first time the expression of IL-17BR in primary lung 
fibroblasts and that IL-17E promotes the production of pro-eosinophilic mediators in 
these cens (CCLII, CCL5, CXCL8 and GM-CSF). 
'Mice overexpressing an IL-17E transgene or treated with exogenous recombinant IL-
17E show eosinophil infiltration in lung tissue, something not seen in transgenic IL-17 A 
animaIs. Indeed, IL-8 is unpregulated in primary bronchial epithelial cens treated with 
IL-17A, but not eotaxin or RANTES 384. The chemokines CCLll (eotaxin) and CCL5 
(RANTES) are selectively chemotactic for eosinophils and promote their infiltration from 
the peripheral blood to the airway mucosa. GM-CSF is a growth factor involved in the 
proliferation of granulocyte progenitors and promotes their differentiation into 
eosinophils. GM-CSF also supports eosinophil chemotaxis and activation. Reports using 
IL-17E transgenic mice also show an increase in neutrophils 413,414, this can be explained 
by the fact that IL-17E also induces CXCL8 (IL-8), an important neutrophil 
chemotattractant, in lung fibroblasts, but also in epithelial cens 412 and eosinophils 407. 
Moreover, CXCL8 also induces chemotaxis of primed eosinophil and favors their 
adhesion to activated endothelium. Thus IL-17E may be involved in the initiation and 
maintenance of an eosinophilic infiltration through the upregulation of CCLll, CCI5, 
CXCL8 and GM-CSF. 
Our data shows that the IL-17E receptor message is upregulated by the 
proinflammatory cytokine TNF a. Consistent with our observation, IL-17BR transcript is 
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elevated in the intestines a rat model of inflammatory bowel disease 418. On the other 
hand, TGFB 1 inhibited the expression of IL-17BR in fibroblasts. This finding may 
support the anti-inflammatory role often attributed to TGFBl. Therefore, TNFa and 
TGFB 1 may affect a ceIl' s sensibility to IL-17E. 
On their own, IL-17E and IL-17 A are not as potent as TNF a in inducing several types 
of cytokines (IL-6, IL-8, GM-CSF, etc), however, they are capable of enhancing an 
inflammatory reaction through a synergistic cooperation with TNFa. We show that IL-
17E potentiates TNFa-mediated expression of GM-CSF and CXCL8 rnRNA. This 
phenomenon might be explained by several mechanisms, either through upregulation of 
IL-17BR by TNF a, through activation of NF -kB or MAPK, since IL-17E and TNF a can 
these pathways 405,412 or because IL-17E, like IL-17 A, could help stabilize TNFa-induced 
mRNA transcripts 164,364,367,374,381,450. Indeed, IL-17 A synergizes with TNFa to upregulate 
GM-CSF production in human colonic myofibroblasts through increased mRNA 
stabilization and possibly though increased mobilization of NF-kB 364. However, there 
was no difference in CCLll or CCL5 expression between TNFa-stimulated ceIls versus 
those treated with IL-17E+TNFa. Interestingly, while several reports show the 
synergistic effect ofIL-17A coupled with TNFa, it can also antagonize TNFa-mediated 
secretion of chemokines such as CCL5 (RANTES) and CCL27 385,386. 
We show here that TGFB 1 downregulates IL-17BR mRNA in fibroblasts, and this 
could affect their response to IL-17E. We observe that TGFtH inhibits IL-17E-induced 
increase in CCLll mRNA and does the same with GM-CSF, although it is only a 
transient effect observed at 4 h and not at 24 h. However, TGFBl synergized with IL-17E 
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to upregulate CXCL8 rnRNA. Collectively these results suggest altemate pathways that 
either synergize or antagonize IL-17E-rnediated cytokine production. 
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Chapter 4 - General discussion 
4.1 Introductory remarks 
There as been a longstanding interest in uncovering molecules that may be involved in 
the pathogenesis of asthma, and whether they contribute to the development or 
maintenance of this disease. Several newly discovered cytokines hold the potential to be 
targets of treatment. Conceming the IL-17 family of cytokines, the expression of its 
founding member, IL-17 A, is increased in asthmatics and correlates with disease severity. 
Asthma is regarded as a condition where there is an imbalance between Th2 vs Thl type 
cytokines. Among the Th2 cytokines now recognized, IL-17E appears to be one of the 
latest additions, mainly because of the asthma-like features it induces in mice. 
Importantly, cens that are known to infiltrate the airway mucosa such as Th2 cens, 
mastocytes and eosinophils express IL-17E. These leukocytes are in fact surrounded by 
resident structural cens and are likely targets of IL-17E in human airways. For this 
reason, we choose to investigate whether bronchial epithelial cens, lung fibroblasts and 
airway smooth cens can respond to IL-17E. This thesis contributes data that clarifies our 
understanding of the biology of IL-17E and its receptor (lL-17BR) in vitro. 
4.2 Discussion of results 
Our data shows that IL-17E is present in human airways and overlaps with positive 
eosinophil staining, suggesting this ceIl as a potential source of IL-17E in the airways. No 
data yet exists in the literature on the presence of the IL-17E receptor in the bronchial 
mucosa or the effect of its ligand on cultured structural ceIls of the airways. We show 
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here that IL-I 7BR is expressed by the bronchial epithelium and airway smooth muscle in 
vivo. Likewise, the IL-17R is present on the human lung epithelium. We demonstrated 
that IL-17BR was present at baseline in cultured airway smooth muscle cells, bronchial 
epithelial cells and lung fibroblasts. The expression of several cytokine and chemokine 
receptors can be modulated by cytokines such as TNFa, which increases CCR3 on 
ASMC 231, as well as the decoy IL-13 receptor, IL-13Ra2, but does not affect expression 
of the signaling IL-13Ral 340. Similarly, TNFa upregulates the IL-17R transcript in 
human colonic myofibroblasts 364 but not in human chondrocytes or synovial fibroblasts 
398. IL-17BR mRNA is strongly increased in a rat model of intestinal inflammation 418, a 
condition in humans that is characterized by elevated levels ofTNFa. In accordance with 
these data, we observed that TNF a consistently increased IL-17BR expression in all three 
strucutal cell types. Using ASMC, we have shown that the increase in IL-17BR by TNFa 
was very sensitive to the corticosteroid dexamethasone, as it efficiently downregulated 
IL-17BR mRNA in TNFa-treated cells. NF-kB is a chief downstream target of TNFa 
signaling and has been shown to be a target of corticosteroid action. Activation ofNF-kB 
requires the phosphorylation of the inhibitory protein IkB by the IkB kinase (IKK) 
complex. The IKK2 subunit of the IkB kinase complex is though to play a crucial role in 
activating NF-kB. Using a specific inhibitor of IKK2 (AS602868) we show that the 
induction of IL-17BR mRNA by TNF a is totally dependent on NF -kB, and it is thus 
likely that IL-17BR gene transcription is dependent on the mobilization of NF -kB to its 
promoter. 
In ASMC, IFNy decreases the basallevel ofIL-17BR and also inhibits TNFa from 
increasing the receptor mRNA. Furthermore, IFNy also has an inhibitory effect on IL-
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l7BR expression by human monocytes 426. Unlike IL-17BR, IL-17R appears unsensitive 
to IFNy in bronchial epithelial cells and keratinocytes 351,384. IFNy has also been shown to 
decrease the expression of IL-4Ra and the chemokine receptor CCR2 451,452. 
Interestingly, both IL-4R and CCR2 are downregulated by IFNy through an increase in 
mRNA decay rather than a decrease in transcription. Inhibition of IL-17BR mRNA in 
ASMC by IFNy was completely reverted by preventing ERKl/2 phosphorylation through 
the use of the U0126 compound. U0126 inhibits MEKl/2, a kinase that phosphorylates 
ERKl/2. p38 or JNK phosphorylation inhibitors had no effect. Thus IFNy-induced 
downregulation of the receptor is mediated at least in part through the MEK-ERK 
pathway. A similar observation has been made in PBMCs, treatment with PMA leads to a 
decrease in the production the amyloid precursor protein mRNA and this can be reversed 
by addition ofU0126 453. 
IL-17E appears to be profibrotic in ASMC as it promotes collagen 1 gene 
expression. Interestingly, ASMC have been shown to be a potent source of ECM 308. 
Ligation of IL-17BR on mouse embryonic fibroblasts stimulates an increase in TGFf31 
mRNA 405 and TGFf3l is known to strongly promote collagen 1 expression in fibroblasts 
and ASMC. IL-17E might directly induce collagen 1 expression, or indirectly through 
TGFf3l which might then act in an autocrine/paracrine fashion on ASMC and enhance its 
synthesis 240. There seems to be a profibrotic role for members of the IL-17 family, IL-
17 A induces the expression of the profibrotic cytokines IL-6 and IL-Il in lung fibroblasts 
297 and its expression is correlated with an increased collagen 1 and III deposition in 
asthmatic airways 150. 
We have also shown by antibody array that IL-17E-treated ASMC respond by 
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releasing more cytokines such as IL-6, IL-8, IL-lO, GROu, and GM-CSF. IL-17E is 
associated with increased IL-6 and IL-8 release from eosinophils, epithelial cells and 
human articular cartilage 393,407,412. Moreover, IL-lO, GROu and to a lesser extent GM-
CSF are upregulated in the kidneys and lungs of IL-17E transgenic mice 414. IL-8 and 
GROu are known neutrophil chemoattractants, and while IL-17E is known to induce 
eosinophilia in mice, sorne have noted an increase in neutrophils as weIl 413,414. It is 
possible that IL-17E could have a dual effect on both types of granulocytes. A key action 
of IL-17 A in vivo is to attract neutrophils through the release of CXC chemokines (IL-8, 
GROu) and this effect is efficiently diminished by a blocking antibody to IL-17A 367,454. 
Unexpectedly, blocking IL-17 A enhances IL-5 levels in the BAL and blood and worsens 
bronchial eosinophilia induced by allergen in mice 454. IL-17 A could thus have a 
regulatory role in controlling airway eosinophilia. However, sputum expression of IL-
17 A and IL-5 mRNA correlates in asthmatics 356. Taken together, these results suggest 
that the regulation of neutrophil and eosinophil influx into the airways by IL-17 A or IL-
17E is likely to be more complex than first thought. 
In human lung fibroblasts, IL-17E also induces RANTES and eotaxin mRNA, in 
addition to IL-8 and GM-CSF. Our observation ofincreased RANTES and eotaxin in IL-
l7E-treated fibroblasts might account for the pro-eosinophilic effect of IL-17E in mouse 
models, as both are chemotactic for eosinophils. Moreover, GM-CSF prolongs eosinophil 
survival 455,456 and can prime them to increase their release of eosinophil cationic protein 
and eosinophil-derived neurotoxin 288,457. The combination of IL-17 A and TNF u offer 
strong synergistic effects on the rnRNA levels and protein release of several cytokines 
including GM -CSF. Similarly, in lung fibroblasts, the combination of IL-17E and TNF u 
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appears to induce more GM-CSF than with TNFa alone. However, addition of IL-17E to 
TNFa-treated fibroblasts does not further increase IL-8 release. The potentiating effect of 
IL-17E might occur via TNFa-mediated increase in IL-17BR in fibroblasts, rendering the 
cens more responsive to IL-17E. This phenomenon can be seen in the synergistic 
antiproliferative effect of TNFa and IFNy on HT-29 epithelial adenocarcinoma cens. 
Ruggiero et al. demonstrated that pretreating cens with IFNy upregulated the TNF 
receptor and rendered them much more responsive to TNFa 265. It is also quite likely that 
IL-17E stabilizes the GM-CSF mRNA transcript induced by TNFa. This mechanism of 
increased transcript stability has often been reported for IL-17 A 164,364,371. We have also 
reported that TGFj31 downregulates the basal expression of IL-17BR mRNA in 
fibroblasts and downregulates IL-17E-induced eotaxin mRNA. Yet, TGFj31 is synergistic 
in combination with IL-17E on IL-8 message levels. Conversely, TGFj31 antagonizes 
eotaxin mRNA induced by IL-17E, though it is synergistic with the Th2 cytokine IL-13 
on the induction of eotaxin in lung fibroblasts 331. 
The hum an bronchial epithelium stains positively for IL-17BR and is thus a likely 
target for IL-17E in vivo. Cultured bronchial epithelial cens, isolated from biopsies taken 
from non-asthmatics (control) and mi Id asthmatics donors, also reveal basal expression of 
IL-17BR mRNA. We detected more IL-17BR transcript in unstimulated cens from the 
asthmatics, but this difference was not significant. Nevertheless, it does not preclude the 
possibility that IL-17BR might be increased in cens from moderate or severe asthmatics. 
In accordance with our findings in ASMC, fibroblast and A549 cens, IL-17BR mRNA is 
increased by treatment with TNFa in bronchial epithelial cens from both control and 
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asthmatics, but unexpectedly, cells fron controls responded much more to TNFa 
stimulation than asthmatic cells. We tested the levels of the CXC family chemokine 
GROa as well as IL-6 in epithelial cells. These mediators were elevated in the 
supematants from IL-17E-treated in ASMC, as assessed by the antibody array. GROa 
and IL-8 share a very similar sequence and function in attracting neutrophils. 
Interestingly, GROa is also produced by human eosinophils and might be released in 
asthmatic airways 458. In a murine model of allergic airway disease, GROa is increased in 
the early phase of the inflammatory response after allergen challenge and remains 
elevated throughout the experimental period 459. Similarly, IL-l7E induces the release of 
IL-8 in a renal epithelial cellline as well as by eosinophils 407,412. GROa is upregulated 
by IL-17 A and IL-17F in bronchial epithelial cells 293,368,460, we show however that IL-
17E on its own has almost no effect on the level of GROa and IL-6 message in A549 
cells. Nonetheless, IL-l7E can synergize with TNFa to increase GROa message, but not 
with IL-6. IL-17E has been shown to physically bind IL-17BR using techniques that 
isolated both molecules and tested them outside of an in vitro or in vivo biological 
context 342,412. So far, no data in the literature has shown that blocking the receptor or 
using a competitor abrogates IL-17E's biological activity. For that reason, we incubated 
IL-17E with recombinant IL-17BR before adding it to the cells in combination with 
TNFa. We observed that this abrogated the effect caused by IL-l7E. Moreover, this 
effect is specific, as incubating IL-17 A with IL-17BR had no effect on its biological 
activity. As discussed earlier, it is probable that IL-l7E enhances TNFa-induced GROa 
by stabilization of its mRNA. In line with our findings, GROa was also elevated in IL-
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17E transgenic mlce 414 and could III part account for the increase III circulating 
neutrophil numbers 413,414. 
Hypertrophy and hyperplasia of the alrway epithelium was among the biological 
changes noticed in mice receiving IL-17E 408,414, although no direct association was made 
between IL-17E and enhanced epithelial proliferation. We demonstrate that bronchial 
epithelial cells isolated from normal and mild asthmatic donors proliferate when 
stimulated with IL-17E and moreso in asthmatic-derived epithelial cells. Though, these 
cells also proliferate more in the presence of TNFa, suggesting that BAE cells might be 
more proliferative in response to mitogens, rather than this being a specific response to 
IL-17E. In support for our observations, IL-17E promotes the proliferation of the B cell 
line BaF3 and enhances the survival of eosinophils 405,461. By comparison, IL-17 A has 
recently been shown to induce the proliferation of human tracheal epithelial cells 448 in 
addition to enhancing vascular endothelial growth factor (VEGF)-induced endothelial 
cell proliferation 370,462. It is likely that in vivo, in addition to inducing cytokine 
expression, IL-17E is a pro-proliferative and/or pro-survival factor for various cell types. 
So far, only in vivo data show distinct differences in the biological behavior of IL-17E 
versus IL-17 A or IL-17F, namely its Th2-promoting effects. In contrast, epithelial 
hyperplasia/hypertrophy 353,415, as well as mucus production 353 appear to be common 
observations. In vitro, our data on the functional role of IL-17E on structural cells do not 
depart radically from observations made with either recombinant IL-17 A or IL-17F, that 
is, its synergistic effect with TNFa, and a possible pro-fibrotic role 150,344. Moreover, we 
and others, have shown that like IL-17 A, IL-17E also induces IL-6 and IL-8 (in ASMe). 
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So far, none of the IL-I7' s are able to promote pro-eosinophilic chemokines like eotaxin 
or RANTES, as we have demonstrated for IL-17E in lung fibroblasts 384. 
4.3 Summary 
We have observed for the first time the IL-17E receptor on human structural cells of 
the airways both in vivo and in vitro. Airway smooth muscle cells, fibroblasts and 
bronchial epithelial cells constitutively express IL-17BR. TNFa consistently increases its 
expression in these cells. We thus suggest that in asthma, Th2 lymphocytes mast cells and 
eosinophils that are infiltrated in the airway mucosa might act as sources of IL-l 7E and 
that the local inflammatory environment characterized by increased TNF a could 
upregulate IL-17BR on airway structural cells and render these more responsive to IL-
17E. Furthermore, we have observed that IL-17E promotes pro-collagen 1 synthesis by 
ASMC, as well as the increased synthesis of proinflammatory mediators by AS MC (IL-8, 
GROa, GM-CSF, IL-6), lung fibroblasts (eotaxin, RANTES, GM-CSF and IL-8) and 
A549 epithelial cells (GROa). In asthmatic airways, it is possible that IL-17E induces the 
release of pro-inflammatory, pro-eosinophilic and pro-neutrophilic mediators by these 
structural cells. In this respect, IL-17E might contribute yo the influx and survival of 
inflammatory cells and maintain a state of inflammation in asthmatic airways. IL-17E 
could also promote the increased deposition of collagen 1 by ASMC and thus contribute 
to increased subepithelial fibrosis that occurs in airway remodelling. In addition, we have 
observed that IL-17E supports the proliferation of bronchial epithelial cells isolated from 
control and mi Id asthmatic donors, in accordance with in vivo data in mi ce that shows 
hyperplasia of the airway and gut epithelium. In asthma, the epithelium shows signs of 
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increased proliferation and as such, IL-17E might participate in the repair of damaged or 
wounded bronchial mucosa. 
4.4 Future directions 
It would be of considerable interest to assess IL-17E leve1s in non-asthmatic and 
asthmatics of different severities either in the BAL fluid or sputum and in bronchial 
tissue, as weIl as to acertain to cellular sources of this cytokine in the airways. Moreover, 
now that IL-17E knockout mice are available 416,417, it would be particularly interesting to 
use them as mode1s of allergic airway disease to see if the absence of IL-17E results in a 
milder asthma phenotype. 
4.5 Perspectives 
IL-17E is part of a complex cytokine network and because of the paucity of 
information on it, it is difficult to evaluate its real life contribution in normal physiology 
and disease. Compounding the situation, cytokines are known to have redundant 
functions, as weIl as synergistic and antagonistic effects, depending on the conditions. In 
the case of the IL-17 family members, they share many in vitro as weIl as in vivo 
biological effects. Indeed, the problematic part when studying a cytokine in vitro, is to be 
able to appreciate its output in the context of a whole organism as weIl as to understand 
how it distinguishes itself from a sea of mediators by its unique biological effects. 
Interestingly, the same research institute that has contributed to the discovery of IL-17E 
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has recently found a novel Th2 cytokine, tenned IL-33, which, very much like IL-17E, 
upregulates IL-4, IL-5 and IL-B, increases IgE, induces eosinophilia, promotes 
epithelium hypertrophy and mucus secretion in mice 463. This brings about questions that 
are often asked in cytokine biology: what are the unique biological effects of these two 
seemingly similar interleukins and are they just molecules with redundant properties? 
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4.6 Schematic representation of the potential role of IL-17E in asthma. Th2 and mast 
cells are infiltrated in the bronchial mucosa in asthmatic airways and could locally 
produce IL-17E. Surrounding structural cells, such as airway smooth muscle cells 
(ASM), fibroblasts and epithelial cells express the IL-17E receptor (lL-17BR) and are 
thus likely targets for the action of IL-17E in vivo. IL-17E could act on these cell types to 
164 
induce the release of several cytokines involved in airway inflammation. IL-17E could 
participate in remodeling by enhancing the production of collagen 1 from ASM and 
increase the thickening of the basement membrane (subepithelial fibrosis). In addition, 
IL-17E could also promo te a greater proliferative response in bronchial epithelial cells. 
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